
<html lang="en"     class="pb-page"  data-request-id="00d8b910-cbe2-42bc-bf8e-04e43516cc19"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2016.59.issue-14;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01985"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers" /></meta><meta name="dc.Creator" content="Gérald  Lelais" /></meta><meta name="dc.Creator" content="Robert  Epple" /></meta><meta name="dc.Creator" content="Thomas H.  Marsilje" /></meta><meta name="dc.Creator" content="Yun O.  Long" /></meta><meta name="dc.Creator" content="Matthew  McNeill" /></meta><meta name="dc.Creator" content="Bei  Chen" /></meta><meta name="dc.Creator" content="Wenshuo  Lu" /></meta><meta name="dc.Creator" content="Jaganmohan  Anumolu" /></meta><meta name="dc.Creator" content="Sangamesh  Badiger" /></meta><meta name="dc.Creator" content="Badry  Bursulaya" /></meta><meta name="dc.Creator" content="Michael  DiDonato" /></meta><meta name="dc.Creator" content="Rina  Fong" /></meta><meta name="dc.Creator" content="Jose  Juarez" /></meta><meta name="dc.Creator" content="Jie  Li" /></meta><meta name="dc.Creator" content="Mari  Manuia" /></meta><meta name="dc.Creator" content="Daniel E.  Mason" /></meta><meta name="dc.Creator" content="Perry  Gordon" /></meta><meta name="dc.Creator" content="Todd  Groessl" /></meta><meta name="dc.Creator" content="Kevin  Johnson" /></meta><meta name="dc.Creator" content="Yong  Jia" /></meta><meta name="dc.Creator" content="Shailaja  Kasibhatla" /></meta><meta name="dc.Creator" content="Chun  Li" /></meta><meta name="dc.Creator" content="John  Isbell" /></meta><meta name="dc.Creator" content="Glen  Spraggon" /></meta><meta name="dc.Creator" content="Steven  Bender" /></meta><meta name="dc.Creator" content="Pierre-Yves  Michellys" /></meta><meta name="dc.Description" content="Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a..." /></meta><meta name="Description" content="Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 19, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01985" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01985" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01985" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01985" /></link>
        
    
    

<title>Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01985" /></meta><meta property="og:title" content="Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0013.jpeg" /></meta><meta property="og:description" content="Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed. Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations. Through molecular docking studies we converted a mutant-selective high-throughput screening hit (7) into a number of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity. We used an abbreviated in vivo efficacy study for prioritizing compounds with good tolerability and efficacy that ultimately led to the selection of 47 as the clinical candidate." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01985"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01985">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01985&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01985&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01985&amp;href=/doi/10.1021/acs.jmedchem.5b01985" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 6671-6689</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01871" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00056" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=G%C3%A9rald++Lelais">Gérald Lelais</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Epple">Robert Epple</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Marsilje">Thomas H. Marsilje</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yun+O.++Long">Yun O. Long</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++McNeill">Matthew McNeill</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bei++Chen">Bei Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenshuo++Lu">Wenshuo Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jaganmohan++Anumolu">Jaganmohan Anumolu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangamesh++Badiger">Sangamesh Badiger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Badry++Bursulaya">Badry Bursulaya</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++DiDonato">Michael DiDonato</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rina++Fong">Rina Fong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jose++Juarez">Jose Juarez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jie++Li">Jie Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mari++Manuia">Mari Manuia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+E.++Mason">Daniel E. Mason</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Perry++Gordon">Perry Gordon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Todd++Groessl">Todd Groessl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Johnson">Kevin Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Jia">Yong Jia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shailaja++Kasibhatla">Shailaja Kasibhatla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chun++Li">Chun Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John++Isbell">John Isbell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Glen++Spraggon">Glen Spraggon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Bender">Steven Bender</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pierre-Yves++Michellys">Pierre-Yves Michellys</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Genomics Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Aurigene Discovery Technologies, Bollaram Road, Miyapur, Hyderabad 500 049, India</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Aurigene Discovery Technologies, 39-40, Electronic City Phase 2, Bangalore 560 100, India</span></div><div class="corresp-info"><strong>*</strong>Phone: +1-858-332-4452; e-mail: <a href="/cdn-cgi/l/email-protection#385f545d5459514b785f565e16574a5f"><span class="__cf_email__" data-cfemail="7a1d161f161b13093a1d141c5415081d">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01985&amp;href=/doi/10.1021%2Facs.jmedchem.5b01985" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 6671–6689</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 19, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 December 2015</li><li><span class="item_label"><b>Published</b> online</span>19 July 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 July 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01985</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6671%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DG%25C3%25A9rald%2BLelais%252C%2BRobert%2BEpple%252C%2BThomas%2BH.%2BMarsilje%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D14%26contentID%3Dacs.jmedchem.5b01985%26title%3DDiscovery%2Bof%2B%2528R%252CE%2529-N-%25287-Chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimidazol-2-yl%2529-2-methylisonicotinamide%2B%2528EGF816%2529%252C%2Ba%2BNovel%252C%2BPotent%252C%2Band%2BWT%2BSparing%2BCovalent%2BInhibitor%2Bof%2BOncogenic%2B%2528L858R%252C%2Bex19del%2529%2Band%2BResistant%2B%2528T790M%2529%2BEGFR%2BMutants%2Bfor%2Bthe%2BTreatment%2Bof%2BEGFR%2BMutant%2BNon-Small-Cell%2BLung%2BCancers%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6689%26publicationDate%3DJuly%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01985"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4227</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">49</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01985" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gérald&quot;,&quot;last_name&quot;:&quot;Lelais&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Epple&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Marsilje&quot;},{&quot;first_name&quot;:&quot;Yun&quot;,&quot;last_name&quot;:&quot;O. Long&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;McNeill&quot;},{&quot;first_name&quot;:&quot;Bei&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Wenshuo&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Jaganmohan&quot;,&quot;last_name&quot;:&quot;Anumolu&quot;},{&quot;first_name&quot;:&quot;Sangamesh&quot;,&quot;last_name&quot;:&quot;Badiger&quot;},{&quot;first_name&quot;:&quot;Badry&quot;,&quot;last_name&quot;:&quot;Bursulaya&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;DiDonato&quot;},{&quot;first_name&quot;:&quot;Rina&quot;,&quot;last_name&quot;:&quot;Fong&quot;},{&quot;first_name&quot;:&quot;Jose&quot;,&quot;last_name&quot;:&quot;Juarez&quot;},{&quot;first_name&quot;:&quot;Jie&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Mari&quot;,&quot;last_name&quot;:&quot;Manuia&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;E. Mason&quot;},{&quot;first_name&quot;:&quot;Perry&quot;,&quot;last_name&quot;:&quot;Gordon&quot;},{&quot;first_name&quot;:&quot;Todd&quot;,&quot;last_name&quot;:&quot;Groessl&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Jia&quot;},{&quot;first_name&quot;:&quot;Shailaja&quot;,&quot;last_name&quot;:&quot;Kasibhatla&quot;},{&quot;first_name&quot;:&quot;Chun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Isbell&quot;},{&quot;first_name&quot;:&quot;Glen&quot;,&quot;last_name&quot;:&quot;Spraggon&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Bender&quot;},{&quot;first_name&quot;:&quot;Pierre-Yves&quot;,&quot;last_name&quot;:&quot;Michellys&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;6671-6689&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01985&quot;},&quot;abstract&quot;:&quot;Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed. Herein, we describe our approach toward the discovery of 47 (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations. Through molecular docking studies we converted a mutant-selective high-throughput screening hit (7) into a number of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity. We used an abbreviated in vivo efficacy study for prioritizing compounds with good tolerability and efficacy that ultimately led to the select&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01985&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01985" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01985&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01985" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01985&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01985" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01985&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01985&amp;href=/doi/10.1021/acs.jmedchem.5b01985" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01985" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01985" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26pmid%3D27433829%26genre%3Darticle%26aulast%3DLelais%26date%3D2016%26atitle%3DDiscovery%2Bof%2B%2528R%252CE%2529-N-%25287-Chloro-1-%25281-%255B4-%2528dimethylamino%2529but-2-enoyl%255Dazepan-3-yl%2529-1H-benzo%255Bd%255Dimidazol-2-yl%2529-2-methylisonicotinamide%2B%2528EGF816%2529%252C%2Ba%2BNovel%252C%2BPotent%252C%2Band%2BWT%2BSparing%2BCovalent%2BInhibitor%2Bof%2BOncogenic%2B%2528L858R%252C%2Bex19del%2529%2Band%2BResistant%2B%2528T790M%2529%2BEGFR%2BMutants%2Bfor%2Bthe%2BTreatment%2Bof%2BEGFR%2BMutant%2BNon-Small-Cell%2BLung%2BCancers%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/jmcmar.2016.59.issue-14/20160728/jmcmar.2016.59.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Over the past decade, first and second generation EGFR inhibitors have significantly improved outcomes for lung cancer patients with activating mutations in EGFR. However, both resistance through a secondary T790M mutation at the gatekeeper residue and dose-limiting toxicities from wild-type (WT) EGFR inhibition ultimately limit the full potential of these therapies to control mutant EGFR-driven tumors and new therapies are urgently needed. Herein, we describe our approach toward the discovery of <b>47</b> (EGF816, nazartinib), a novel, covalent mutant-selective EGFR inhibitor with equipotent activity on both oncogenic and T790M-resistant EGFR mutations. Through molecular docking studies we converted a mutant-selective high-throughput screening hit (<b>7</b>) into a number of targeted covalent EGFR inhibitors with equipotent activity across mutants EGFR and good WT-EGFR selectivity. We used an abbreviated in vivo efficacy study for prioritizing compounds with good tolerability and efficacy that ultimately led to the selection of <b>47</b> as the clinical candidate.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05054" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05054" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inhibitors of epidermal growth factor receptor (EGFR), such as erlotinib (<b>1</b>), gefitinib (<b>2</b>), and afatinib (<b>3</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) deliver high objective response rates and increased overall survival (OS) for non-small-cell lung cancer (NSCLC) patients with oncogenic EGFR mutation cancers (i.e., exon 19 deletions or exon 21 L858R single-point mutation).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> However, upon continuous treatment, patients become resistant and, in 50–60% of cases, develop a secondary T790M mutation at the gatekeeper residue of EGFR.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Evidence suggests that this modification does not block inhibitor binding but rather confers resistance by increasing affinity to ATP.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected EGFR inhibitors: (a) reversible pan-EGFR inhibitors; (b) irreversible pan-EGFR inhibitors; (c) irreversible mutant-selective EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To overcome drug resistance caused by the T790M mutation, several irreversible pan-EGFR inhibitors belonging to the same structural class as their reversible counterparts (4-anilinoquinazolines) have been developed.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7-11)</a> These include afatinib (<b>3</b>)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), dacomitinib (<b>4</b>)<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), and ceritinib.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Their mode of action (MoA) relies on the inactivation of EGFR by forming a covalent bond between an electrophilic Michael acceptor and a conserved cysteine (Cys797) near the ATP binding domain,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> leading to a more complete and sustained inhibition of the target. Although <b>3</b> showed promise in preclinical models of T790M,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> it is lacking efficacy in the clinic as a single agent for patients with T790M mutation<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and is unable to achieve an efficacious concentration due to dose-limiting WT EGFR-driven toxicities (e.g., GI-tox and rash).<a onclick="showRef(event, 'ref7 ref14'); return false;" href="javascript:void(0);" class="ref ref7 ref14">(7, 14)</a></div><div class="NLM_p">More recently, a new class of mutant-selective irreversible EGFR inhibitors containing an anilinopyrimidine core has been described in the literature.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22">(15-22)</a> Importantly, these inhibitors have low nanomolar activity on EGFR-T790M mutant cells and demonstrate good selectivity toward WT EGFR. On November 13, 2015, osimertinib (AZD9291, <b>5</b>)<a onclick="showRef(event, 'ref20 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref23">(20, 23)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) was granted accelerated approval by FDA<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and rociletinib (CO-1686, <b>6</b>)<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) was in pivotal registration trials. Although more clinical data are required, both compounds have the potential to overcome EGFR-T790M resistance mutations while reducing WT EGFR-driven toxicities.<a onclick="showRef(event, 'ref23 ref25 ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref23 ref25 ref26 ref27 ref28">(23, 25-28)</a></div><div class="NLM_p last">In this article we report the discovery of <b>47</b> (EGF816, nazartinib), a potent covalent mutant-selective EGFR inhibitor with a unique structural motif, currently being evaluated in a number of clinical trials for the treatment of NSCLC.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72843" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72843" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Hit Identification and Modeling</h3><div class="NLM_p">Our strategy for identifying mutant-selective EGFR inhibitors started with a HTS campaign against the EGFR L858R-T790M kinase domain using a homogeneous time-resolved fluorescence (HTRF) based biochemical assay.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> To achieve maximal inhibitory sensitivity, the compounds were profiled at 1 μM ATP concentrations (ATP <i>K</i><sub>m</sub> ≈ 2 μM) in single point inhibition. The hits were then reconfirmed with IC<sub>50</sub> curves at both 1 μM and 1000 μM ATP allowing for the identification of both ATP and non-ATP competitive hits. This communication focuses on the identification of ATP-competitive hits, and the latter ones will be discussed in a separate publication. To further assess the compound’s selectivity, we used biochemical counterscreens against EGFR L858R and WT EGFR kinase constructs. Compounds with good activity on EGFR L858R-T790M and selectivity against WT EGFR were considered to be good starting points for further optimization. Activity on EGFR L858R was deemed beneficial but not necessary for hit selection, as we hoped to increase EGFR L858R activity during the hit-to-lead process (vide infra). Among the identified hits, compound <b>7</b> displayed an interesting profile, with submicromolar activity on the L858R-T790M construct and selectivity against WT EGFR (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), and its rather uncommon, but not unprecedented,<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33-36)</a> hinge binding motif further stimulated our interest. In fact, although there are a number of aminobenzimidazoles targeting IRAK4<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> and ITK,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> analogue <b>7</b> was the only mutant EGFR inhibitor not derived from an aminopyrimidine core, making it a unique structural motif in the EGFR field. Docking of <b>7</b> into the active site of EGFR T790M (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu">2jiu</a>)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> revealed a similar binding mode to what had been reported in the literature for IRAK-4 and ITK kinases. It showed a hydrogen bond between the amide carbonyl group of <b>7</b> and the hinge-NH of Met793, with the meta-trifluorobenzamide group extending toward the methionine gatekeeper residue (Met790) and the cyclohexanol group projecting toward the lip of the ATP-pocket’s Cys797 (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), a residue that had been successfully targeted by irreversible EGFR inhibitors.<a onclick="showRef(event, 'ref7 ref11 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref7 ref11 ref37 ref38">(7, 11, 37, 38)</a> With this information in hand, we evaluated the structure–activity relationship (SAR) of reversible analogs with the goal of identifying potent ATP-competitive EGFR inhibitors. At the same time, we rationalized that converting mutant-selective ATP-competitive hits into targeted covalent inhibitors would provide compounds with retained selectivity against WT EGFR, with the added benefit of more complete target inhibition as it had been first demonstrated with the identification of the mutant-selective EGFR inhibitor <i>N</i>-(3-((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)acrylamide (WZ4002).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) High throughput screening (HTS) approach that culminated in the identification of both allosteric and ATP-competitive EGFR hits. Biochemical IC<sub>50</sub> (μM) of ATP-competitive hit <b>7</b> as average of at least duplicate measurements assessed at 10 μM ATP concentration for either mutants (L858R and L858R-T790M) and WT EGFR constructs. (b) Docking model for the binding of <b>7</b> in the ATP-pocket of EGFR T790M-AEE788 cocrystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu">2jiu</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Compounds were prepared from commercially available 1-fluoro-2-nitroarenes according to the general procedures described in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>. S<sub>N</sub>Ar reaction with primary amines or appropriately protected diamines followed by nitro reduction and cyclization with cyanogen bromide afforded 2-aminobenzimidazole intermediates <b>18</b>–<b>22</b>, <b>30a</b>–<b>s</b>, <b>37</b>, or <b>38</b> in moderate yields (14–85% over several steps). Amide coupling of <b>18</b>–<b>22</b>, <b>30a</b>–<b>s</b>, or <b>37</b> with 3-(trifluoromethyl)benzoic acid provided <b>23</b>–<b>27</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) or intermediates <b>31a</b>–<b>s</b> and <b>39</b>, respectively. The latter were deprotected and transformed to the desired products <b>32a</b>–<b>s</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) or <b>43</b> and <b>44</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), in acceptable yields (17–71%). Amide coupling of <b>37</b> and <b>38</b> with 2-substituted isonicotinic acids afforded <b>40</b>–<b>42</b> that were deprotected and further coupled with (<i>E</i>)-4-(dimethylamino)but-2-enoic acid to provide <b>45</b>–<b>47</b> in moderate yields (35–61%, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, DIPEA, 120 °C; (b) Pd/C, H<sub>2</sub>, MeOH; (c) CNBr, MeCN/H<sub>2</sub>O/MeOH 55 °C; (d) 3-(trifluoromethyl)benzoic acid, HATU, DIPEA, DMF or 3-(trifluoromethyl)benzoic acid, HOBt, EDCI, Et<sub>3</sub>N, DMF.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup> = Boc: DMF, base (DIPEA or K<sub>2</sub>CO<sub>3</sub>), 110–130 °C; R<sup>1</sup> = H: neat or DMF, 130–150 °C. (b) For <b>p</b>, <b>q</b>, <b>s</b>, R<sup>1</sup> = H: Boc<sub>2</sub>O, Et<sub>3</sub>N, dioxane. (c) Pd/C, H<sub>2</sub>, MeOH; (d) CNBr, MeCN/H<sub>2</sub>O/MeOH 45–50 °C; (e) 3-(trifluoromethyl)benzoic acid, HATU, DIPEA, DMF; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (g) acryloyl chloride, with or without Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0–20 °C.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) neat, DMA or DMF, DIPEA, 110–140 °C. (b) For <b>35</b>: Pd/C, H<sub>2</sub>, MeOH. For <b>36</b>: Zn, AcOH, room temperature. (c) CNBr, MeCN/H<sub>2</sub>O/MeOH 55 °C; (d) acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub> or acid, HATU, DIPEA, DMF; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub> or HCl, dioxane/MeOH. (g) For <b>43</b>: acryloyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, 0–20 °C. For <b>44</b>–<b>47</b>: (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride, HOBt, EDCI, Et<sub>3</sub>N, DMF or (<i>E</i>)-4-(dimethylamino)but-2-enoic acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> In Vitro SAR</h3><div class="NLM_p">The docking of <b>7</b> in the kinase domain revealed the solvent exposed nature of the ethoxymethyl group. The lack of stabilizing interactions with the protein provided a rationale for investigating simpler benzimidazole core substitutions as shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. As expected, the unsubstituted derivative <b>23</b> was well tolerated, demonstrating 2-fold improved biochemical activity on the L858R-T790M construct. Comparable potency was observed with the 6-methyl analogue (<b>26</b>), while slight potency improvements were noted with compounds that had a methyl substitution at positions 5 and 7 (<b>25</b> and <b>27</b>). Conversely, as predicted by modeling, compound <b>24</b> was less potent, likely due to the methyl group pointing toward the hinge binding domain of EGFR. Importantly, in all cases, selectivity against WT EGFR was maintained, and hints of activity on the oncogenic L858R mutant were observed with <b>23</b> and <b>27</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of Benzimidazole Core<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">L858R-T790M</th><th class="colsep0 rowsep0" align="center">L858R</th><th class="colsep0 rowsep0" align="center">WT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.26 ± 0.07</td><td class="colsep0 rowsep0" align="left">2.00 ± 0.41</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">1.37 ± 0.56</td><td class="colsep0 rowsep0" align="left">11.75 ± 5.22</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">5-Me</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.10</td><td class="colsep0 rowsep0" align="left">>8.48</td><td class="colsep0 rowsep0" align="left">>11.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">6-Me</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.12</td><td class="colsep0 rowsep0" align="left">>16</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">7-Me</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.68 ± 0.07</td><td class="colsep0 rowsep0" align="left">5.27 ± 2.42</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Biochemical IC<sub>50</sub> (μM) assessed at 10 μM ATP concentration for either mutants (L858R and L858R-T790M) and WT EGFR constructs. All data are an average of at least duplicate measurements.</p></div></div></div><div class="NLM_p">Unfortunately, all attempts to further improve the potency of these ATP-competitive hits resulted in little success. A number of amide and cyclohexanol replacements were prepared, none of which resulted in potency improvements (data not shown). Nonetheless, the exquisite WT EGFR selectivity observed in the biochemical assays prompted us to investigate the possibility of adding a well-placed Michael acceptor capable of reacting with Cys797 and result in a targeted covalent inhibitor that could demonstrate improved potency on the mutant EGFR but retain WT EGFR selectivity. As such, compounds of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were synthesized and a broad variety of lengths and geometries around the reactive thiol of Cys797 were interrogated.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship of the Linker Region Aimed at Identifying the Optimal Length and Geometry for Covalent Bond to Cys797<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">0 min</th><th class="colsep0 rowsep0" align="center">90 min</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">0 min</th><th class="colsep0 rowsep0" align="center">90 min</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32a</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left"><b>32k</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.05 ± 0.008</td><td class="colsep0 rowsep0" align="left"><b>32l</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32c</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left"><b>32m</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32d</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left"><b>32n</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32e</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.02 ± 0.002</td><td class="colsep0 rowsep0" align="left"><b>32o</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32f</b></td><td class="colsep0 rowsep0" align="left">>37.67</td><td class="colsep0 rowsep0" align="left">16.46 ± 7.86</td><td class="colsep0 rowsep0" align="left"><b>32p</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>32.77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32g</b></td><td class="colsep0 rowsep0" align="left">0.83 ± 0.14</td><td class="colsep0 rowsep0" align="left"><0.002</td><td class="colsep0 rowsep0" align="left"><b>32q</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">0.004 ± 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32h</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left"><b>32r</b></td><td class="colsep0 rowsep0" align="left">22.31 ± 24.75</td><td class="colsep0 rowsep0" align="left">0.01 ± 0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32i</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">6.81 ± 1.88</td><td class="colsep0 rowsep0" align="left"><b>32s</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32j</b></td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left">>50</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Biochemical IC<sub>50</sub> (μM) assessed with or without a 90 min preincubation of compound and EGFR L858R-T790M enzyme at 1 mM ATP concentrations using HTRF assay as described in the methods section. All data are an average of at least duplicate measurements.</p></div></div></div><div class="NLM_p">The inhibitory activity of compounds <b>32a</b>–<b>s</b> was assessed against the L858R-T790M biochemical construct at 0 and 90 min enzyme/compound preincubation. We employed 90 min preincubation times based on time dependent inhibition studies of irreversible EGFR inhibitors to ensure maximal inhibition of covalent inhibitors (data not shown). These assays were carried out in the presence of 1 mM ATP to simulate physiological intracellular levels of ATP. Importantly, striking differences in EGFR L858R-T790M inactivation were observed, with few linkers (compounds <b>32b</b>, <b>32e</b>, <b>32g</b>, <b>32l</b>, <b>32m</b>, <b>32q</b>, and <b>32r</b>) capable of inhibiting the enzyme at nanomolar ranges after a 90 min preincubation and only compound <b>32g</b>, with a racemic 3-substituted azepane linker, demonstrating submicromolar activity without preincubation. With these data in hand, we further profiled the most active compounds in various cellular target modulation assays of oncogenic (e.g., H3255, HCC827), resistance (e.g., H1975), and WT (e.g., HaCaT) EGFR settings as shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. The cellular potency on H1975 was in good agreement with the biochemical inhibitory concentration on the L858R-T790M construct, with <b>32g</b> demonstrating superior activity (IC<sub>50</sub> = 0.006 μM), followed by <b>32e</b> (IC<sub>50</sub> = 0.02 μM; <i>R</i>-enantiomer). In addition, compound <b>32g</b> was highly potent across all mutant EGFR lines and displayed acceptable WT EGFR selectivity (≥50-fold).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activity Profiles of <b>32b</b>, <b>32e</b>, <b>32g</b>, <b>32l</b>, <b>32m</b>, <b>32q</b>, <b>32r</b>, and Reference Compounds <b>5</b> and <b>6</b> from Patient-Derived Cell Lines H1975 (EGFR L858R-T790M), H3255 (EGFR L858R), and HCC827 (EGFR Del E746-A750) and the Immortalized Human Keratinocyte Cell Line HaCaT (WT EGFR)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">H1975</th><th class="colsep0 rowsep0" align="center">H3255</th><th class="colsep0 rowsep0" align="center">HCC827</th><th class="colsep0 rowsep0" align="center">HaCaT</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32b</b></td><td class="colsep0 rowsep0" align="left">525 ± 126.4</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">1653 ± 717</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32e</b><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">24.7 ± 5.3</td><td class="colsep0 rowsep0" align="left">421 ± 139.3</td><td class="colsep0 rowsep0" align="left">153 ± 29.4</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32g</b></td><td class="colsep0 rowsep0" align="left">6.1 ± 2.0</td><td class="colsep0 rowsep0" align="left">74.9 ± 31.9</td><td class="colsep0 rowsep0" align="left">15.9 ± 1.9</td><td class="colsep0 rowsep0" align="left">4330 ± 779</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32l</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">41.4 ± 8.7</td><td class="colsep0 rowsep0" align="left">543 ± 0.195</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32m</b><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">409 ± 338</td><td class="colsep0 rowsep0" align="left">>3716</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32q</b></td><td class="colsep0 rowsep0" align="left">134.8 ± 29.3</td><td class="colsep0 rowsep0" align="left">1041 ± 327</td><td class="colsep0 rowsep0" align="left">272.1 ± 48.5</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32r</b></td><td class="colsep0 rowsep0" align="left">181 ± 45.3</td><td class="colsep0 rowsep0" align="left">660 ± 169.1</td><td class="colsep0 rowsep0" align="left">267.5 ± 48.1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">2.5 ± 0.7</td><td class="colsep0 rowsep0" align="left">4.1 ± 1.4</td><td class="colsep0 rowsep0" align="left">2.5 ± 0.5</td><td class="colsep0 rowsep0" align="left">73.7 ± 16.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">4.1 ± 1.4</td><td class="colsep0 rowsep0" align="left">13.8 ± 3.2</td><td class="colsep0 rowsep0" align="left">9.5 ± 0.9</td><td class="colsep0 rowsep0" align="left">262.3 ± 79.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Target modulation IC<sub>50</sub> values (nM) were determined after a 3 h compound treatment to the cells. All data are an average of at least duplicate measurements.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Cellular IC<sub>50</sub> values for the active <i>R</i>-enantiomer, obtained after chiral HPLC separation (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Data for <b>32l</b> and <b>32m</b> are from engineered NIH-3T3 cells of the corresponding L858R-T790M, L858R, or WT-EGFR mutants.</p></div></div></div><div class="NLM_p">Intrigued by the initial observation that 7-methyl derivative <b>27</b> displayed a preferred substitution pattern, we prepared both enantiomers of the 7-methyl analogue of <b>32g</b>. Interestingly, the <i>R</i>-enantiomer <b>43</b> demonstrated very good activity across mutants cell lines with acceptable WT EGFR selectivity (≥25-fold, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), whereas the <i>S</i>-enantiomer was >200-fold less potent across assays (H1975 IC<sub>50</sub> = 401 nM, H3255 IC<sub>50</sub> = 3125 nM, HCC827 IC<sub>50</sub> = 863 nM, HaCaT IC<sub>50</sub> ≥ 10 000 nM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro and in Vivo Profile of Select Mutant-Selective EGFR Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>43</b></th><th class="colsep0 rowsep0" align="center"><b>44</b></th><th class="colsep0 rowsep0" align="center"><b>45</b></th><th class="colsep0 rowsep0" align="center"><b>46</b></th><th class="colsep0 rowsep0" align="center"><b>47</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1975 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">1.39 ± 0.03</td><td class="colsep0 rowsep0" align="left">2.18 ± 0.75</td><td class="colsep0 rowsep0" align="left">1.51 ± 0.01</td><td class="colsep0 rowsep0" align="left">2.11 ± 0.17</td><td class="colsep0 rowsep0" align="left">4.18 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H3255 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">14.84 ± 0.91</td><td class="colsep0 rowsep0" align="left">45.90 ± 15.78</td><td class="colsep0 rowsep0" align="left">2.65 ± 0.07</td><td class="colsep0 rowsep0" align="left">3.05 ± 0.14</td><td class="colsep0 rowsep0" align="left">6.11 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HCC827 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">3.93 ± 2.03</td><td class="colsep0 rowsep0" align="left">12.45 ± 5.91</td><td class="colsep0 rowsep0" align="left">1.48 ± 0.56</td><td class="colsep0 rowsep0" align="left">1.01 ± 0.33</td><td class="colsep0 rowsep0" align="left">1.52 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HaCaT IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (nM)</td><td class="colsep0 rowsep0" align="left">249.6 ± 94.0</td><td class="colsep0 rowsep0" align="left">351.0 ± 240.4</td><td class="colsep0 rowsep0" align="left">72.0 ± 15.5</td><td class="colsep0 rowsep0" align="left">68.0 ± 22.8</td><td class="colsep0 rowsep0" align="left">160.6 ± 12.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1975 LipE</td><td class="colsep0 rowsep0" align="left">3.65</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">4.59</td><td class="colsep0 rowsep0" align="left">4.83</td><td class="colsep0 rowsep0" align="left">4.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HT-sol., pH 6.8 (μM)</td><td class="colsep0 rowsep0" align="left"><2</td><td class="colsep0 rowsep0" align="left">10.5</td><td class="colsep0 rowsep0" align="left">12.7</td><td class="colsep0 rowsep0" align="left">>175</td><td class="colsep0 rowsep0" align="left">>175</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP3A4 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">22.2</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2D6 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">16.7</td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C9 IC<sub>50</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">17.6</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human CL<sub>int</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse CL<sub>int</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">245</td><td class="colsep0 rowsep0" align="left">233</td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse iv CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">54.0</td><td class="colsep0 rowsep0" align="left">57.2</td><td class="colsep0 rowsep0" align="left">62.5</td><td class="colsep0 rowsep0" align="left">68.5</td><td class="colsep0 rowsep0" align="left">31.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse po AUC (h·nM)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">808</td><td class="colsep0 rowsep0" align="left">4391</td><td class="colsep0 rowsep0" align="left">2839</td><td class="colsep0 rowsep0" align="left">3527</td><td class="colsep0 rowsep0" align="left">12789</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse <i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">60</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All IC<sub>50</sub> data given in μM unless otherwise noted and are an average of at least duplicate measurements.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">CL<sub>int</sub> is intrinsic clearance in liver microsomes, μL min<sup>–1</sup> mg<sup>–1</sup>.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">AUC from 20 mg/kg oral dose to male balb/c mice. <b>43</b> and <b>45</b> were formulated in 0.5% methylcellulose and 0.5% Tween 80 suspension. <b>44</b> was formulated in solution containing 75% PEG300 and 25% D5W (5% dextrose in water). <b>46</b> was formulated in solution containing 5% ethanol, 30% PEG300, and 65% Solutol (20%), and <b>47</b> was formulated in a solution containing 5% ethanol, 25% PEG300, and 70% D5W (5% dextrose in water).</p></div></div></div><div class="NLM_p">To gain confidence that these analogues were indeed binding to EGFR L858R-T790M via a covalent bond to Cys797, we performed crystallization studies with a variety of mutant and WT EGFR constructs. The structures of <b>43</b> bound to either WT EGFR or the T790M single mutant were determined and exhibit an overall structure consistent with a kinase in the active conformation, DFG-in and intact salt bridge to helix-C. Comparison of the two <b>43</b>-bound structures revealed nearly identical binding site residues and compound conformations (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B) and hence did not provide any clues that could explain the observed selectivity toward the T790M mutant versus the WT enzyme. However, examining the apo structures of both the WT enzyme (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2">2gs2</a>)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and the T790M mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit">2jit</a>)<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> revealed a network of water molecules bound to the hinge region of the WT enzyme that is not present in the apo structure of the T790M mutant (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). In the WT apo structure, the Thr790 side chain mediates a hydrogen bonding interaction to two water molecules that are also coordinated to the backbone of several residues in the hinge region (Ala743, Gln791, and Leu788). In addition, there is a third water molecule coordinated to the backbone amide of Met793. These three water molecules are absent in the apo T790M mutant structure and are instead replaced by two loosely coordinated water molecules that interact with the DFG aspartic acid side chain, Asp855 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). In the compound-bound structures (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B), analogue <b>43</b> is covalently linked to Cys797 and makes a hydrogen bonding interaction to the backbone amide NH of Met793. Binding of the compound to the WT enzyme requires the displacement of the three strongly coordinated water molecules present in this region. We hypothesize that the cost of displacing these water molecules that are not present in the T790M apo structure may lead to the observed selectivity profile of <b>43</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of apo and drug bound hinge region. (A) Superposition of apo WT EGFR (white sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2">2gs2</a>)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and EGFR T790M mutant (cyan sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit">2jit</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Water molecules associated with the WT structure are shown in gray spheres; those associated with the T790M structure are shown in cyan spheres. Polar interaction is depicted by magenta dotted line. (B) Superposition of the apo WT EGFR (white sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2">2gs2</a>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> WT EGFR-<b>43</b> complex (green sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed">5fed</a>), and EGFR T790M-<b>43</b> complex (cyan sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee">5fee</a>). Polar interactions are depicted by yellow dotted line. In both drug bound structures, <b>43</b> is shown in yellow sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although <b>43</b> demonstrated promising cellular activity, it had very low aqueous solubility (<2 μM) and poor ADME and PK properties. It is a moderate inhibitor of CYP3A4 and 2C9 with an IC<sub>50</sub> of ∼3.5 μM. It also has high intrinsic microsomal clearance,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> especially in rodents, which correlated with high in vivo clearance (CL) in mice. The high in vitro liver metabolism and poor solubility resulted in only 6% oral bioavailability in mice (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In vitro metabolism study in mouse, rat, and human liver microsomes showed that oxidation of 7-methyl groups and oxidation of acrylate groups are the two main metabolic pathways (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">Figure S1 in Supporting Information</a>). To modulate the compound’s reactivity, we first investigated a number of Michael acceptors similar to those reported in the literature.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> Amino-substituted crotonamides had been identified as optimal groups for a number of covalent pan-EGFR inhibitors (e.g., afatinib, dacomitinib, neratinib). The dimethylamino crotonamide analogue <b>44</b> retained comparable activity to <b>43</b> in H1975, but it was consistently a few fold less potent toward cell lines with oncogenic mutations (H3255 and HCC827). Conversely, it demonstrated measurable improvements in solubility and metabolic stability (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) and resulted in increased oral exposure and bioavailability in mice. Additionally, the amino-substituted crotonamide resulted in improved CYP inhibition profiles with IC<sub>50</sub> > 10 μM for CYP3A4 and 2C9.</div><div class="NLM_p">Next, we sought to improve the compound’s lipophilic efficiency (LipE)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and explore opportunities to increase activity on the oncogenic mutations while maintaining good WT EGFR selectivity. As the only difference between mutants resides at the gatekeeper residue, we investigated the SAR of the trifluorobenzamide group. In general, (hetero)alkyl and (hetero)cycloalkyl groups led to complete loss in activity (data not shown), whereas heteroaromatic groups were tolerated. In particular, the trifluoromethylpiridyl <b>45</b> demonstrated single digit nM activity on H1975 and was nearly equipotent on the activating mutations, resulting in a 10-fold potency improvement compared to <b>44</b>. It is important to note that increased potency was also observed on HaCaT but to a lesser extent than the L858R and L858R-T790M mutant cell lines. From docking and X-ray cocrystallization structures (vide infra) we believe the reason for improved activity on oncogenic and WT EGFR cell lines results from the displacement of one of the conserved water molecules by the pyridine group, with the nitrogen serving as H-bond acceptor and interacting with Thr854. The difference in the extent of increased activity toward oncogenic versus WT EGFR cell lines may be due to the difference in ATP <i>K</i><sub>m</sub> between enzymes and because the oncogenic mutations are constitutively active, whereas WT EGFR is in equilibrium between active and inactive forms.<a onclick="showRef(event, 'ref6 ref42'); return false;" href="javascript:void(0);" class="ref ref6 ref42">(6, 42)</a></div><div class="NLM_p">Although solubility was slightly improved, <b>45</b> was still relatively insoluble (12.7 μM HT-sol. at pH 6.8). Replacing the trifluoromethyl functionality by a methyl group resulted in <b>46</b>, a compound with comparable potency across mutants EGFR and selectivity against WT EGFR but with much improved water solubility (>175 μM HT-sol. at pH 6.8). Both derivatives had relatively high in vivo clearance in mice and low to moderate oral bioavailability (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). As mentioned above, one of the main metabolic soft spots was the 7-methyl group. Replacing this residue by a chloro group led to analogue <b>47</b>. Gratifyingly, <b>47</b> had single digit activity on the mutant cell lines (4, 6, 2 nM IC<sub>50</sub> in H1975, H3255, and HCC827, respectively) with less than 2-fold loss of potency on H3255 compared to <b>46</b>. At the same time, it displayed reduced activity on HaCaT (0.18 μM), providing similar WT EGFR selectivity (∼36-fold). Importantly, <b>47</b> demonstrated improved ADME and PK properties as compared to other compounds.</div><div class="NLM_p last">The chemical reactivity of <b>43</b>–<b>47</b> and potential for nonspecific covalent binding to proteins were assessed in comparison to afatinib. Upon incubation for 1 h with 10 mM glutathione (GSH) or with human liver microsomes in the presence of NADPH and GSH, compounds <b>43</b>–<b>47</b> formed only minor GSH adducts (<5%). In contrast, afatinib showed high level of GSH conjugate (60%). The much reduced reactivity of <b>43</b>–<b>47</b> toward GSH suggests a lower risk of nonspecific covalent binding to proteins.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vivo Efficacy Studies for Compound Selection</h3><div class="NLM_p">An integrated approach evaluating PK, tolerability, and efficacy was incorporated into the in vivo studies for compound selection. As such, <b>45</b>–<b>47</b> were profiled in a short-term in vivo efficacy study using a H1975 mouse xenograft model and compared to afatinib as positive control (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). In short, H1975 tumor cells were inoculated subcutaneously in Foxn1 female nude mice. Mice were then randomized into groups of 5 animals and dosed orally once daily for 5 days at 50 and 20 mg/kg or 25 mg/kg once tumors reached 150–200 mm<sup>3</sup>. Afatinib was dosed at maximum tolerated dose of 25 mg/kg. Body weight was measured daily and change in tumor volume compared to control (<i>T</i>/<i>C</i>) was assessed on days 4 and 6. Plasma samples were collected after last dose on day 5, and exposures of each compound were determined. Afatinib demonstrated tumor growth inhibition with 38% <i>T</i>/<i>C</i>, consistent with what was reported in the literature.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> All other compounds demonstrated dose-dependent efficacy with near complete regression at the highest dose tested (50 mg/kg), and free drug concentrations in plasma were well above their in vitro IC<sub>50</sub> values for at least 14 h within each dosing interval. Compound <b>47</b> was very well tolerated with body weight gains comparable to vehicle at both doses. On the other hand, <b>45</b> and <b>46</b> displayed up to 5% body weight loss.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Mouse H1975 abbreviated efficacy study. Compounds were dosed po q.d. for 5 days. Δ % body weights were recorded on day 5, and percent mean tumor volume of the drug-treated group versus mean tumor volume of the control group (<i>T</i>/<i>C</i>) was measured at end of study (day 6). (b) End of study free plasma exposure of compounds <b>45</b>–<b>47</b> for 50 mg/kg dose. Plasma PK samples were collected on day 5 at 30 min, 3 h, 7 h, and 24 h postdosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For this reason, compound <b>47</b> was further profiled in preclinical in vivo PK studies in mouse, rat, and dog (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The compound showed moderate volume of distribution and low to moderate clearance in rodents (30% and 35% of rat and mouse liver blood flow, respectively). In the dog, <b>47</b> showed high clearance and high volume of distribution. The high clearance in dog was consistent with higher in vitro dog microsomal clearance and higher fraction unbound in dog plasma as compared to other species. In contrast, the human liver microsomal CL of <b>47</b> is relatively low, and the compound is predicted to have favorable human PK profile with low to moderate clearance and good oral exposure.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vivo PK Parameters of <b>47</b> in Mouse, Rat, and Dog</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">mouse</th><th class="rowsep1 colsep0" colspan="2" align="center">rat</th><th class="rowsep1 colsep0" colspan="2" align="center">dog</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">iv<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">po<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">iv<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">po<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">iv<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">po<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">31.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">15.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">43.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">35.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h)</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">13.8</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC (h·nM)</td><td class="colsep0 rowsep0" align="left">5343</td><td class="colsep0 rowsep0" align="left">12786</td><td class="colsep0 rowsep0" align="left">6527</td><td class="colsep0 rowsep0" align="left">11951</td><td class="colsep0 rowsep0" align="left">783</td><td class="colsep0 rowsep0" align="left">5230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2938</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">987</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">435</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.83</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">67</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Free base formulated in a solution of 5% ethanol, 25% PEG300, and 70% D5W (5% dextrose in water).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">HCl salt formulated in a solution of 100% D5W (5% dextrose in water).</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">HCl salt formulated in a solution of 0.5% (w/v) aqueous methylcellulose and 0.5% Tween 80.</p></div></div></div><div class="NLM_p last">On the basis of these results, analogue <b>47</b> was selected for further profiling as described by Jia et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and was ultimately nominated as our clinical candidate after confirming adequate safety profile (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">Tables S2–S4</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Compound <b>47</b> and Close Analogue <b>46</b> Covalently Bind to Cys797</h3><div class="NLM_p">Attempts to cocrystallize <b>47</b> with various EGFR constructs have not yet been successful. Instead, we obtained cocrystals of the close analogue <b>46</b> with the EGFR T790M construct that confirmed the covalent bond to Cys797 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a). The covalent nature of <b>47</b> with EGFR L858R and EGFR T790M-L858R mutant constructs was assessed by mass spectrometry (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b,c). Incubation of <b>47</b> with both EGFR constructs resulted in one main product per protein that had an average mass 495 Da higher than the unmodified protein. This was consistent with addition of one molecule of <b>47</b> to the protein on average. LC/MS/MS of the enzymatic digests identified adducts of <b>47</b> that localized to Cys797 and Cys775. Spectral counting was used for relative comparison of adduction; 96% of MS/MS acquired for Cys797 was identified as modified with <b>47</b> (96 out of 100 spectra), while only 0.3% of Cys775 was modified (1 out of 324 spectra). The relative number of <b>47</b>-modified to total spectra for the two cysteines suggested that Cys797 is the main site of <b>47</b> modification.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds <b>46</b> and <b>47</b> bind irreversibly to EGFR constructs: (a) cocrystal structure of EGFR T790M-<b>46</b> complex; (b) deconvoluted mass spectrum of EGFR L858R-T790M after in vitro incubation with <b>47</b>; (c) MS/MS of EGFR peptide covalently modified with <b>47</b> at Cys797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46163" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46163" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the identification of a novel, covalent, mutant-selective EGFR inhibitor with nearly equipotent activity on both oncogenic (L858R and ex19del) and T790M-resistant mutations and good selectivity over WT EGFR. From a high-throughput screen, we converted a reversible mutant-selective EGFR hit (<b>7</b>) into an irreversible inhibitor lead (<b>43</b>) by carefully investigating the linker length and geometry necessary to engage Cys797. Molecular docking and metabolite identification experiments were used to increase potency on cell lines with oncogenic mutations while retaining adequate WT EGFR selectivity. Finally, we employed an abbreviated in vivo efficacy study to select <b>47</b> for further profiling and ultimately as the clinical candidate. Compound <b>47</b> is currently being tested in numerous clinical trials,<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> and it has already demonstrated encouraging efficacy in NSCLC patients with T790M mutations. As previously disclosed, efficacy was seen across all dose levels with an overall response rate of 60% and a disease control rate of 93% in early assessments.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Full results from clinical trials will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Procedures</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless otherwise noted, materials were obtained from commercial suppliers and were used without further purification. Removal of solvent under reduced pressure or concentration refers to distillation using Büchi rotary evaporator attached to a vacuum pump (3 mmHg). Products obtained as solids or high boiling oils were dried under vacuum (1 mmHg).</div><div class="NLM_p">Purification of compounds by preparative RP-HPLC was achieved using a Waters autopurification system consisting of a 2767 autosampler/fraction collector, a 2525 binary gradient module, a 2487 UV detector, and a ZQ mass spectrometer. Compounds were purified using flow rate of 30 mL/min with a 50 mm × 20 mm i.d. Ultra 120 5 μm C18Q column (Peeke Scientific, Novato, CA). A 7.5 min linear gradient from 10% solvent A (acetonitrile with 0.035% trifluoroacetic acid) in solvent B (water with 0.05% trifluoroacetic acid) to 30–90% A was used, followed by a 2.5 min hold at 90% A. Silica gel chromatography was performed by CombiFlash (separation system Sg. 100c, ISCO). Elemental analyses were carried out by Midwest Microlabs LLC, Indianapolis, IN. <sup>1</sup>H NMR spectra were recorded on Bruker XWIN-NMR (400 MHz) spectrometer. Proton resonances are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). <sup>1</sup>H NMR data are reported as multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; br s, broad singlet). For spectra obtained in CDCl<sub>3</sub>, DMSO-<i>d</i><sub>6</sub>, CD<sub>3</sub>OD, CD<sub>3</sub>CN the residual protons (7.27, 2.50, 3.31, and 1.94 ppm, respectively) were used as the internal reference. In general, peaks associated with the azepane and (hetero)aromatic rings display two distinct sets of peaks (approximately 50:50 intensity) in spectra acquired at 300 K (atropoisomers). The peaks collapse to a single set at higher temperature (383 K) (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">Figures S2 and S3</a> for <sup>1</sup>H and <sup>13</sup>C NMR spectra of <b>47</b>). Optical rotations were measured at the sodium D line, using an ATAGO POLAX-2L polarimeter and a 100 mm cell at 23 °C and are reported as follows: concentration (<i>c</i> = g/100 mL), solvent.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Purity of Compounds</h3><div class="NLM_p last">All final compounds were analyzed with a Waters ZQ 2000 LC/MS system, which used an Agilent binary pump or Shimadzu LC10 and Agilent photodiode array detector (PDA) along with a Sedere 75 evaporative light scattering detector (ELSD). Samples were injected from 96-well or 384-well plates with a Leap Technologies HTS Pal autosampler. The mobile phases used were (A) H<sub>2</sub>O + 0.05% TFA and (B) acetonitrile + 0.05% TFA. A gradient HPLC method with flow of 1.0 mL/min started at 5% B, with a hold of 0.1 min before a linear increase to 90% B at 2.60 min. At 2.71 min the B mobile phase was increased to 100% and held until 2.98 min before returning to 5% B at 2.99 min. Total run time was 3.0 min. The column was re-equilibrated in the time between injections. The column used was a Waters Atlantis dC18 2.1 mm × 30 mm, 3 μm. The mass spectrometer was operated in positive mode, with a spray voltage of 3.2 kV and cone voltage of 30 V. The source and desolvation temperatures were 130 and 400 °C, respectively, with 600 L/h of nitrogen desolvation flow. The progress of reactions and the purity of products were measured using 254 and 214 nm wavelengths and electrospray ionization (ESI) positive or negative mode. Mass spectra were obtained in ESI positive or negative mode. All of the final compounds were found to be >95% when analyzed at either the 254 or 214 nm wavelengths. Chiral compounds were also analyzed by chiral HPLC or chiral SFC and demonstrated to have at least 95% ee.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure for the Synthesis of Compounds <b>13</b>–<b>17</b>, <b>29a</b>–<b>o</b>, <b>29r</b>, <b>35</b>, and <b>36</b></h3><div class="NLM_p last">A solution of the desired 1-fluoro-2-nitroarene <b>8</b>–<b>12</b> or <b>33</b> (1–1.5 equiv) in a suitable solvent, such as DMF or DMA (0.2–0.8 M), or neat was treated with the requisite amine (1 equiv) and a base such as DIPEA or K<sub>2</sub>CO<sub>3</sub> (1.5–4 equiv), and the reaction mixture was warmed to 110–140 °C for 2–16 h. The reaction mixture was then cooled to room temperature and partitioned between water and EtOAc. The aqueous layer was extracted twice more with EtOAc, and the pooled extracts were washed consecutively with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to afford the desired nitroanilines (<b>13</b>–<b>17</b>, <b>29a</b>–<b>o</b>, <b>29r</b>, <b>35</b>, and <b>36</b>).</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> <i>trans</i>-4-((2-Nitrophenyl)amino)cyclohexan-1-ol (<b>13</b>)</h3><div class="NLM_p last">Yield, 69%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>trans</i>-4-((3-Methyl-2-nitrophenyl)amino)cyclohexan-1-ol (<b>14</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 11.98 (s, 1H), 7.26 (t, <i>J</i> = 8.3 Hz, 1H), 6.85 (d, <i>J</i> = 8.3 Hz, 1H), 6.54 (d, <i>J</i> = 7.3 Hz, 1H), 6.08 (d, <i>J</i> = 7.9 Hz, 1H), 4.58 (m, 1H), 3.42 (m, 1H), 2.29 (s, 3H), 2.15 (m, 2H), 1.95 (m, 2H), 1.82 (m, 2H), 1.25 (m, 2H). MS calculated for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub> (M – H)<sup>−</sup> 249.13, found 249.0.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>trans</i>-4-((4-Methyl-2-nitrophenyl)amino)cyclohexan-1-ol (<b>15</b>)</h3><div class="NLM_p last">Yield, 35%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.97 (s, 1H), 7.25 (d, <i>J</i> = 8.3 Hz, 1H), 6.78 (d, <i>J</i> = 8.8 Hz, 1H), 3.82 (m, 1H), 3.45 (m, 1H), 2.25 (s, 3H), 2.21 (m, 2H), 2.05 (m, 2H), 1.52 (m, 4H). MS calculated for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub> (M – H)<sup>−</sup> 249.13, found 248.9.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>trans</i>-4-((5-Methyl-2-nitrophenyl)amino)cyclohexan-1-ol (<b>16</b>)</h3><div class="NLM_p last">Yield, 68%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.05 (d, <i>J</i> = 7.5 Hz, 1H), 6.61 (s, 1H), 6.42 (d, <i>J</i> = 7.5 Hz, 1H), 3.78 (m, 1H), 3.45 (m, 1H), 2.35 (s, 3H), 2.15 (m, 4H), 1.55 (m, 4H). MS calculated for C<sub>13</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 251.13, found 251.3.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>trans</i>-4-((2-Methyl-6-nitrophenyl)amino)cyclohexan-1-ol (<b>17</b>)</h3><div class="NLM_p last">Yield, 68%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.78 (d, <i>J</i> = 7.4 Hz, 1H), 7.45 (d, <i>J</i> = 6.9 Hz, 1H), 6.89 (t, <i>J</i> = 7.8 Hz, 1H), 6.13 (d, <i>J</i> = 9.8 Hz, 1H), 4.54 (d, <i>J</i> = 4.4 Hz, 1H), 3.38 (m, 1H), 3.33 (m, 1H), 2.32 (s, 3H), 1.77 (m, 4H), 1.19 (m, 4H). MS calculated for C<sub>13</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> (M + H)<sup>+</sup> 251.13, found 251.2.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>tert</i>-Butyl (2-((4-Methyl-2-nitrophenyl)amino)ethyl)carbamate (<b>29a</b>)</h3><div class="NLM_p last">Yield, 43%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>tert</i>-Butyl (3-((4-Methyl-2-nitrophenyl)amino)propyl)carbamate (<b>29b</b>)</h3><div class="NLM_p last">Yield, 45%. MS calculated for C<sub>15</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 310.18, found 310.2.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>tert</i>-Butyl 3-((4-Methyl-2-nitrophenyl)amino)azetidine-1-carboxylate (<b>29c</b>)</h3><div class="NLM_p last">Yield, 56%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.05 (s, 1H), 8.01 (s, 1H), 7.30 (d, <i>J</i> = 7.9 Hz, 1H), 6.44 (d, <i>J</i> = 8.3 Hz, 1H), 4.38 (m, 2H), 4.32 (m, 1H), 3.87 (m, 2H), 2.29 (s, 3H), 1.46 (s, 9H). MS calculated for C<sub>15</sub>H<sub>21</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 308.15, found 308.3.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 3-((4-Methyl-2-nitrophenyl)amino)pyrrolidine-1-carboxylate (<b>29d</b>)</h3><div class="NLM_p last">Yield, 66%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 3-((4-Methyl-2-nitrophenyl)amino)piperidine-1-carboxylate (<b>29e</b>)</h3><div class="NLM_p last">Yield, 65%. MS calculated for C<sub>17</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 336.19, found 336.1.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>tert</i>-Butyl 4-((4-Methyl-2-nitrophenyl)amino)piperidine-1-carboxylate (<b>29f</b>)</h3><div class="NLM_p last">Yield, 78%.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl 3-((4-Methyl-2-nitrophenyl)amino)azepane-1-carboxylate (<b>29g</b>)</h3><div class="NLM_p last">Yield, 93%. MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.21, found 350.1.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>tert</i>-Butyl 4-((4-Methyl-2-nitrophenyl)amino)azepane-1-carboxylate (<b>29h</b>)</h3><div class="NLM_p last">Yield, 88%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.04 (d, <i>J</i> = 7.3 Hz, 1H), 7.98 (s, 1H), 6.70 (d, <i>J</i> = 8.8 Hz, 1H), 3.21–3.75 (m, 5H), 2.31 (s, 3H), 1.61–2.05 (m, 6H), 1.53 (s, 9H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.20, found 350.2.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>tert</i>-Butyl (3-((4-Methyl-2-nitrophenyl)amino)cyclopentyl)carbamate (<b>29i</b>)</h3><div class="NLM_p last">Yield, 54%. MS calculated for C<sub>17</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 336.19, found 336.2.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>tert</i>-Butyl <i>cis</i>-(2-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29j</b>)</h3><div class="NLM_p last">Yield, 53%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.31 (d, <i>J</i> = 8.3 Hz, 1H), 7.98 (s, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 6.85 (d, <i>J</i> = 8.8 Hz, 1H), 4.55–4.75 (m, 1H), 3.98–4.18 (m, 1H), 3.75–3.95 (m, 1H), 2.25 (s, 3H), 1.45–1.81 (m, 8H), 1.39 (s, 9H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.20, found 350.2.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>tert</i>-Butyl <i>trans</i>-(2-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29k</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.17 (d, <i>J</i> = 7.4 Hz, 1H), 7.96 (s, 1H), 7.24 (d, <i>J</i> = 8.3 Hz, 1H), 6.87 (d, <i>J</i> = 8.8 Hz, 1H), 4.4–4.5 (m, 1H), 3.31–3.75 (m, 2H), 2.25 (s, 3H), 2.05–2.21 (m, 4H), 1.22–1.85 (m, 4H), 1.25 (s, 9H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.20, found 350.2.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>tert</i>-Butyl <i>cis</i>-(3-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29l</b>)</h3><div class="NLM_p last">Yield, 46%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.86 (s, 1H), 7.79 (d, <i>J</i> = 8.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.07 (d, <i>J</i> = 8.8 Hz, 1H), 6.83 (d, <i>J</i> = 7.6 Hz, 1H), 3.66–3.64 (m, 1H), 3.41–3.37 (m, 1H), 2.22 (s, 3H), 2.11 (d, <i>J</i> = 11.2 Hz, 1H), 1.95 (d, <i>J</i> = 12.0 Hz, 1H), 1.80–1.71 (m, 2H), 1.37 (s, 9H), 1.23–1.05 (m, 1H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.21 found 350.1.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>tert</i>-Butyl <i>trans</i>-(3-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29m</b>)</h3><div class="NLM_p last">Yield, 34%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.86 (s, 1H), 7.79 (d, <i>J</i> = 7.8 Hz, 1H), 7.38 (d, <i>J</i> = 8.3 Hz, 1H), 7.07 (d, <i>J</i> = 8.8 Hz, 1H), 6.84 (d, <i>J</i> = 7.8 Hz, 1H), 3.55–3.75 (m, 1H), 3.31–3.42 (m, 1H), 2.22 (s, 3H), 1.62–2.19 (m, 4H), 1.45 (s, 9H), 1.05–1.25 (m, 4H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.20, found 350.1.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>tert</i>-Butyl <i>cis</i>-(4-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29n</b>)</h3><div class="NLM_p last">Yield, 62%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.25 (br s, 1H), 8.15 (s, 1H), 7.25 (d, <i>J</i> = 9.3 Hz, 1H), 6.77 (d, <i>J</i> = 8.8 Hz, 1H), 4.45–4.61 (m, 1H), 3.51–3.79 (m, 2H), 2.26 (s, 3H), 1.65–1.95 (m, 8H), 1.45 (s, 9H).</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>tert</i>-Butyl <i>trans</i>-(4-((4-Methyl-2-nitrophenyl)amino)cyclohexyl)carbamate (<b>29o</b>)</h3><div class="NLM_p last">Yield, 78%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.85 (s, 1H), 7.80 (d, <i>J</i> = 7.8 Hz, 1H), 7.35 (d, <i>J</i> = 7.5 Hz, 1H), 7.12 (d, <i>J</i> = 7.9 Hz, 1H), 6.81 (d, <i>J</i> = 7.5 Hz, 1H), 3.41–3.58 (m, 1H), 3.19–3.31 (m, 1H), 2.21 (s, 3H), 1.75–2.15 (m, 4H), 1.41 (s, 9H), 1.21–1.45 (m, 4H).</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>tert</i>-Butyl Methyl(3-((4-methyl-2-nitrophenyl)amino)phenyl)carbamate (<b>29r</b>)</h3><div class="NLM_p last">Yield, 33%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.17 (s, 1H), 7.93 (s, 1H), 7.38–7.05 (m, 6H), 3.18 (s, 3H), 2.27 (s, 3H), 1.39 (s, 9H). MS calculated for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>4</sub> (M – H)<sup>−</sup> 356.16, found 356.2.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>R</i>)-<i>tert</i>-Butyl 3-((2-Methyl-6-nitrophenyl)amino)azepane-1-carboxylate (<b>35</b>)</h3><div class="NLM_p last">Yield, 60%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.93–7.87 (m, 1H), 7.37–7.31 (m, 1H), 6.91–6.79 (m, 1.5H), 6.50–6.47 (m, 0.5H), 3.88–3.76 (m, 2H), 3.57–3.52 (m, 1H), 3.22–2.78 (m, 2H), 2.43–2.41 (m, 3H), 1.92–1.60 (m, 5H), 1.47–1.38 (m, 10H). MS calculated for C<sub>18</sub>H<sub>28</sub>N<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 350.20, found 350.0. [α]<sub>D</sub><sup>23</sup> +71.42° (<i>c</i> 0.420, MeOH).</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>R</i>)-<i>tert</i>-Butyl 3-((2-Chloro-6-nitrophenyl)amino)azepane-1-carboxylate (<b>36</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.00–7.91 (m, 1H), 7.58–7.49 (m, 1H), 7.02–6.51 (m, 2H), 4.31–4.03 (m, 1H), 3.84–2.98 (m, 4H), 1.98–1.60 (m, 5H), 1.46–1.39 (m, 10H). MS calculated for C<sub>17</sub>H<sub>25</sub>ClN<sub>3</sub>O<sub>4</sub> (M + H)<sup>+</sup> 370.15, found 370.10. [α]<sub>D</sub><sup>23</sup> −95.06° (<i>c</i> 0.263, MeOH).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> General Procedure for the Synthesis of Compounds <b>29p</b>–<b>q</b> and <b>29s</b>. Synthesis of <i>tert-</i>Butyl (3-((4-Methyl-2-nitrophenyl)amino)phenyl)carbamate (<b>29q</b>)</h3><div class="NLM_p last">A 100 mL round-bottom flask was charged with 1-fluoro-4-methyl-2-nitrobenzene (3.4 g, 22.08 mmol) and 1,3-phenylenediamine (2.0 g, 18.40 mmol), and the neat mixture was warmed to 150 °C for 3 h. The reaction mixture was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and purified by silica gel chromatography: 0–30% EtOAc/hexanes gradient. The resulting <i>N</i><sup>1</sup>-(4-methyl-2-nitrophenylbenzene-1,3-diamine was dissolved in 1,4-dioxane (10 mL) and treated with (Boc)<sub>2</sub>O (4.66 g, 21.3 mmol) and Et<sub>3</sub>N (4.4 mL, 31.8 mmol). The red solution was stirred for 24 h at room temperature and then diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and washed with water. The resulting organic layer was separated, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to a viscous red residue, which was purified by silica gel chromatography (0–30% EtOAc/hexanes gradient) to afford <i>tert</i>-butyl (3-((4-methyl-2-nitrophenyl)amino)phenyl)carbamate <b>29q</b> (1.5 g, 20%). MS calculated for C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> (M – H)<sup>−</sup> 342.15, found 342.1.</div></div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>tert-</i>Butyl (2-((4-Methyl-2-nitrophenyl)amino)phenyl)carbamate (<b>29p</b>)</h3><div class="NLM_p last">Yield, 22%. MS calculated for C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>4</sub> (M – H)<sup>−</sup> 342.15, found 342.1.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>tert-</i>Butyl (4-((4-Methyl-2-nitrophenyl)amino)phenyl)carbamate (<b>29s</b>)</h3><div class="NLM_p last">Yield, 31%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.41 (br s, 1H), 9.24 (s, 1H), 7.91 (s, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.31 (dd, <i>J</i> = 9.8 Hz, 2.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 2H), 6.99 (d, <i>J</i> = 8.8 Hz, 1H), 2.25 (s, 3H), 1.47 (s, 9H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> General Procedure for the Synthesis of Compounds <b>18</b>–<b>22</b>, <b>30a</b>–<b>s</b>, and <b>37</b>. Synthesis of <i>trans</i>-4-(2-Amino-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexan-1-ol (<b>18</b>)</h3><div class="NLM_p last">A solution of <b>13</b> (350 mg, 1.48 mmol) in methanol (15 mL) was degassed with nitrogen, treated with Pd/C (55 mg, 15.7 mol %), and then stirred under H<sub>2</sub> atmosphere for 1 h. The reaction mixture was filtered through Celite, the Celite rinsed with MeOH (40 mL), and the filtrate concentrated under reduced pressure to afford a crude residue, which was dissolved in water (1 mL) and added to a solution of cyanogen bromide (185 mg, 1.75 mmol) in MeOH/MeCN (3:1, 4 mL). The reaction mixture was then warmed to 50 °C for 2 h, cooled to 0 °C, treated with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> to pH 10, and then stirred for 30 min while warming to room temperature. The resulting suspension was filtered and dried under high vacuum to afford <b>18</b> (280 mg, 77%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.33 (d, <i>J</i> = 7.8 Hz, 1H), 7.11 (d, <i>J</i> = 7.4 Hz, 1H), 6.91 (t, <i>J</i> = 7.4 Hz, 1H), 6.82 (t, <i>J</i> = 7.8 Hz, 1H), 6.34 (br s, 2H), 4.58–4.67 (m, 1H), 4.15–4.24 (m, 1H), 3.55–3.73 (m, 1H), 2.11–2.35 (m, 2H), 1.85–2.01 (m, 2H), 1.31–1.51 (m, 2H).</div></div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>trans</i>-4-( 2-Amino-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexan-1-ol (<b>19</b>)</h3><div class="NLM_p last">Yield, 26%.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>trans</i>-4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexan-1-ol (<b>20</b>)</h3><div class="NLM_p last">Yield, 91%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.17 (d, <i>J</i> = 7.8 Hz, 1H), 6.91 (s, 1H), 6.63 (d, <i>J</i> = 8.3 Hz, 1H), 6.20 (br s, 2H), 4.65 (m, 1H), 4.15 (m, 1H), 2.65 (m, 1H), 2.28 (s, 3H), 2.21 (m, 2H), 1.85 (m, 2H), 1.65 (m, 2H), 1.41 (m, 2H). MS calculated for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O (M + H)<sup>+</sup> 246.15, found 246.2.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>trans</i>-4-(2-Amino-6-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexan-1-ol (<b>21</b>)</h3><div class="NLM_p last">Yield, 67%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.13 (s, 1H), 6.98 (d, <i>J</i> = 7.9 Hz, 1H), 6.71 (d, <i>J</i> = 7.9 Hz, 1H), 6.18 (br s, 2H), 4.68 (br s, 1H), 4.15 (m, 1H), 3.65 (m, 1H), 2.33 (s, 3H), 2.11 (m, 2H), 1.95 (m, 2H), 1.66 (m, 2H), 1.42 (m, 2H). MS calculated for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O (M + H)<sup>+</sup> 246.15, found 246.1.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>trans</i>-4-(2-Amino-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexan-1-ol (<b>22</b>)</h3><div class="NLM_p last">Yield, 33%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 6.95 (d, <i>J</i> = 7.9 Hz, 1H), 6.80 (t, <i>J</i> = 7.3 Hz, 1H), 6.61 (d, <i>J</i> = 7.4 Hz, 1H), 5.97 (br s, 2H), 4.55 (m, 1H), 3.63 (m, 1H), 2.57 (s, 3H), 2.26 (m, 2H), 1.95 (m, 2H), 1.72 (m, 2H), 1.35 (m, 2H). MS calculated for C<sub>14</sub>H<sub>20</sub>N<sub>3</sub>O (M + H)<sup>+</sup> 246.15, found 246.1.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>tert</i>-Butyl (2-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)ethyl)carbamate (<b>30a</b>)</h3><div class="NLM_p last">Yield, 80%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 6.98 (d, <i>J</i> = 7.5 Hz, 1H), 6.94 (s, 1H), 6.85 (m, 1H), 6.65 (d, <i>J</i> = 7.5 Hz, 1H), 6.21 (br s, 2H), 3.98 (m, 2H), 3.18 (m, 2H), 2.31 (s, 3H), 1.35 (s, 9H).</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>tert</i>-Butyl (3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)propyl)carbamate (<b>30b</b>)</h3><div class="NLM_p last">Yield, 84%. MS calculated for C<sub>16</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 305.20, found 305.2.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>tert</i>-Butyl 3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azetidine-1-carboxylate (<b>30c</b>)</h3><div class="NLM_p last">Yield, 81%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.00 (s, 1H), 6.74 (d, <i>J</i> = 7.8 Hz, 1H), 6.31 (br s, 2H), 5.24 (m, 1H), 4.31 (m, 4H), 2.32 (s, 3H), 1.45 (s, 9H).</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)pyrrolidine-1-carboxylate (<b>30d</b>)</h3><div class="NLM_p last">Yield, 78%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.04 (d, <i>J</i> = 7.8 Hz, 1H), 6.96 (s, 1H), 6.66 (d, <i>J</i> = 7.9 Hz, 1H), 6.34 (br s, 2H), 4.98 (m, 1H), 3.62 (m, 4H), 2.21 (m, 1H), 2.29 (s, 3H), 2.13 (m, 1H), 1.45 (s, 9H).</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)piperidine-1-carboxylate (<b>30e</b>)</h3><div class="NLM_p last">Yield, 64%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.24 (s, 1H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 6.85 (d, <i>J</i> = 8.0 Hz, 1H), 4.64 (br s, 2H), 4.17 (t, <i>J</i> = 14.8 Hz, 2H), 3.99–3.93 (m, 1H), 3.32 (d, <i>J</i> = 11.6 Hz, 1H), 2.79 (t, <i>J</i> = 12.4 Hz, 1H), 2.41 (s, 3H), 2.38–2.37 (m, 1H), 2.34 (d, <i>J</i> = 3.2 Hz, 1H), 1.91 (d, <i>J</i> = 13.6 Hz, 1H), 1.69–1.61 (m, 1H), 1.47 (s, 9H). MS calculated for C<sub>18</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 331.21, found 331.0.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>tert</i>-Butyl 4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)piperidine-1-carboxylate (<b>30f</b>)</h3><div class="NLM_p last">Yield, 72%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.55 (d, <i>J</i> = 7.5 Hz, 1H), 7.41 (m, 2H), 7.07 (s, 1H), 6.86 (d, <i>J</i> = 8.3 Hz, 1H), 4.2–4.4 (m, 1H), 3.82–4.02 (m, 2H), 3.31–3.3.45 (m, 1H), 2.79–3.01 (m, 1H), 2.34 (s, 3H), 2.19–2.38 (m, 1H), 1.78–1.99 (m, 2H), 1.43–1.61 (m, 1H), 1.1 (s, 9H). MS calculated for C<sub>18</sub>H<sub>27</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 331.21, found 331.3.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>30g</b>)</h3><div class="NLM_p last">Yield, 91%. <sup>1</sup>H NMR (DMSO-d6, 400 MHz): δ 7.15–7.12 (m, 1H), 6.93 (s, 1H), 6.66 (d, <i>J</i> = 7.6 Hz, 1H), 6.26 (s, 2H), 4.29 (br s, 1H), 3.81–3.75 (m, 1H), 3.55–3.36 (m, 3H), 2.29 (s, 3H), 2.08 (s, 2H), 1.86–1.68 (m, 5H), 1.40 (s, 9H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.23, found 345.1.</div></div><div id="sec4_4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>tert</i>-Butyl 4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>30h</b>)</h3><div class="NLM_p last">Yield, 94%. MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.22, found 345.1.</div></div><div id="sec4_4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>tert</i>-Butyl (3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclopentyl)carbamate (<b>30i</b>)</h3><div class="NLM_p last">Yield, 77%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.55 (br s, 1H), 7.93 (br s, 2H), 7.42 (d, <i>J</i> = 8.2 Hz, 1H), 7.21 (d, <i>J</i> = 1.4 Hz, 1H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 4.88–4.71 (m, 1H), 3.99–3.79 (m, 1H), 2.40 (s, 3H), 2.25–1.81 (m, 6H), 1.40 (s, 9H).</div></div><div id="sec4_4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>tert</i>-Butyl <i>cis</i>-(2-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30j</b>)</h3><div class="NLM_p last">Yield, 77%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.19 (s, 1H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 6.82 (d, <i>J</i> = 7.8 Hz, 1H), 4.81 (br s, 2H), 4.21–4.39 (m, 1H), 4.01–4.19 (m, 1H), 2.47–2.61 (m, 1H), 2.38 (s, 3H), 1.35–2.12 (m, 6H), 1.05 (s, 9H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.22, found 345.0.</div></div><div id="sec4_4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>tert</i>-Butyl <i>trans</i>-(2-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30k</b>)</h3><div class="NLM_p last">Yield, 75%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.32 (d, <i>J</i> = 7.3 Hz, 1H), 7.26 (s, 1H), 7.02 (d, <i>J</i> = 7.8 Hz, 1H), 4.81–4.95 (m, 1H), 4.41–4.50 (m, 1H), 4.01–4.15 (m, 1H), 3.61 (m, 1H), 3.15–3.31 (m, 1H), 2.41 (s, 3H), 1.62–2.19 (m, 4H), 1.11–1.38 (m, 4H), 1.42 (s, 9H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.22, found 345.0.</div></div><div id="sec4_4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>tert</i>-Butyl <i>cis</i>-(3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30l</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6,</sub> 400 MHz): δ 7.12 (d, <i>J</i> = 8.0 Hz, 1H), 6.93 (s, 1H), 6.83 (d, <i>J</i> = 7.6 Hz, 1H), 6.66 (t, <i>J</i> = 6.8 Hz, 1H), 6.26 (s, 2H), 4.21 (dd, <i>J</i> = 3.6 Hz, 1H), 3.52–3.31 (m, 1H), 2.28 (s, 3H), 2.07–1.94 (m, 2H), 1.81 (d, <i>J</i> = 10.4 Hz, 2H), 1.66 (d, <i>J</i> = 11.6 Hz, 1H), 1.36 (s, 9H), 1.28–1.20 (m, 3H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.23, found 345.0.</div></div><div id="sec4_4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>tert</i>-Butyl <i>trans</i>-(3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30m</b>)</h3><div class="NLM_p last">Yield, 95%.</div></div><div id="sec4_4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>tert</i>-Butyl <i>cis</i>-(4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30n</b>)</h3><div class="NLM_p last">Yield, 98%.</div></div><div id="sec4_4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>tert</i>-Butyl <i>trans</i>-(4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>30o</b>)</h3><div class="NLM_p last">Yield, 95%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.22 (d, <i>J</i> = 7.8 Hz, 1H), 6.92 (s, 1H), 6.81 (d, <i>J</i> = 7.5 Hz, 1H), 6.41 (d, <i>J</i> = 7.5 Hz, 1H), 6.25 (br s, 2H), 4.15 (m, 1H), 3.41 (m, 1H), 2.35 (s, 3H), 2.21 (m, 2H), 1.95 (m, 2H), 1.85 (m, 2H), 1.41 (s, 9H), 1.39 (m, 2H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.2, found 345.2.</div></div><div id="sec4_4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>tert</i>-Butyl (2-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>30p</b>)</h3><div class="NLM_p last">Yield, 96%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 8.28 (s, 1H), 7.75 (d, <i>J</i> = 8.2 Hz, 1H), 7.45 (m, 1H), 7.27 (m, 2H), 7.02 (s, 1H), 6.63 (d, <i>J</i> = 7.9 Hz, 1H), 6.47 (d, <i>J</i> = 7.6 Hz, 1H), 5.99 (br s, 2H), 2.32 (s, 3H), 1.45 (s, 9H). MS calculated for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 339.15, found 339.3.</div></div><div id="sec4_4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>tert</i>-Butyl (3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>30q</b>)</h3><div class="NLM_p last">Yield, 93%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.61(s, 1H), 7.48–7.39 (m, 2H), 7.25 (d, <i>J</i> = 10.4 Hz, 1H), 7.10 (t, <i>J</i> = 1.6 Hz, 1H), 6.95–6.85 (m, 3H), 2.41 (s, 3H), 2.17 (s, 2H), 1.51 (s, 9H). MS calculated for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 339.18, found 339.1.</div></div><div id="sec4_4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> <i>tert</i>-Butyl (3-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)(methyl)carbamate (<b>30r</b>)</h3><div class="NLM_p last">Yield, 93%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 7.55 (t, <i>J</i> = 8.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.4 Hz, 1H), 7.37 (s, 1H), 7.24 (d, <i>J</i> = 7.2 Hz, 1H), 7.03 (s, 1H), 6.77 (t, <i>J</i> = 8.4 Hz, 1H), 6.68–6.19 (m, 1H), 6.19 (s, 2H), 3.26 (s, 3H), 2.32 (s, 3H), 1.42 (s, 9H). MS calculated for C<sub>20</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 353.20, found 353.0.</div></div><div id="sec4_4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>tert</i>-Butyl (4-(2-Amino-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>30s</b>)</h3><div class="NLM_p last">Yield, 80%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.64 (br s, 1H), 7.67 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (m, 2H), 7.07 (s, 1H), 6.61–6.80 (m, 4H), 2.38 (s, 3H), 1.45 (s, 9H).</div></div><div id="sec4_4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>tert</i>-Butyl (<i>R</i>)-3-(2-Amino-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>37</b>)</h3><div class="NLM_p last">Yield, 86%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 6.99 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 6.83 (t, <i>J</i> = 7.6 Hz, 1H), 6.72–6.56 (m, 1H), 6.07 (d, <i>J</i> = 20.8 Hz, 2H), 4.84–4.58 (m, 1H), 3.85–3.61 (m, 2H), 3.59–3.47 (m, 1H), 3.36 (dt, <i>J</i> = 16.1, 5.8 Hz, 1H), 2.59 (d, <i>J</i> = 9.2 Hz, 3H), 2.31–2.14 (m, 1H), 1.97–1.69 (m, 5H), 1.44 (s, 5H), 1.32 (s, 4H). MS calculated for C<sub>19</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 345.22, found 345.2. [α]<sub>D</sub><sup>23</sup> +74.07° (<i>c</i> 0.272, MeOH).</div></div><div id="sec4_4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>tert</i>-Butyl (<i>R</i>)-3-(2-Amino-7-chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>38</b>)</h3><div class="NLM_p last">A mixture of <b>36</b> (7.5 g, 19.5 mmol) and Zn (12.8 g, 195 mmol) in AcOH (22 mL) was stirred at room temperature for 2 h. The reaction was basified with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>, filtered and the filtrate extracted with EtOAc (3 × 80 mL). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to afford <i>tert</i>-butyl (<i>R</i>)-3-((2-amino-6-chlorophenyl)amino)azepane-1-carboxylate (6.62 g, 19.48 mmol), which was immediately dissolved in MeOH (200 mL) and treated with a solution of cyanogen bromide (3.09 g, 29.22 mmol) in H<sub>2</sub>O (75 mL) and MeCN (75 mL). The reaction mixture was stirred at 50 °C for 6 h, concentrated under reduced pressure, basified with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>, and then extracted with EtOAc (3 × 90 mL). The combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The crude material was purified by HPLC to afford <b>38</b> (3.3 g, 46%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.34–7.26 (m, 1H), 7.04–6.97 (m, 2H), 6.05–5.85 (m, 1H), 5.84–5.72 (m, 1H), 5.50–5.37 (m, 0.5H), 5.10–4.80 (m, 0.5H), 4.41–4.23 (m, 1H), 4.09–3.96 (m, 0.5H), 3.94–3.81 (m, 1H), 3.76–3.57 (m, 1H), 3.22–3.14 (m, 0.5H), 2.84–2.63 (m, 1H), 2.34–2.17 (m, 1H), 2.07–1.84 (m, 1H), 1.82–1.64 (m, 2H), 1.53 (s, 9H), 1.48–1.37 (m, 1H). MS calculated for C<sub>18</sub>H<sub>26</sub>ClN<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 365.17, found 365.1. [α]<sub>D</sub><sup>23</sup> +71.17° (<i>c</i> 0.281, MeOH).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> General Procedure for the Synthesis of Compounds <b>23</b>–<b>27</b>, <b>31a</b>–<b>s</b>, and <b>39</b>–<b>42</b>. Synthesis of <i>N</i>-(1-(<i>trans</i>-4-Hydroxycyclohexyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>23</b>)</h3><div class="NLM_p last">To a solution of <b>18</b> (100 mg, 0.433 mmol) and 3-(trifluoromethyl)benzoic acid (82 mg, 0.433 mmol) in DMF (5 mL) were added HATU (197 mg, 0.519 mmol) and DIPEA (167 mg, 1.30 mmol), and the reaction mixture was stirred at room temperature for 14 h. The reaction mixture was then diluted with water (20 mL), extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL), and the pooled organics were washed with water and then brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The material thus obtained was purified by silica gel chromatography (0–2% MeOH in CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford <b>23</b> (110 mg, 64%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.91 (s, 1H), 8.52 (m, 2H), 7.93 (m, 1H), 7.80 (m, 1H), 7.75 (m, 1H), 7.61 (m, 1H), 7.27 (m, 2H), 4.79 (m, 2 H), 3.72 (m, 1H), 2.59 (m, 2H), 2.06 (d, <i>J</i> = 10.4 Hz, 2H), 1.84 (d, <i>J</i> = 12.4, 2H), 1.49 (m, 2H). MS calculated for C<sub>21</sub>H<sub>21</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup> 404.16, found 403.9.</div></div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>-(1-(<i>trans</i>-4-Hydroxycyclohexyl)-4-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>24</b>)</h3><div class="NLM_p last">Yield, 20%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.44 (s, 1H), 8.49 (m, 2H), 7.92 (m, 1H), 7.77 (m, 1H), 7.58 (d, <i>J</i> = 7.6 Hz, 1H), 7.20 (m, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 4.76 (m, 2H), 3.68 (m, 1H), 2.51 (m, 2H), 2.50 (s, 3H), 2.02 (d, <i>J</i> = 10.4 Hz, 2H), 1.81 (d, <i>J</i> = 11.2 Hz, 2H), 1.46 (m, 2H). MS calculated for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup> 418.17, found 418.0.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> <i>N</i>-(1-(<i>trans</i>-4-Hydroxycyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>25</b>)</h3><div class="NLM_p last">Yield, 18%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.79 (s, 1H), 8.48 (m, 2H), 7.89 (d, <i>J</i> = 7.2 Hz, 1H), 7.75 (t, <i>J</i> = 8.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (s, 1H), 7.07 (d, <i>J</i> = 8.0 Hz, 1H), 4.75 (m, 2H), 3.68 (m, 1H), 2.61 (m, 2H), 2.39 (s, 3H), 2.02 (d, <i>J</i> = 10.4 Hz, 2H), 1.79 (d, <i>J</i> = 11.2 Hz, 2H), 1.43 (m, 2H). MS calculated for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup> 418.17, found 418.2.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>N</i>-(1-(<i>trans</i>-4-Hydroxycyclohexyl)-6-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>26</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.79 (s, 1H), 8.48 (m, 2H), 7.90 (d, <i>J</i> = 7.2 Hz, 1H), 7.75 (t, <i>J</i> = 8.0 Hz, 1H), 7.54 (s, 1H), 7.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 4.77 (m, 1H), 4.74 (br s, 1H), 3.70 (m, 1H), 2.56 (m, 2H), 2.43 (s, 3H), 2.03 (d, <i>J</i> = 10.0 Hz, 2H), 1.79 (d, <i>J</i> = 10.8 Hz, 2H), 1.46 (m, 2H). MS calculated for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup> 418.17, found 418.1.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>N</i>-(1-(<i>trans</i>-4-Hydroxycyclohexyl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>27</b>)</h3><div class="NLM_p last">Yield, 39%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.93 (s, 1H), 8.52 (s, 1H), 8.43 (d, <i>J</i> = 7.6 Hz, 1H), 7.90 (d, <i>J</i> = 7.6 Hz, 1H), 7.77 (t, <i>J</i> = 7.6 Hz, 1H), 7.46 (d, <i>J</i> = 7.2 Hz, 1H), 7.12 (t, <i>J</i> = 7.2 Hz, 1H), 7.03 (d, <i>J</i> = 7.2 Hz, 1H), 4.76 (m, 1H), 4.74 (br s, 1H), 3.64 (m, 1H), 3.00 (q, <i>J</i> = 12.0 Hz, 2H), 2.71 (s, 3H), 2.03 (d, <i>J</i> = 10.4 Hz, 2H), 1.89 (d, <i>J</i> = 11.6 Hz, 2H), 1.41 (m, 2H). MS calculated for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (M + H)<sup>+</sup> 418.17, found 418.2.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> <i>tert</i>-Butyl (2-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)ethyl)carbamate (<b>31a</b>)</h3><div class="NLM_p last">Yield, 68%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.69 (br s, 1H), 8.54 (d, <i>J</i> = 7.8 Hz, 1H), 8.48 (s, 1H), 7.88 (d, <i>J</i> = 7.3 Hz, 1H), 7.73 (t, <i>J</i> = 5.4 Hz, 1H), 7.71 (t, <i>J</i> = 7.9 Hz, 1H), 7.38 (m, 1H), 7.08 (d, <i>J</i> = 7.8 Hz, 1H), 6.86 (br s, 1H), 4.28 (m, 2H), 3.37 (m, 2H), 2.39 (s, 3H), 1.25 (s, 9H).</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>tert</i>-Butyl (3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)propyl)carbamate (<b>31b</b>)</h3><div class="NLM_p last">Yield, 68%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.7 (br s, 1H), 8.53 (d, <i>J</i> = 7.6 Hz, 1H), 8.46 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.4 Hz, 1H), 7.36 (s, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.85 (br s, 1H), 4.26 (t, <i>J</i> = 6.8 Hz, 2H), 3.29–2.98 (m, 2H), 2.40 (s, 3H), 1.92 (t, <i>J</i> = 7.2 Hz, 2H), 1.32 (s, 9H). MS calculated for C<sub>24</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 477.21, found 477.2.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>tert</i>-Butyl 3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azetidine-1-carboxylate (<b>31c</b>)</h3><div class="NLM_p last">Yield, 60%.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>tert</i>-Butyl 3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)pyrrolidine-1-carboxylate (<b>31d</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.83 (s, 1H), 8.50 (d, <i>J</i> = 7.9 Hz, 1H), 8.45 (s, 1H), 7.95 (m, 1H), 7.72 (m, 1H), 7.42 (m, 1H), 7.41 (s, 1H), 7.09 (d, <i>J</i> = 7.8 Hz, 1H), 5.62 (m, 1H), 3.95 (m, 2H), 3.85 (m, 2H), 3.41 (m, 1H), 2.39 (s, 3H), 2.35 (m, 1H), 1.45 (s, 9H).</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>tert</i>-Butyl 3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)piperidine-1-carboxylate (<b>31e</b>)</h3><div class="NLM_p last">Yield, 54%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.46 (s, 1H), 8.58 (s, 1H), 8.46 (d, <i>J</i> = 7.6 Hz, 1H), 7.73 (d, <i>J</i> = 7.6 Hz, 1H), 7.58–7.55 (m, 1H), 7.28 (s, 1H), 7.15 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 4.60 (br s, 1H), 4.3 (br s, 2H), 3.79 (t, <i>J</i> = 8.0 Hz, 1H), 2.90–2.65 (m, 2H), 2.46 (s, 3H), 2.17–1.93 (m, 2H), 1.85–1.8 (m, 1H), 1.47 (s, 9H). MS calculated for C<sub>26</sub>H<sub>30</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 503.23, found 503.0.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>tert</i>-Butyl 4-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)piperidine-1-carboxylate (<b>31f</b>)</h3><div class="NLM_p last">Yield, 66%. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz): δ 8.50 (s, 1H), 8.47 (d, <i>J</i> = 7.5 Hz, 1H), 7.80 (d, <i>J</i> = 7.4 Hz, 1H), 7.62 (t, <i>J</i> = 7.5 Hz, 1H), 7.42 (d, <i>J</i> = 7.9 Hz, 1H), 7.35 (s, 1H), 7.36 (d, <i>J</i> = 7.5 Hz, 1H), 4.85–5.05 (m, 1H), 4.25–4.41 (m, 2H), 2.91–3.12 (m, 2H), 2.55–2.75 (m, 2H), 2.41 (s, 3H), 1.82–1.96 (m, 2H), 1.45 (s, 9H). MS calculated for C<sub>26</sub>H<sub>30</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 503.22, found 503.4.</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> <i>tert</i>-Butyl 3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>31g</b>)</h3><div class="NLM_p last">Yield, 80%. MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.24, found 517.3.</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>tert</i>-Butyl 4-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>31h</b>)</h3><div class="NLM_p last">Yield, 51%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.80 (d, <i>J</i> = 15.0 Hz, 1H), 8.51 (d, <i>J</i> = 6.8 Hz, 1H), 8.46 (s, 1H), 7.89 (d, <i>J</i> = 7.4 Hz, 1H), 7.61–7.81 (m, 1H), 7.54 (d, <i>J</i> = 8.3 Hz, 1H), 7.39 (s, 1H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 4.65–5.01 (m, 1H), 3.15–4.05 (m, 4H), 2.49 (s, 3H), 1.65–2.15 (m, 6H), 1.21 and 1.41 (2s, 9H).</div></div><div id="sec4_5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> <i>tert</i>-Butyl (3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclopentyl)carbamate (<b>31i</b>)</h3><div class="NLM_p last">Yield, 64%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.78 (s, 1H), 8.55 (d, <i>J</i> = 8.4 Hz, 1H), 8.43 (s, 1H), 7.88 (d, <i>J</i> = 7.6 Hz, 1H), 7.71 (d, <i>J</i> = 7.6 Hz, 1H), 7.53 (d, <i>J</i> = 8.0 Hz, 1H), 7.40 (s, 1H), 7.18–7.08 (m, 3H), 5.42 (t, <i>J</i> = 8.4 Hz, 1H), 4.01 (br s, 1H), 3.29 (s, 1H), 2.40–1.9 (m, 7H), 1.39 (s, 9H).</div></div><div id="sec4_5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>tert</i>-Butyl (<i>cis</i>-2-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31j</b>)</h3><div class="NLM_p last">Yield, 55%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.55 (br s, 1H), 8.56 (s, 1H), 8.43 (d, <i>J</i> = 7.3 Hz, 1H), 7.74 (d, <i>J</i> = 7.3 Hz, 1H), 7.58 (t, <i>J</i> = 7.9 Hz, 1H), 7.21 (m, 1H), 7.14 (s, 1H), 7.08 (d, <i>J</i> = 7.8 Hz, 1H), 4.55 (m, 1H), 4.21 (m, 1H), 3.15 (m, 1H), 2.44 (s, 3H), 1.45–2.15 (m, 8H), 1.06 (s, 9H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.23, found 517.3.</div></div><div id="sec4_5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>tert</i>-Butyl (<i>trans</i>-2-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31k</b>)</h3><div class="NLM_p last">Yield, 44%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.40 (s, 1H), 8.57 (s, 1H), 8.45 (d, <i>J</i> = 7.9 Hz, 1H), 7.74 (d, <i>J</i> = 7.3 Hz, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.36 (d, <i>J</i> = 7.4 Hz, 1H), 7.12 (s, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 4.11–4.95 (m, 3H), 2.44 (s, 3H), 1.85–2.35 (m, 4H), 1.31–1.55 (m, 4H), 1.15 (s, 9H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.23, found 517.4.</div></div><div id="sec4_5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>tert</i>-Butyl (<i>cis</i>-3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31l</b>)</h3><div class="NLM_p last">Yield, 49%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.78 (s, 1H), 8.52 (d, <i>J</i> = 7.2 Hz, 1H), 8.46 (s, 1H), 7.89 (d, <i>J</i> = 7.2 Hz, 1H), 7.76–7.51 (m, 1H), 7.52 (d, <i>J</i> = 7.2 Hz, 1H), 7.38 (s, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 8.4 Hz, 1H), 4.91–4.75 (m, 1H), 3.62–3.41 (m, 1H), 2.39 (s, 3H), 2.35–2.24 (m, 2H), 1.99–1.75 (m, 4H), 1.35 (s, 9H), 1.59–1.29 (m, 2H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.24, found 517.3.</div></div><div id="sec4_5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>tert</i>-Butyl (<i>trans</i>-3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31m</b>)</h3><div class="NLM_p last">Yield, 70%.</div></div><div id="sec4_5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>tert</i>-Butyl (<i>cis</i>-4-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31n</b>)</h3><div class="NLM_p last">Yield, 32%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.49 (s, 1H), 8.55 (s, 1H), 8.49 (d, <i>J</i> = 7.8 Hz, 1H), 7.73 (d, <i>J</i> = 7.3 Hz, 1H), 7.60 (d, <i>J</i> = 7.3 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 1H), 7.16 (s, 1H), 7.10 (d, <i>J</i> = 8.3 Hz, 1H), 4.61–4.85 (m, 2H), 3.81–3.99 (m, 1H), 2.41–2.59 (m, 2H), 2.42 (s, 3H), 2.01–2.19 (m, 2H), 1.65–1.95 (m, 4H), 1.41 (s, 9H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.23, found 517.1.</div></div><div id="sec4_5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>tert</i>-Butyl (<i>trans</i>-4-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)cyclohexyl)carbamate (<b>31o</b>)</h3><div class="NLM_p last">Yield, 71%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.78 (s, 1H), 8.47 (s, 1H), 8.46 (s, 1H), 7.89 (d, <i>J</i> = 7.7 Hz, 1H), 7.74 (t, <i>J</i> = 8.2 Hz, 1H), 7.64 (d, <i>J</i> = 8.2 Hz, 1H), 7.39 (s, 1H), 7.06 (d, <i>J</i> = 7.2 Hz, 1H), 6.86 (d, <i>J</i> = 7.2 Hz, 1H),4.75 (m, 1H), 3.45 (m, 1H), 2.35 (s, 3H), 1.75–2.05 (m, 4H), 1.45 (s, 9H), 1.3–1.51 (m, 4H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.23, found 517.2.</div></div><div id="sec4_5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>tert</i>-Butyl (2-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>31p</b>)</h3><div class="NLM_p last">Yield, 71%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.93 (s, 1H), 8.98 (s, 1H), 8.26 (s, 1H), 8.24 (d, <i>J</i> = 7.8 Hz, 1H), 7.86 and 7.81 (2d, <i>J</i> = 7.8 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.53 (m, 2H), 7.43 (s, 1H), 7.31 (m, 1H), 7.01 (d, <i>J</i> = 8.3 Hz, 1H), 6.79 (d, <i>J</i> = 8.3 Hz, 1H), 2.41 (s, 3H), 1.24 (s, 9H). MS calculated for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 511.19, found 511.1.</div></div><div id="sec4_5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>tert</i>-Butyl (3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>31q</b>)</h3><div class="NLM_p last">Yield, 76%. MS calculated for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 511.20, found 511.1.</div></div><div id="sec4_5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>tert</i>-Butyl Methyl(3-(5-methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>31r</b>)</h3><div class="NLM_p last">Yield, 67%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.99 (s, 1H), 8.32 (d, <i>J</i> = 6.8 Hz, 2H), 7.84 (d, <i>J</i> = 7.2 Hz, 1H), 7.67–7.45 9 (m, 6H), 7.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (d, <i>J</i> = 8.0 Hz, 1H), 3.28 (s, 3H), 2.42 (s, 3H), 1.41 (s, 9H). MS calculated for C<sub>28</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 525.21, found 524.9.</div></div><div id="sec4_5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> <i>tert</i>-Butyl (3-(5-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)phenyl)carbamate (<b>31s</b>)</h3><div class="NLM_p last">Yield, 60%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.94 (s, 1H), 9.67 (s, 1H), 8.32 (s, 1H), 8.28 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.3 Hz, 1H), 7.45–7.75 (m, 6H), 7.24 (s, 1H), 7.03 (s, 1H), 2.41 (s, 3H), 1.52 (s, 9H). MS calculated for C<sub>27</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 511.19, found 511.3.</div></div><div id="sec4_5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> <i>tert</i>-Butyl (<i>R</i>)-3-(7-Methyl-2-(3-(trifluoromethyl)benzamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>39</b>)</h3><div class="NLM_p last"><sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 500 MHz) δ 12.94 (s, 1H), 8.59–8.47 (m, 1H), 8.43 (t, <i>J</i> = 6.7 Hz, 1H), 7.91 (d, <i>J</i> = 7.6 Hz, 1H), 7.84–7.67 (m, 1H), 7.46 (d, <i>J</i> = 7.7 Hz, 1H), 7.13 (t, <i>J</i> = 7.7 Hz, 1H), 7.09–6.97 (m, 1H), 4.96–4.72 (m, 1H), 4.50–4.21 (m, 1H), 3.86 (d, <i>J</i> = 12.6 Hz, 1H), 3.83–3.73 (m, 1H), 3.26–3.13 (m, 1H), 2.83–2.74 (m, 1H), 2.71 (s, 3H), 2.07 (m, 2H), 1.96 (m, 1H), 1.78 (m, 1H), 1.45 (s, 9H), 1.23 (m, 1H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>4</sub>O<sub>3</sub> (M + H)<sup>+</sup> 517.24, found 517.4. [α]<sub>D</sub><sup>23</sup> +121.95° (<i>c</i> 0.123, MeOH).</div></div><div id="sec4_5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> <i>tert</i>-Butyl (<i>R</i>)-3-(7-Methyl-2-(2-(trifluoromethyl)isonicotinamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>40</b>)</h3><div class="NLM_p last">Yield, 63%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 12.53 (s, 1H), 8.89 (d, <i>J</i> = 4.6 Hz, 1H), 8.54 (d, <i>J</i> = 7.1 Hz, 1H), 8.27 (d, <i>J</i> = 4.6 Hz, 1H), 7.21 (dt, <i>J</i> = 7.8, 21.3 Hz, 2H), 7.08 (t, <i>J</i> = 9.2 Hz, 1H), 5.12–4.85 (m, 1H), 4.34 (dd, <i>J</i> = 10.6, 13.6 Hz, 1H), 4.16–3.85 (m, 2H), 3.36–3.21 (m, 1H), 2.94–2.82 (m, 1H), 2.80 (s, 3H), 2.30–2.15 (m, 1H), 2.15–2.00 (m, 2H), 2.00–1.81 (m, 1H), 1.48 (s, 9H), 1.43–1.36 (m, 1H). MS calculated for C<sub>26</sub>H<sub>31</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 518.23, found 518.2. [α]<sub>D</sub><sup>23</sup> +99.60° (<i>c</i> 0.251, MeOH).</div></div><div id="sec4_5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> <i>tert</i>-Butyl (<i>R</i>)-3-(7-Methyl-2-(2-methylisonicotinamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>41</b>)</h3><div class="NLM_p last">Yield, 100%. <sup>1</sup>H NMR (DMSO-d6, 400 MHz) δ 12.95 (s, 1H), 8.60 (t, <i>J</i> = 4.6 Hz, 1H), 7.89 (d, <i>J</i> = 5.7 Hz, 1H), 7.81 (t, <i>J</i> = 4.9 Hz, 1H), 7.46 (d, <i>J</i> = 7.2 Hz, 1H), 7.14 (t, <i>J</i> = 7.7 Hz, 1H), 7.10–7.02 (m, 1H), 4.96–4.71 (m, 1H), 4.32 (dd, <i>J</i> = 10.5, 13.4 Hz, 1H), 3.88–3.78 (m, 1H), 3.78–3.65 (m, 1H), 3.29–3.17 (m, 1H), 2.83–2.74 (m, 1H), 2.71 (s, 3H), 2.57 (s, 3H), 2.14–2.02 (m, 2H), 2.02–1.91 (m, 1H), 1.89–1.71 (m, 1H), 1.45 (s, 9H), 1.39–1.33 (m, 1H); MS calculated for C<sub>26</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 464.26, found 464.2. [α]<sub>D</sub><sup>23</sup> +35.46° (<i>c</i> 0.282, MeOH).</div></div><div id="sec4_5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> <i>tert</i>-Butyl (<i>R</i>)-3-(7-Chloro-2-(2-methylisonicotinamido)-1<i>H</i>-benzo[<i>d</i>]imidazol-1-yl)azepane-1-carboxylate (<b>42</b>)</h3><div class="NLM_p last">Yield, 100%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.81 (br s, 1H), 8.65–8.62 (m, 1H), 7.95–7.85 (m, 2H), 7.27–7.11 (m, 3H), 5.64–5.51 (m, 1H), 4.56–4.44 (m, 1H), 4.07–3.92 (m, 1H), 3.79–3.71 (m, 0.5H), 3.41–3.35 (m, 0.5H), 3.29–3.23 (m, 1H), 2.71–2.59 (m, 1H), 2.65 (s, 3H), 2.22–2.00 (m, 3H), 1.93–1.80 (m, 1H), 1.51–1.45 (m, 1H), 1.50 (s, 3.5H), 1.41 (s, 5.5H). MS calculated for C<sub>25</sub>H<sub>31</sub>ClN<sub>5</sub>O<sub>3</sub> (M + H)<sup>+</sup> 484.20, found 484.20. [α]<sub>D</sub><sup>23</sup> +89.29° (<i>c</i> 0.112, MeOH).</div></div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> General Procedure for the Synthesis of Compounds <b>32a</b>–<b>s</b> and <b>43</b>. Synthesis of <i>N</i>-(1-(1-Acryloylpiperidin-3-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32e</b>)</h3><div class="NLM_p last">To a stirred solution of <b>31e</b> (0.300 g, 0.59 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (25 mL) at room temperature was added TFA (0.170 g, 1.49 mmol), and the reaction mixture was stirred for 2 h, and then the volatiles were removed under reduced pressure. The residue was then partitioned between saturated aqueous NaHCO<sub>3</sub> (15 mL) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and the aqueous layer was extracted once more with CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The pooled organic extracts were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford (<i>S</i>)-<i>N</i>-(5-methyl-1-(piperidin-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (0.200 g, 83%), which was used as is without further purification. To a 0 °C solution of (<i>S</i>)-<i>N</i>-(5-methyl-1-(piperidin-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (0.150 g, 0.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added acryloyl chloride (0.050 g, 0.55 mmol), and the reaction mixture was stirred for 30 min at 0 °C. The reaction mixture was partitioned between water (10 mL) and CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the layers were separated. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 20 mL), and the combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, concentrated under reduced pressure, and the resulting residue was purified by column chromatography (50% EtOAc/hexane gradient) to give <b>32e</b> (0.120 g, 0.329 mmol, 70%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.84 (s, 1H), 8.46 (d, <i>J</i> = 8.0 Hz, 2H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.75–7.63 (m, 2H), 7.39 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.95–6.79 (m, 1H), 6.19–6.13 (m, 1H), 5.75–5.59 (m, 1H), 4.79–4.56 (m, 2H), 4.31–4.19 (m, 1H), 4.15–3.65 (m, 1H), 3.27–2.66 (m, 2H), 2.39 (s, 3H), 2.00–1.91 (m, 2H), 1.64–1.5 (m, 1H); MS calculated for C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 457.19, found 456.9.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> <i>N</i>-(1-(2-Acrylamidoethyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32a</b>)</h3><div class="NLM_p last">Yield, 45%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.73 (s, 1H), 8.53 (d, <i>J</i> = 8.0 Hz, 1H), 8.47 (s, 1H), 8.26–8.23 (m, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.70 (t, <i>J</i> = 8.0 Hz, 1H), 7.38–7.32 (m, 2H), 7.08 (d, <i>J</i> = 7.8 Hz, 1H), 6.97 (d, <i>J</i> = 7.6 Hz, 2H), 5.43 (7, <i>J</i> = 8.0 Hz, 1H), 4.40–4.37 (m, 2H), 3.59–3.56 (m, 2H), 2.40 (s, 3H). MS calculated for C<sub>21</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 417.15, found 416.8.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> <i>N</i>-(1-(3-Acrylamidopropyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32b</b>)</h3><div class="NLM_p last">Yield, 35%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.74 (s, 1H), 8.51 (d, <i>J</i> = 8.0 Hz, 1H), 8.45 (s, 1H), 8.21 (d, <i>J</i> = 5.6 Hz, 1H), 7.88 (d, <i>J</i> = 7.6 Hz, 1H), 7.72–7.68 (m, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (m, 1H), 7.10 (d, <i>J</i> = 7.2 Hz, 1H), 6.23–6.02 (m, 2H), 5.56 (d, <i>J</i> = 2.0, 8.0 Hz, 1H), 4.32–4.28 (m, 2H), 3.33 (s, 1H), 3.25–3.20 (m, 1H), 2.40 (s, 3H), 1.99–1.94 (m, 2H). MS calculated for C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 431.17, found 431.1.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>N</i>-(1-(1-Acryloylazetidin-3-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32c</b>)</h3><div class="NLM_p last">Yield, 58%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.86 (s, 1H), 8.46–8.42 (m, 2H), 7.87 (d, <i>J</i> = 7.8 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.40 (s, 1H), 7.13 (d, <i>J</i> = 7.8 Hz, 1H), 6.45 (dd, <i>J</i> = 10.2, 16.6 Hz, 1H), 6.24 (dd, <i>J</i> = 1.9, 17.1 Hz, 1H), 5.86–5.74 (m, 2H), 5.03–5.0 (m, 1H), 4.77–4.68 (m, 2H), 4.46 (t, <i>J</i> = 9.7 Hz, 1H), 2.40 (s, 3H). MS calculated for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 429.15, found 429.0.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> <i>N</i>-(1-(1-Acryloylpyrrolidin-3-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32d</b>)</h3><div class="NLM_p last">Yield, 28%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.83 (s, 1H), 8.51–8.48 (m, 1H), 8.42 (s, 1H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.69–7.64 (m, 1H), 7.48–7.39 (m, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 1H), 6.78–6.54 (m, 1H), 6.26–6.17 (m, 1H), 5.78–5.60 (m, 2H), 4.27–4.22 (m, 0.5H), 4.13–4.00 (m, 1.5H), 3.95–3.86 (m, 1H), 3.79–3.73 (m, 0.5H), 3.58–3.51 (m, 0.5H), 2.83–2.71 (m, 1H), 2.40 (s, 3H), 2.38–2.25 (m, 1H). MS calculated for C<sub>23</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 443.13, found 442.8.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> <i>N</i>-(1-(1-Acryloylpiperidin-4-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32f</b>)</h3><div class="NLM_p last">Yield, 41%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.79 (s, 1H), 8.46–8.40 (m, 2H), 7.88 (d, <i>J</i> = 8.0 Hz, 1H), 7.70–7.63 (m, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (s, 1H), 7.07 (d, <i>J</i> = 8.4 Hz, 1H), 6.96–6.89 (m, 1H), 6.22–6.18 (m, 1H), 5.75–5.69 (m, 1H), 5.04–4.97 (m, 1H), 4.73–4.65 (m, 1H), 4.34–4.29 (m, 1H), 3.30–3.28 (m, 1H), 2.87–2.81 (m, 1H), 2.68–2.54 (m, 2H), 2.40 (s, 3H), 2.00–1.93 (m, 2H). MS calculated for C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 457.19, found 457.3.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> <i>N</i>-(1-(1-Acryloylazepan-3-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32g</b>)</h3><div class="NLM_p last">Yield, 38%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.81 (d, <i>J</i> = 19.6 Hz, 1H), 8.54 (s, 1H), 8.48–8.44 (m, 1H), 7.90–7.51 (m, 3H), 7.39 (d, <i>J</i> = 4.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.87–6.81 (m, 1H), 6.25–6.17 (m, 1H), 5.76–5.50 (m, 1H), 4.88 (br s, 1H), 4.16–4.03 (m, 2H), 3.90–3.63 (m, 1H), 3.37–3.22 (m, 1H), 2.40 (s, 4H), 2.05–1.85 (m, 4H), 1.43–1.40 (m, 1H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.2.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> <i>N</i>-(1-(1-Acryloylazepan-4-yl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32h</b>)</h3><div class="NLM_p last">Yield, 41%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.74 (s, 1H), 8.45–8.37 (m, 2H), 7.87 (d, <i>J</i> = 7.4 Hz, 1H), 7.67 (t, <i>J</i> = 7.8 Hz, 1H), 7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.38 (s, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 1H), 6.92–6.81 (m, 1H), 6.29–6.24 (m, 1H), 5.78–5.67 (m, 1H), 4.90 (br s, 1H), 3.92–3.43 (m, 4H), 2.60–2.56 (m, 1H), 2.39 (s, 3H), 2.10–1.78 (m, 4H), 1.25–1.21 (m, 1H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.0.</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> <i>N</i>-(1-(3-Acrylamidocyclopentyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32i</b>)</h3><div class="NLM_p last">Yield, 17%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.78 (s, 1H), 8.55 (d, <i>J</i> = 8.0 Hz, 1H), 8.45 (s, 1H), 8.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.89 (d, <i>J</i> = 8.0 Hz, 1H), 7.75–7.73 (m, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.40 (s, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.27–6.20 (m, 1H), 6.11 (dd, <i>J</i> = 2.0, 14.4 Hz, 1H), 5.61 (d, <i>J</i> = 2.0 Hz, 1H), 5.59–5.42 (m, 1H), 4.35–4.29 (m, 1H), 2.40 (s, 3H), 2.37–1.92 (m, 6H). MS calculated for C<sub>24</sub>H<sub>24</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 457.19, found 457.40.</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> <i>N</i>-(1-(<i>cis</i>-2-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32j</b>)</h3><div class="NLM_p last">Yield, 45%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.61 (s, 1H), 8.91 (s, 1H), 8.55 (s, 1H), 8.41 (d, <i>J</i> = 7.9 Hz, 1H), 7.79 (d, <i>J</i> = 5.8 Hz, 1H), 7.66–7.62 (m, 1H), 7.19–7.11 (m, 3H), 6.0 (d, <i>J</i> = 16.7 Hz, 1H), 5.60–5.52 (m, 1H), 5.20 (d, <i>J</i> = 10.2 Hz, 1H), 4.46–4.44 (m, 2H), 3.50–3.41 (m, 1H), 2.53–2.46 (m, 1H), 2.45 (s, 3H), 2.13–2.10 (m, 1H), 1.98–1.94 (m, 1H), 1.69–1.56 (m, 3H), 1.55–1.43 (m, 1H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.8.</div></div><div id="sec4_6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> <i>N</i>-(1-(<i>trans</i>-2-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32k</b>)</h3><div class="NLM_p last">Yield, 45%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.32 (s, 1H), 8.57 (s, 1H), 8.47 (d, <i>J</i> = 7.3 Hz, 1H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.62–7.58 (m, 1H), 7.42–7.40 (m, 1H), 7.12–7.06 (m, 2H), 6.18 (br s, 1H), 5.91 (dd, <i>J</i> = 1.5, 17.1 Hz, 1H), 5.73–5.67 (m, 1H), 5.36 (dd, <i>J</i> = 1.5, 10.3 Hz, 1H), 5.01–4.96 (m, 1H), 4.56 (br s, 1H), 2.43–2.38 (m, 4H), 2.12–1.94 (m, 3H), 1.56–1.42 (m, 4H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.2.</div></div><div id="sec4_6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> <i>N</i>-(1-(<i>cis</i>-3-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32l</b>)</h3><div class="NLM_p last">Yield, 26%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.79 (s, 1H), 8.52 (d, <i>J</i> = 8.0 Hz, 1H), 8.49 (s, 1H), 8.15 (d, <i>J</i> = 7.6 Hz, 1H), 7.90 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.38 (s, 1H), 7.09 (d, <i>J</i> = 8.4 Hz, 1H), 6.22–6.08 (m, 1H), 6.04 (d, <i>J</i> = 2.0 Hz, 1H), 5.55 (dd, <i>J</i> = 2.4, 8.0 Hz, 1H), 4.98–4.77 (m, 1H), 3.99–3.83 (m, 1H), 2.41 (s, 3H), 2.50–2.35 (m, 2H), 1.96–1.80 (m, 4H), 1.62–1.30 (m, 2H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.2.</div></div><div id="sec4_6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> <i>N</i>-(1-(<i>trans</i>-3-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32m</b>)</h3><div class="NLM_p last">Yield, 20%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 12.39 (s, 1H), 8.55 (s, 1H), 8.40 (d, <i>J</i> = 7.6 Hz, 1H), 7.72 (d, <i>J</i> = 8.0 Hz, 1H), 7.54 (t, <i>J</i> = 7.6 Hz, 1H), 7.30–7.28 (m, 1H), 7.14 (s, 1H), 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 6.99–6.20 (m, 2H), 5.88 (br s, 1H), 5.71 (d, <i>J</i> = 10.4 Hz, 1H), 5.06 (t, <i>J</i> = 12.8 Hz, 1H), 4.56 (br s, 1H), 2.55 (t, <i>J</i> = 12.4 Hz, 1H), 2.44–2.22 (m, 5H), 2.03–2.01 (m, 3H), 1.76–1.41 (m, 2H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.2.</div></div><div id="sec4_6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> <i>N</i>-(1-(<i>cis</i>-4-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32n</b>)</h3><div class="NLM_p last">Yield, 30%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.80 (s, 1H), 8.56 (d, <i>J</i> = 7.8 Hz, 1H), 8.43 (s, 1H), 8.27 (d, <i>J</i> = 5.9 Hz, 1H), 7.89 (d, <i>J</i> = 7.8 Hz, 1H), 7.73–7.64 (m, 2H), 7.40 (s, 1H), 7.11 (d, <i>J</i> = 8.1 Hz, 1H), 6.58–6.51 (m, 1H), 6.18–6.13 (m, 1H), 5.67–5.64 (m, 1H), 4.98–4.89 (m, 1H), 4.05 (br s, 1H), 3.34–3.28 (m, 2H), 2.40 (s, 3H), 2.06–2.02 (m, 2H), 1.83–1.68 (m, 4H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.0.</div></div><div id="sec4_6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> <i>N</i>-(1-(<i>trans</i>-4-Acrylamidocyclohexyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32o</b>)</h3><div class="NLM_p last">Yield, 44%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.80 (s, 1H), 8.46 (m, 2H), 8.10 (d, <i>J</i> = 7.8 Hz, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.78–7.65 (m, 2H), 7.40 (s, 1H), 7.10 (d, <i>J</i> = 8.0 Hz, 1H), 6.28–6.21 (m, 1H), 6.16–6.11 (m, 1H), 5.61–5.58 (m, 1H), 4.87–4.81 (m, 1H), 3.98–3.89 (m, 1H), 3.34–3.28 (m, 2H), 2.40 (s, 3H), 2.08–2.02 (m, 2H), 1.90–1.82 (m, 2H), 1.57–1.43 (m, 2H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.0.</div></div><div id="sec4_6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> <i>N</i>-(1-(2-Acrylamidophenyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32p</b>)</h3><div class="NLM_p last">Yield, 24%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.94 (s, 1H), 9.61 (s, 1H), 8.25–8.22 (m, 2H), 8.15 (d, <i>J</i> = 7.8 Hz, 1H), 7.81 (d, <i>J</i> = 7.8 Hz, 2H), 7.64–7.54 (m, 2H), 7.43 (s, 1H), 7.39–7.35 (m, 1H), 6.99 (d, <i>J</i> = 7.3 Hz, 1H), 6.72 (d, <i>J</i> = 7.8 Hz, 1H), 6.23–6.16 (m, 1H), 6.10–6.05 (m, 1H), 5.56–5.52 (m, 1H), 2.40 (s, 3H). MS calculated for C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 465.15, found 465.1.</div></div><div id="sec4_6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> <i>N</i>-(1-(3-Acrylamidophenyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32q</b>)</h3><div class="NLM_p last">Yield, 35%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.99 (s, 1H), 10.44 (s, 1H), 8.36 (s, 1H), 8.32 (d, <i>J</i> = 7.6 Hz, 1H), 8.19 (s, 1H), 7.83 (d, <i>J</i> = 7.6 Hz, 1H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.67–7.58 (m, 2H), 7.46–7.41 (m, 2H), 7.20–7.09 (m, 2H), 6.49–6.30 (m, 1H), 6.29–6.25 (m, 1H), 5.80–5.75 (m, 1H), 2.42 (s, 3H). MS calculated for C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 465.15, found 465.2.</div></div><div id="sec4_6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> <i>N</i>-(5-Methyl-1-(3-(<i>N</i>-methylacrylamido)phenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32r</b>)</h3><div class="NLM_p last">Yield, 44%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 13.01 (s, 1H), 8.30 (d, <i>J</i> = 6.4 Hz, 2H), 7.84 (d, <i>J</i> = 7.6 Hz, 1H), 7.75–7.62 (m, 4H), 7.50 (d, <i>J</i> = 1.6 Hz, 1H), 7.49–7.45 (m, 1H), 7.17–7.08 (m, 2H), 6.27–6.16 (m, 2H), 5.58–5.55 (m, 1H), 3.34 (s, 3H), 2.42 (s, 3H). MS calculated for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 479.17, found 478.7.</div></div><div id="sec4_6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> <i>N</i>-(1-(4-Acrylamidophenyl)-5-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>32s</b>)</h3><div class="NLM_p last">Yield, 48%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.99 (s, 1H), 10.43 (s, 1H), 8.38 (s, 1H), 8.32 (d, <i>J</i> = 7.6 Hz, 1H), 7.97 (d, <i>J</i> = 7.6 Hz, 2H), 7.83 (d, <i>J</i> = 7.6 Hz, 1H), 7.67–7.58 (m, 2H), 7.42 (m, 2H), 7.12–7.05 (m, 2H), 6.56–6.48 (m, 1H), 6.35–6.32 (m, 1H), 5.82–5.80 (m, 1H), 2.42 (s, 3H). MS calculated for C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 465.15, found 465.3.</div></div><div id="sec4_6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> (<i>R</i>)-<i>N</i>-(1-(1-Acryloylazepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>43</b>)</h3><div class="NLM_p last">Yield, 71%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 12.80 (br s, 1H), 8.52 (s, 1H), 8.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.85–7.70 (m, 2H), 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.02 (d, <i>J</i> = 7.6 Hz, 1H), 6.82–6.75 (m, 1H), 6.15 (dd, <i>J</i> = 2.4, 14.0 Hz, 1H), 5.66 (br s, 1H), 5.0 (br s, 1H), 4.25–4.22 (m, 2H), 4.0 (br s, 1H), 3.50 (br s, 1H), 2.7–2.65 (m, 4H), 2.10–1.89 (m, 4H), 1.42–1.39 (m, 1H). MS calculated for C<sub>25</sub>H<sub>26</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> (M + H)<sup>+</sup> 471.20, found 471.3. [α]<sub>D</sub><sup>23</sup> +127.2° (<i>c</i> 0.0786, MeOH).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> General Procedure for the Synthesis of Compounds <b>44</b>–<b>46</b>. Synthesis of (<i>R</i>,<i>E</i>)-<i>N</i>-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (<b>46</b>)</h3><div class="NLM_p last">A solution of <b>41</b> (6.81 g, 14.7 mmol) in MeOH (15 mL) was treated with 4 M HCl in dioxane (100 mL, 400 mmol) and stirred for 12 h. The volatiles were removed under reduced pressure to afford (<i>R</i>)-<i>N</i>-(1-(azepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide, which was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (70 mL) and Et<sub>3</sub>N (6.15 mL, 44.1 mmol). In a separate flask, a mixture of (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (2.60 g, 19.1 mmol) and HATU (7.34 g, 19.1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) was treated with Et<sub>3</sub>N (3.07 mL, 22.0 mmol) and stirred at room temperature for 30 min. This was then treated with the CH<sub>2</sub>Cl<sub>2</sub>/Et<sub>3</sub>N solution of (<i>R</i>)-<i>N</i>-(1-(azepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide, and the transfer was assisted with an additional volume of CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The reaction mixture was stirred for 30 min and then washed with 1 M NaOH (100 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2 × 150 mL), and the pooled organics were washed with 1 M NaOH (100 mL) and then brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography (0–70% (9:1:0.175N CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3</sub>)/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford <b>46</b> (4.26 g, 61%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.57 (d, <i>J</i> = 5.2 Hz, 1H), 8.06 (s, 1H), 7.98 (d, <i>J</i> = 5.2 Hz, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.19 (t, <i>J</i> = 7.8 Hz, 1H), 7.10 (t, <i>J</i> = 8.7 Hz, 1H), 6.99 (t, <i>J</i> = 15.8 Hz, 1H), 6.75 (m, 1H), 5.14 (m, 2H), 4.60 (m, 1H), 4.32 (d, <i>J</i> = 13.0 Hz, 1H), 3.98 (m, 3H), 3.71 (m, 1H), 3.16 (m, 1H), 3.03 (m, 1H), 2.93 (s, 6H), 2.77 (s, 3H), 2.53 (s, 3H), 2.22 (m, 1H), 2.12 (m, 2H). MS calculated for C<sub>27</sub>H<sub>35</sub>N<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup> 475.28, found 475.1. [α]<sub>D</sub><sup>23</sup> +72.46° (<i>c</i> 0.069, MeOH).</div></div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> (<i>R</i>,<i>E</i>)-<i>N</i>-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-(trifluoromethyl)benzamide (<b>44</b>)</h3><div class="NLM_p last">Yield, 55%. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 12.61 (s, 1H), 8.66 (s, 1H), 8.44 (d, <i>J</i> = 7.6 Hz, 1H), 7.77 (d, <i>J</i> = 7.2 Hz, 1H), 7.62 (t, <i>J</i> = 7.7 Hz, 1H), 7.18 (m, 2H), 7.03 (m, 1H), 6.92 (dt, <i>J</i> = 6.1, 15.2 Hz, 1H), 6.59 (d, <i>J</i> = 15.2 Hz, 1H), 5.10 (m, 1H), 4.46 (m, 2H), 4.01 (dt, <i>J</i> = 7.3, 14.4 Hz, 1H), 3.66 (m, 1H), 3.25 (s, 2H), 2.97 (s, 1H), 2.80 (s, 3H), 2.41 (s, 6H), 2.08 (m, 3H), 1.58 (m, 2H). MS calculated for C<sub>28</sub>H<sub>33</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> (M + H)<sup>+</sup> 528.26, found 528.2. [α]<sub>D</sub><sup>23</sup> +106.38° (<i>c</i> 0.141, MeOH).</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> (<i>R</i>,<i>E</i>)-<i>N</i>-(1-(1-(4-(Dimethylamino)but-2-enoyl)azepan-3-yl)-7-methyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-(trifluoromethyl)isonicotinamide (<b>45</b>)</h3><div class="NLM_p last">Yield, 55%. <sup>1</sup>H NMR (CD<sub>3</sub>OD, 400 MHz) δ 8.88 (d, <i>J</i> = 4.9 Hz, 1H), 8.56 (s, 1H), 8.34 (d, <i>J</i> = 4.9 Hz, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (t, <i>J</i> = 7.8 Hz, 1H), 7.12 (m, 1H), 6.86 (t, <i>J</i> = 13.8 Hz, 1H), 6.78 (m, 1H), 5.12 (m, 1H), 4.54 (dd, <i>J</i> = 10.8, 13.0 Hz, 1H), 4.27 (m, 1H), 4.02 (m, 1H), 3.65 (m, 3H), 2.92 (m, 1H), 2.78 (s, 3H), 2.67 (s, 6H), 2.22 (m, 1H), 2.08 (m, 3H), 1.49 (m, 1H). MS calculated for C<sub>27</sub>H<sub>32</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup> 529.25, found 529.2. Anal. Calcd for C<sub>27</sub>H<sub>31</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> (528.58): C 61.35, H 5.91, N 15.90. Found: C 61.10, H 5.93, N 15.75. [α]<sub>D</sub><sup>23</sup> +153.06° (<i>c</i> 0.098, MeOH).</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Synthesis of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-(4-(dimethylamino)but-2-enoyl)azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (<b>47</b>)</h3><div class="NLM_p last">A solution of <b>42</b> (8.62 g, 16.4 mmol) in MeOH (67 mL) was treated with HCl in dioxane (4 M, 67 mL), and the mixture was stirred at room temperature for 7 h. The mixture was then concentrated under reduced pressure to afford (<i>R</i>)-<i>N</i>-(1-(azepan-3-yl)-7-chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (7.2 g) as the HCl salt. The product was used in the next step without further purification. A mixture of (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride (2.76 g, 21.4 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (4.10 g, 21.4 mmol) in DMF (80 mL) was treated with hydroxybenzotriazole (3.27 g, 21.4 mmol) and stirred at room temperature for 1 h. The resulting mixture was added to a solution of (<i>R</i>)-<i>N</i>-(1-(azepan-3-yl)-7-chloro-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (6.1 g, 13.4 mmol) in DMF (20 mL). Et<sub>3</sub>N (13.0 mL, 93.5 mmol) was then added, and the mixture was stirred for 24 h. Water (2 mL) was added, and the mixture was concentrated under reduced pressure. The residue was diluted with water (250 mL) and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with water (100 mL), NaHCO<sub>3</sub> (100 mL), and brine (2 × 50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude was purified by column chromatography (0–100% (9:1:0.175N CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3</sub>)/CH<sub>2</sub>Cl<sub>2</sub> gradient) to afford <b>47</b> (3.67 g, 56%). <sup>1</sup>H NMR (CD<sub>3</sub>CN, 400 MHz): δ 12.55 (br s, 1H), 8.61 (d, <i>J</i> = 5.2 Hz, 1H), 7.98 (s, 0.6H), 7.95 (s, 0.4H), 7.88–7.85 (m, 1H), 7.53 (dd, <i>J</i> = 1.2, 8.0 Hz, 0.6H), 7.51 (dd, <i>J</i> = 1.2, 8.0 Hz, 0.4H), 7.33–7.23 (m, 2H), 6.81–6.72 (m, 1H), 6.60 (dt, <i>J</i> = 15.2, 1.6 Hz, 1H), 5.66–5.55 (m, 1H), 4.81–4.74 (m, 1H), 4.61–4.55 (m, 1H), 4.29–4.01 (m, 2H), 3.89–3.82 (m, 1H), 3.71–3.65 (m, 1H), 3.44–3.38 (m, 1H), 3.14 (d, <i>J</i> = 6.0 Hz, 1.2H), 2.92 (d, <i>J</i> = 6.0 Hz, 0.8H), 2.85–2.72 (m, 1H), 2.61 (d, <i>J</i> = 2.0 Hz, 3H), 2.27 (s, 6H), 2.16–2.00 (m, 1H), 1.52–1.41 (m, 1H). MS calculated for C<sub>26</sub>H<sub>32</sub>ClN<sub>6</sub>O<sub>2</sub> (M + H)<sup>+</sup> 495.23, found 495.20. Anal. Calc. for C<sub>26</sub>H<sub>31</sub>ClN<sub>6</sub>O<sub>2</sub> (495.02): C 63.09, H 6.31, N 16.98; found: C 62.90, H 6.21, N 16.90. [α]<sub>D</sub><sup>23</sup> +53.76° (<i>c</i> 0.186, MeOH).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Molecular Docking Experiments</h3><div class="NLM_p last">Flexible ligand docking was performed using Glide 6.5 (Schrodinger Inc., Portland, OR, 2014). The protein coordinates were taken from cocrystal structure of AEE788 with EGFR T790M mutant (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu">2jiu</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The grid box was centered on the cocrystallized ligand and extended 10 Å from the center, with the outer box extending an additional 20 Å. The ligand was docked using the standard precision (SP) algorithm, and during docking, constraints were imposed, requiring at least one H-bonding contact in the hinge region. The final pose was selected based on the lowest docking score using GlideScore.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Cloning, Expression, and Purification</h3><div class="NLM_p">DNA encoding the kinase domain of human WT EGFR (residues 696–1022) was amplified by PCR from a cDNA template and cloned into pFastBACHTb (Life Technologies) in-frame with the N-terminal 6xHIS tag and TEV (Tobacco Etch Virus) protease cleavage site. The T790M mutation was created using site-directed mutagenesis (QuikChange, Agilent Technologies). Bacmids were created via standard methods and transfected into Sf9 cells to generate recombinant baculovirus. Large scale expression of protein was also carried out in Sf9 cells with cultures being infected at a cell density of 1 × 10<sup>6</sup> cells/mL. The culture was harvested by centrifugation when cell viability reached 50% (∼3–4 days post-transfection), and cell pellets were stored at −80 °C.</div><div class="NLM_p last">To purify the proteins (WT or T790M mutant), the cell pellets were resuspended in lysis buffer containing 20 mM Tris, pH 8.0, 150 mM NaCl, 2 mM TCEP, 5% v/v glycerol, and protease inhibitor cocktail tablets without EDTA (Roche). Cells were lysed by sonication, and the lysate was cleared by centrifugation at 20 000<i>g</i> at 4 °C for 45 min. The clarified lysate was applied to a 5 mL Ni-NTA column pre-equilibrated with lysis buffer. The bound protein was washed with lysis buffer supplemented with 20 mM imidazole. Bound protein was then eluted with lysis buffer supplemented with 300 mM imidazole. Fractions containing protein were combined and desalted into 20 mM Tris, pH 8.0, 50 mM NaCl, 2 mM TCEP using a PD10 column (GE Healthcare). To remove the 6xHIS tag, TEV protease was added to the desalted fractions at a ratio of 1 mg of TEV/20 mg of fusion protein and incubated at 4 °C overnight. Following overnight digest, the cleaved protein was applied to Ni-NTA resin to remove uncleaved protein, the flow through was collected and concentrated to 6 mg/mL. Aliquots were flash frozen in liquid nitrogen and stored at −80 °C.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> Crystallization and Data Collection</h3><div class="NLM_p last">Crystallization experiments were carried out using the sitting-drop vapor diffusion setup. The protein drug complex was formed by incubating the concentrated protein (WT EGFR kinase domain or T790M mutant) with 2 mM MgCl<sub>2</sub> and 0.5 mM drug (either racemic <b>43</b> or <b>46</b> from 10 mM DMSO stock). After addition of the inhibitor, the solution was incubated at room temperature for 90 min prior to crystallization plate setup. Crystallization plates were incubated at 20 °C. After 1–2 weeks, crystals of the EGFR T790M-<b>43</b> complex were visible in a well containing 1.2 M potassium sodium tartrate, 0.1 M HEPES, pH 7.5. Crystals of the EGFR T790M-<b>46</b> complex were visible in a well containing 32% v/v PEG 3350, 0.2 M lithium sulfate, 0.1 M HEPES, pH 7.25. Crystals of the WT EGFR-<b>43</b> complex grew out of a well containing 1.35 M potassium sodium tartrate, 0.1 M HEPES, pH 7.9. Crystals were cryopreserved in reservoir solution supplemented with 20% v/v ethylene glycol and flash frozen in liquid nitrogen prior to data collection. X-ray diffraction data were collected from frozen crystals on ALS beamline 5.0.3.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Structure Determination and Refinement</h3><div class="NLM_p last">Diffraction data were processed using HKL2000,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and structures were solved by molecular replacement using PHASER.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Structure refinement was carried out in PHENIX<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> alternated with manual fitting in Coot.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Selection of TLS groups was carried out using the automated procedure implemented in PHENIX. Refinement statistics for cocrystals with <b>43</b> and <b>46</b> are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> EGFR Biochemical Assays</h3><div class="NLM_p last">Biochemical assays for WT EGFR and each mutant were carried out using a homogeneous time-resolved fluorescence (HTRF) assay as described previously.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Assays were optimized for each ATP concentration. Assays were carried out with or without 90 min enzyme/compound preincubation step. Compound IC<sub>50</sub> values were determined by 12-point inhibition curves (from 50 to 0.000282 μM) in duplicate.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> H1975, H3255, HCC827, and HaCaT Cellular EGFR Target Modulation Assays</h3><div class="NLM_p">Tissue culture cells were maintained in 10% FBS/RPMI supplemented with 100 μg/mL penicillin/streptomycin (Hyclone no. SH30236.01). The cells were harvested with 0.25% trypsin/EDTA (Hyclone no. SH30042.1), resuspended in 5% FBS/RPMI Pen/Strep, and plated at 7500 cells per well in 50 μL of medium in a 384-well black plate with clear bottoms (Greiner no. 789068G). The cells were allowed to incubate overnight in a 37 °C, 5% CO<sub>2</sub> humidified tissue culture incubator. The 12-point serial diluted test compounds were transferred to the plate containing cells by using a 50 nL Pin Head device (PerkinElmer), and the cells were placed back in the incubator for 3 h.</div><div class="NLM_p">Phospho-EGFR (Y1173) target modulation assay HaCaT cells were stimulated with 10 ng/mL EGF (Peprotech no. AF-100-15) for 5 min at room temperature. Constitutively activated EGFR mutant cell lines (H1975, H3255, and HCC827) were not stimulated with EGF. The medium was reduced to 20 μL using a Bio-Tek ELx 405 Select plate washer. Cells were lysed with 20 μL of 2× lysis buffer containing protease and phosphatase inhibitors (2% Triton X-100, 40 mM Tris, pH 7.5, 2 mM EDTA, 2 mM EGTA, 300 mM NaCl, 2× complete cocktail inhibitor (Roche no. 11 697 498 001), 2× phosphatase inhibitor cocktail set II and set III (Sigma no. P5726 and no. P0044)). The plates were shaken for 20 min. An aliquot of 25 μL from each well was transferred to prepared ELISA plates for analysis.</div><div class="NLM_p last">Phospho-EGFR (Y1173) ELISA solid white 384-well high-binding ELISA plates (Greiner no. 781074) were coated with 5 μg/mL goat anti-EGFR capture antibody overnight in 50 mM carbonate/bicarbonate pH 9.5 buffer. Plates were blocked with 1% BSA (Sigma no. A7030) in PBS for 1 h at room temperature, and washes were carried out with a Bio-Tek ELx405 Select using 4 cycles of 100 μL of TBS-T (20 mM Tris, 137 mM NaCl, 0.05% Tween-20) per well. A 25 μL aliquot of lysed cell was added to each well of the ELISA plate and incubated overnight at 4 °C with gentle shaking. A 1:1000 anti-phospho-EGFR in 0.2% BSA/TBS-T was added and incubated for 2 h at room temperature. After washing, 1:2000 anti-rabbit-HRP in 0.2% BSA/TBS-T was added and incubated for 1 h at room temperature. Chemiluminescent detection was carried out with SuperSignal ELISA Pico substrate. Signal was read on EnVision plate reader using built-in UltraLUM setting.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> In Vivo Efficacy Studies</h3><div class="NLM_p">Foxn1 nude mice bearing the H1975 tumors were randomized and used for efficacy studies. Compounds were formulated in 0.5% MC, 0.5% Tween80 suspension formulation and administered by oral gavage at a dosing volume of 10 μL/g of the animal body weight. Animals in each group received one oral dose of either vehicle (<i>n</i> = 6) or the different test compounds (<i>n</i> = 6 in each dose group). Plasma samples were collected for PK measurements at 30 min, 3 h, 7 h, and 24 h after last dose on day 5. Body weight was monitored daily, and the % change in body weight was calculated as [(BW<sub>current</sub> – BW<sub>initial</sub>)/(BW<sub>initial</sub>)] × 100. Data are presented as percent body weight change from the day of treatment initiation. Tumor sizes were assessed three times during the efficacy study for 5 days. Tumor sizes were determined by using caliper measurements. Tumor volumes were calculated with the formula (length × width × width)/2.</div><div class="NLM_p">Percent treatment/control (<i>T</i>/<i>C</i>) values for tumor were calculated using the following formula: % <i>T</i>/<i>C</i> = 100 × Δ<i>T</i>/Δ<i>C</i> if Δ<i>T</i> > 0; % regression = 100 × Δ<i>T</i>/<i>T</i><sub>initial</sub> if Δ<i>T</i> < 0; where <i>T</i> is the mean tumor volume of the drug-treated group on the final day of the study; Δ<i>T</i> is mean tumor volume of the drug-treated group on the final day of the study minus mean tumor volume of the drug-treated group on initial day of dosing; <i>T</i><sub>initial</sub> is the mean tumor volume of the drug-treated group on initial day of dosing; <i>C</i> is the mean tumor volume of the control group on the final day of the study; and Δ<i>C</i> is mean tumor volume of the control group on the final day of the study minus mean tumor volume of the control group on initial day of dosing.</div><div class="NLM_p last">All data were expressed as mean ± standard error of the mean (SEM). The Δ tumor volume and body weight were used for statistical analysis. Between groups comparisons were carried out using a one-way ANOVA followed by a post hoc Tukey or Dunn’s. For all statistical evaluations the level of significance was set at <i>p</i> < 0.05. Significance compared to the vehicle control group is reported unless otherwise stated.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> PK Studies</h3><div class="NLM_p last">Rodent PK studies of <b>43</b>–<b>47</b> were conducted in male balb/c mice and male Wistar rats. Plasma concentrations of compounds were determined by liquid chromatography–tandem mass spectrometry (Applied Biosystems, Foster City, CA, USA). The lower limit of detection was 1 ng/mL. Pharmacokinetic parameters were calculated by noncompartmental regression analysis using an in-house fitting program.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> In Vitro Adducts of <b>47</b> with EGFR</h3><div class="NLM_p">Recombinant kinase domain of EGFR L858R and T790M-L858R mutants were incubated with <b>47</b> to confirm covalent modification of EGFR and site of adduction. Recombinant enzyme was incubated at room temperature with a 20-fold molar excess of compound in 40 mM Tris, pH 8, 500 mM NaCl, 1% glycerol, 5 mM TCEP for 1 h. The reaction was quenched by addition of dithiothreitol (DTT, 80-fold excess to compound) and transfer to ice. A third of the reaction (10 μL) was processed for intact MS by adding an equal volume of 6 M Guan HCl, 100 mM Tris, pH 8, 20 mM DTT, 10 mM TCEP and incubating at room temperature for 15 min. Intact MS analysis was performed on an Agilent 6520 QToF mass spectrometer equipped with a dual spray ion source (IS of 4500 V, fragmentor of 250 V, fas temp of 350 °C, and skimmer of 75 V). The samples were injected onto a PLRP-S column (2.1 mm × 50 mm, Agilent), heated to 60 °C, and desalted for 2 min at 500 μL/min and 3% B prior to elution with a fast gradient of 3–50% B in 3 min (B, 0.1% formic acid, MeCN). The data were analyzed in MassHunter for automatic peak selection, integration, and spectral deconvolution with a mass range of 15 000–75 000 Da.</div><div class="NLM_p last">Reaction solutions were also processed for enzymatic digestion and LC/MSMS. Samples were buffer exchanged to remove excess compound using 10 kDa Amicon Ultra 0.5 mL spin filters and recovered in 30 μL of 100 mM Tris, pH 8, 20 mM DTT and incubated at 60 °C for 20 min. Iodoacetamide was added to 25 mM, and the samples were incubated for 45 min at room temperature in the dark prior to dilution to 150 μL with 100 mM Tris, pH 8, 10 mM DTT. The samples were divided in two, and 1 μL of either 0.5 mg/mL chymotrypsin or sequencing grade modified trypsin was added and incubated overnight at 37 °C. Samples were acidified to 1% formic acid and analyzed on a Q-Exactive mass spectrometer for accurate mass and MS/MS. Samples were injected on a precolumn (360 μm × 100 μm, 4 cm Poros10R2) for desalting and separated on a 360 μm × 75 μm analytical column and integrated emitter (10 cm, 5 μm Monitor C18) with a gradient of 2–27% B in 45 min; 27–36% B in 10 min at a flow rate of 300 nL/min (B, 0.1% formic acid, MeCN). The Q-Exactive parameters were set for “sensitive” analysis as previously defined by Kelstrup et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Briefly, one full scan MS was acquired at 75 000 resolution followed by 12 MS/MS at 35 000 resolution of the top ions in the mass range of 350–1500 <i>m</i>/<i>z</i>. An additional dedicated scan for MS/MS of 898.7184 was added to continuously target the adduct Cys797. The data were converted to Mascot generic format (MGF) using Proteome Discoverer (Thermo) and searched using Mascot against a custom database allowing for variable modification of methionine oxidation, cysteine carbamidomethylation, and the custom modification of Michael addition by <b>47</b> to cysteines. Enzyme specificity was trypsin or no enzyme (chymotrypsin digest), and the peptide and fragment ion tolerances were set to 25 ppm and 50 mmu, respectively. The data were visualized in Scaffold 4.4.3 and filtered for 95% peptide confidence and 99% protein confidence.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01985">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01985" class="ext-link">10.1021/acs.jmedchem.5b01985</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Refinement statistics of cocrystal structures WT-EGFR-<b>43</b>, EGFR T790M-<b>43</b> and EGFR T790M-<b>46</b>; biochemical selectivity profiling of <b>47</b> against a panel of kinase and non-kinase targets; enantiopurity analysis of chiral compounds; analytical LC–MS methods for analysis of intermediates; metabolite identification studies for <b>43</b>; <sup>1</sup>H and <sup>13</sup>C NMR spectra of <b>47</b> at 300 and 383 K (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf">jm5b01985_si_001.pdf (949.46 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_002.csv">jm5b01985_si_002.csv (4.18 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The crystallographic coordinates and structure factors have been deposited in the Protein Data Bank, <a href="http://www.pdb.org" class="extLink">www.pdb.org</a> (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee">5fee</a> for EGFR T790M-<b>43</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed">5fed</a> for WT EGFR-<b>43</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5feq">5feq</a> for EGFR T790M-<b>46</b>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01985" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gérald Lelais</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bddad1d8d1dcd4cefddad3db93d2cfda"><span class="__cf_email__" data-cfemail="bfd8d3dad3ded6ccffd8d1d991d0cdd8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Epple</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Marsilje</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yun O. Long</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew McNeill</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bei Chen</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenshuo Lu</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaganmohan Anumolu</span> - <span class="hlFld-Affiliation affiliation">Aurigene Discovery Technologies, Bollaram Road, Miyapur, Hyderabad 500 049, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangamesh Badiger</span> - <span class="hlFld-Affiliation affiliation">Aurigene Discovery Technologies, 39-40, Electronic City Phase 2, Bangalore 560 100, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Badry Bursulaya</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael DiDonato</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rina Fong</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jose Juarez</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie Li</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mari Manuia</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel E. Mason</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Perry Gordon</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Todd Groessl</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Johnson</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Jia</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shailaja Kasibhatla</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun Li</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Isbell</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Glen Spraggon</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Bender</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pierre-Yves Michellys</span> - <span class="hlFld-Affiliation affiliation">Genomics Institute of the Novartis Research
Foundation, 10675 John
J. Hopkins Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d116e8129-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge the contribution to this work of all past and present members of the mutant EGFR team. A big thank you goes also to all supporting functions including Paul Calvin and his team (compound management), Thomas Hollenbeck and his team (analytical group), Lucas Westling (chiral analysis and purifications), David Jones (NMR), Connie Chen (protein crystallization), and Tove Tuntland and her team (DMPK).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i134" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i134"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i135" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i135"> Abbreviations Used</h2><tr><td class="NLM_term">MoA</td><td class="NLM_def"><p class="first last">mode of action</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">HT-sol</td><td class="NLM_def"><p class="first last">high-throughput solubility</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term"><i>T</i>/<i>C</i></td><td class="NLM_def"><p class="first last">treatment/control</p></td></tr><tr><td class="NLM_term">Da</td><td class="NLM_def"><p class="first last">dalton</p></td></tr><tr><td class="NLM_term">RP-HPLC</td><td class="NLM_def"><p class="first last">reverse phase high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">PDA</td><td class="NLM_def"><p class="first last">photodiode array detector</p></td></tr><tr><td class="NLM_term">ELSD</td><td class="NLM_def"><p class="first last">evaporative light scattering detector</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhDbTgIENsptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhDbTgIENsptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Köhler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span> </span><span class="NLM_article-title">Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review</span> <span class="citation_source-journal">Onkologie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1159/000354627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1159%2F000354627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24051929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpvVymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=510-518&author=J.+K%C3%B6hlerauthor=M.+Schuler&title=Afatinib%2C+erlotinib+and+gefitinib+in+the+first-line+therapy+of+EGFR+mutation-positive+lung+adenocarcinoma%3A+a+review&doi=10.1159%2F000354627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review</span></div><div class="casAuthors">Kohler Jens; Schuler Martin</div><div class="citationInfo"><span class="NLM_cas:title">Onkologie</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">510-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined phenotypes that display an enormous genetic variability.  In recent years, epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma has emerged as a unique subset of NSCLC in terms of etiopathogenesis and tumor biology.  Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum-based chemotherapy.  However, primary or acquired resistance limits the therapeutic success of these targeted agents.  Irreversible inhibitors targeting all ErbB family receptor tyrosine kinases, such as afatinib and dacomitinib, have been developed to confer sustained disease control in ErbB-dependent cancers.  The large LUX-Lung 3 phase III trial recently reported afatinib to be clearly superior over the most effective platinum doublet in patients with EGFR mutation-positive lung cancer.  To fully exploit the clinical activity of afatinib, proactive management of its gastrointestinal and dermatologic toxicities is advised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_92rQXahILN0Q2ypr7jHkfW6udTcc2eYN-rcIWEVgnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpvVymtA%253D%253D&md5=bd1f2c43f11a8c5de2af782a4e220d88</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000354627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000354627%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26atitle%3DAfatinib%252C%2520erlotinib%2520and%2520gefitinib%2520in%2520the%2520first-line%2520therapy%2520of%2520EGFR%2520mutation-positive%2520lung%2520adenocarcinoma%253A%2520a%2520review%26jtitle%3DOnkologie%26date%3D2013%26volume%3D36%26spage%3D510%26epage%3D518%26doi%3D10.1159%2F000354627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYN-rcIWEVgnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lh6TufmhBD9gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.-K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0lh6TufmhBD9gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0lh6TufmhBD9gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0liQqd1AI950qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lhGGWeH-sjdsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhGGWeH-sjdsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+ErbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0lhGGWeH-sjdsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520ErbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.-H.+Ouauthor=M.-J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lihDW7fCI1Qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Targeted therapies: Afatinib - new therapy option for EGFR-mutant lung cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnrclinonc.2013.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=23959269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=551-552&author=H.+A.+Yuauthor=W.+Pao&title=Targeted+therapies%3A+Afatinib+-+new+therapy+option+for+EGFR-mutant+lung+cancer&doi=10.1038%2Fnrclinonc.2013.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies Afatinib-new therapy option for EGFR-mutant lung cancer</span></div><div class="casAuthors">Yu, Helena A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">551-552</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Afatinib improves progression-free survival compared with cisplatin and pemetrexed as first- line treatment for patients with EGFR mutant lung cancersAfatinib monotherapy has limited efficacy in patients with EGFR-mutant lung cancers with disease progression on erlotinib or gefitinibErlotinib, gefitinib and afatinib are all viable treatment options for the first-line treatment of patients with EGFR-mutant non-small-cell lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgXgyFJULHErVg90H21EOLACvtfcHk0lihDW7fCI1Qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7zE&md5=1ad24629a25d9c99d9f56cf870a5d765</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.154%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DTargeted%2520therapies%253A%2520Afatinib%2520-%2520new%2520therapy%2520option%2520for%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D551%26epage%3D552%26doi%3D10.1038%2Fnrclinonc.2013.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lihDW7fCI1Qhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 --> methionine790 mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%2D%2D%3E+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520--%253E%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lh6v4pvp4HN6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="refDoi"> DOI: 10.1039/c2md20078c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1039%2Fc2md20078c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1155&author=S.+Xuauthor=L.+Zhangauthor=S.+Changauthor=J.+Luoauthor=X.+Luauthor=Z.+Tuauthor=Y.+Liuauthor=Z.+zhangauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis+and+biological+evaluation+of+new+molecules+inhibiting+epidermal+growth+factor+receptor+threonine790%E2%86%92+methionine790+mutant&doi=10.1039%2Fc2md20078c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fc2md20078c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20078c%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3Dzhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520molecules%2520inhibiting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1155%26doi%3D10.1039%2Fc2md20078c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8390</span><span class="refDoi"> DOI: 10.1002/anie.201302313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1002%2Fanie.201302313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-4%281H%29-one+derivatives+as+selective+inhibitors+of+EGFR+threonine790+to+methionine790+%28T790M%29+mutants&doi=10.1002%2Fanie.201302313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302313%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-4%25281H%2529-one%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520threonine790%2520to%2520methionine790%2520%2528T790M%2529%2520mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390%26doi%3D10.1002%2Fanie.201302313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0li8-3c6wwyF1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0li8-3c6wwyF1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="refDoi"> DOI: 10.1039/c2md20017a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1039%2Fc2md20017a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=780&author=J.+Singhauthor=E.+Evansauthor=M.+Hagelauthor=M.+Labinskiauthor=A.+Dubrovskiyauthor=M.+Nachtauthor=R.+C.+Petterauthor=A.+Prasadauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Tjin+Tham+Sjinauthor=W.+Westlinauthor=Z.+Zhu&title=Superiority+of+a+novel+EGFR+targeted+covalent+inhibitor+over+its+reversible+counterpart+in+overcoming+drug+resistance&doi=10.1039%2Fc2md20017a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2Fc2md20017a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20017a%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DLabinski%26aufirst%3DM.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DPrasad%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSuperiority%2520of%2520a%2520novel%2520EGFR%2520targeted%2520covalent%2520inhibitor%2520over%2520its%2520reversible%2520counterpart%2520in%2520overcoming%2520drug%2520resistance%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D780%26doi%3D10.1039%2Fc2md20017a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0li7X462Asehzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span>FDA approves new pill to treat certain patients with non-small cell lung cancer. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm</a> (accessed November 13,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+new+pill+to+treat+certain+patients+with+non-small+cell+lung+cancer.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm472525.htm+%28accessed+November+13%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgTU-bDmybY9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1479</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin+Tham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+in+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2eYFMr0PgTYgHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eYFMr0PgTYgHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadziuszko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendenhall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheny, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1700</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span><span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eaW9V1pKBviWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span>Novartis Pharmaceuticals. A phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. NLM Identifier: NCT02108964. <a href="http://clinicaltrials.gov/show/NCT02108964" class="extLink">http://clinicaltrials.gov/show/NCT02108964</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+A+phase+I%2FII%2C+multicenter%2C+open-label+study+of+EGFRmut-TKI+EGF816%2C+administered+orally+in+adult+patients+with+EGFRmut+solid+malignancies.+NLM+Identifier%3A+NCT02108964.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02108964+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span>Novartis Pharmaceuticals. Study of efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in patients with previously treated non-small cell lung cancer. NLM Identifier: NCT02323126. <a href="http://clinicaltrials.gov/show/NCT02323126" class="extLink">http://clinicaltrials.gov/show/NCT02323126</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+Study+of+efficacy+and+safety+of+nivolumab+in+combination+with+EGF816+and+of+nivolumab+in+combination+with+INC280+in+patients+with+previously+treated+non-small+cell+lung+cancer.+NLM+Identifier%3A+NCT02323126.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02323126+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>Novartis Pharmaceuticals. Study of safety and efficacy of EGF816 in combination with INC280 in non-small cell lung cancer patients with EGFR mutation. NLM Identifier: NCT02335944. <a href="http://clinicaltrials.gov/show/NCT02335944" class="extLink">http://clinicaltrials.gov/show/NCT02335944</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+Study+of+safety+and+efficacy+of+EGF816+in+combination+with+INC280+in+non-small+cell+lung+cancer+patients+with+EGFR+mutation.+NLM+Identifier%3A+NCT02335944.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02335944+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Jia, Y.; Manuia, M.; Juarez, J.</span><span> </span><span class="NLM_article-title">HTRF kinase assay development and methods in inhibitor characterization</span>. In  <span class="citation_source-book">Methods in Molecular Biology</span>; <span class="NLM_contrib-group">Zegzouti, H.; Gouell, S. A.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1360</span>, pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span>, DOI: <span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_1</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1007%2F978-1-4939-3073-9_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-18&author=Y.+Jia&author=M.+Manuia&author=J.+Juarezauthor=H.+Zegzouti&author=S.+A.+Gouell&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_1%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26atitle%3DHTRF%2520kinase%2520assay%2520development%2520and%2520methods%2520in%2520inhibitor%2520characterization%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26aulast%3DZegzouti%26aufirst%3DH.%26pub%3DHumana%2520Press%26date%3D2016%26volume%3D1360%26spage%3D1%26epage%3D18%26doi%3D10.1007%2F978-1-4939-3073-9_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2842</span><span class="NLM_x">–</span> <span class="NLM_lpage">2845</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2006.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=16563752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2842-2845&author=J.+P.+Powersauthor=S.+Liauthor=J.+C.+Jaenauthor=J.+Liuauthor=N.+P.+C.+Walkerauthor=Z.+Wangauthor=H.+Wesche&title=Discovery+and+initial+SAR+of+inhibitors+of+interleukin-1+receptor-associated+kinase-4&doi=10.1016%2Fj.bmcl.2006.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span></div><div class="casAuthors">Powers, Jay P.; Li, Shyun; Jaen, Juan C.; Liu, Jinqian; Walker, Nigel P. C.; Wang, Zhulun; Wesche, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2842-2845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High-throughput screening of a small-mol. compd. library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-assocd. kinase-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZ37zw75f-7Vg90H21EOLACvtfcHk0lhPgM9rXBX66w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D&md5=7a8a2ebe4c155ac8999ff4a63e3ed139</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2842%26epage%3D2845%26doi%3D10.1016%2Fj.bmcl.2006.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span> </span><span class="NLM_article-title">Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1835</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1016/j.str.2006.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.str.2006.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17161373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1835-1844&author=Z.+Wangauthor=J.+Liuauthor=A.+Sudomauthor=M.+Ayresauthor=S.+Liauthor=H.+Wescheauthor=J.+P.+Powersauthor=N.+P.+C.+Walker&title=Crystal+structures+of+IRAK-4+kinase+in+complex+with+inhibitors%3A+a+serine%2Fthreonine+kinase+with+tyrosine+as+a+gatekeeper&doi=10.1016%2Fj.str.2006.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper</span></div><div class="casAuthors">Wang, Zhulun; Liu, Jinsong; Sudom, Athena; Ayres, Merrill; Li, Shyun; Wesche, Holger; Powers, Jay P.; Walker, Nigel P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1844</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interleukin-1 (IL-1) receptor-assocd. kinase-4 (IRAK-4) is a serine/threonine kinase that plays an essential role in signal transduction by Toll/IL-1 receptors (TIRs).  Here, we report the crystal structures of the phosphorylated human IRAK-4 kinase domain in complex with a potent inhibitor and with staurosporine to 2.0 and 2.2 Å, resp.  The structures reveal that IRAK-4 has a unique tyrosine gatekeeper residue that interacts with the conserved glutamate from helix αC.  Consequently, helix αC is "pulled in" to maintain the active orientation, and the usual pre-existing hydrophobic back pocket of the ATP-binding site is abolished.  The peptide substrate-binding site is more open when compared with other protein kinases due to a marked movement of helix αG.  The pattern of phosphate ligand interactions in the activation loop bears a close resemblance to that of a tyrosine kinase.  Our results provide insights into IRAK-4 function and the design of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kW8-IrZf47Vg90H21EOLACvtfcHk0lhZA5-ubH-P5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF&md5=6a8f14729eeb6776871ff632f0822f8f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520IRAK-4%2520kinase%2520in%2520complex%2520with%2520inhibitors%253A%2520a%2520serine%252Fthreonine%2520kinase%2520with%2520tyrosine%2520as%2520a%2520gatekeeper%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D1835%26epage%3D1844%26doi%3D10.1016%2Fj.str.2006.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeywardane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khine, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarko, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cywin, C. L.</span><span> </span><span class="NLM_article-title">Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3660</span><span class="NLM_x">–</span> <span class="NLM_lpage">3665</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2007.04.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3660-3665&author=R.+J.+Snowauthor=A.+Abeywardaneauthor=S.+Campbellauthor=J.+Lordauthor=M.+A.+Kashemauthor=H.+H.+Khineauthor=J.+Kingauthor=J.+A.+Kowalskiauthor=S.+S.+Pullenauthor=T.+Romaauthor=G.+P.+Rothauthor=C.+R.+Sarkoauthor=N.+S.+Wilsonauthor=M.+P.+Wintersauthor=J.+P.+Wolakauthor=C.+L.+Cywin&title=Hit-to-lead+studies+on+benzimidazole+inhibitors+of+ITK%3A+discovery+of+a+novel+class+of+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2007.04.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.045%26sid%3Dliteratum%253Aachs%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DAbeywardane%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DKashem%26aufirst%3DM.%2BA.%26aulast%3DKhine%26aufirst%3DH.%2BH.%26aulast%3DKing%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DJ.%2BA.%26aulast%3DPullen%26aufirst%3DS.%2BS.%26aulast%3DRoma%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DG.%2BP.%26aulast%3DSarko%26aufirst%3DC.%2BR.%26aulast%3DWilson%26aufirst%3DN.%2BS.%26aulast%3DWinters%26aufirst%3DM.%2BP.%26aulast%3DWolak%26aufirst%3DJ.%2BP.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26atitle%3DHit-to-lead%2520studies%2520on%2520benzimidazole%2520inhibitors%2520of%2520ITK%253A%2520discovery%2520of%2520a%2520novel%2520class%2520of%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3660%26epage%3D3665%26doi%3D10.1016%2Fj.bmcl.2007.04.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomooka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5546</span><span class="NLM_x">–</span> <span class="NLM_lpage">5550</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2015.10.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5546-5550&author=Z.+Wangauthor=D.+Sunauthor=S.+Johnstoneauthor=Z.+Caoauthor=X.+Gaoauthor=J.+C.+Jaenauthor=J.+Liuauthor=S.+Livelyauthor=S.+Miaoauthor=A.+Sudomauthor=C.+Tomookaauthor=N.+P.+C.+Walkerauthor=M.+Wrightauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+interleukin-1+receptor-associate+kinase-4&doi=10.1016%2Fj.bmcl.2015.10.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLively%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DTomooka%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520interleukin-1%2520receptor-associate%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5546%26epage%3D5550%26doi%3D10.1016%2Fj.bmcl.2015.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)</span></div><div class="casAuthors">Wissner, Allan; Overbeek, Elsebe; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Mamuya, Nellie; Rosfjord, Edward C.; Discafani, Carolyn; Davis, Rachel; Shi, Xiaoqing; Rabindran, Sridhar K.; Gruber, Brian C.; Ye, Fei; Hallett, William A.; Nilakantan, Ramaswamy; Shen, Ru; Wang, Yu-Fen; Greenberger, Lee M.; Tsou, Hwei-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles, e.g., I, that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepd.  These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles, e.g., II, with unsatd. acid chlorides or mixed anhydrides.  Competitive reactivity studies were performed, showing that attaching a dialkylamino group onto the end of the Michael acceptor results in compds. with greater reactivity due to intramol. catalysis of the Michael addn.  This, along with improved water-soly. results in compds. with enhanced biol. properties.  Mol. modeling results consistent with the proposed mechanism of inhibition are presented.  One compd., I (EKB-569), which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq317fAvBYUW7Vg90H21EOLACvtfcHk0lgE86II_AJYXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D&md5=db70c2f78c62824810854295d06ef6a4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0lgI0nvhSEC4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gureasko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lgI0nvhSEC4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wogan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span> </span><span class="NLM_article-title">Interstrain differences of in vitro metabolic stability and impact on early drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">4463</span><span class="NLM_x">–</span> <span class="NLM_lpage">4468</span><span class="refDoi"> DOI: 10.1002/jps.22179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1002%2Fjps.22179" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=4463-4468&author=W.+Richmondauthor=M.+Woganauthor=J.+Isbellauthor=W.+P.+Gordon&title=Interstrain+differences+of+in+vitro+metabolic+stability+and+impact+on+early+drug+discovery&doi=10.1002%2Fjps.22179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjps.22179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22179%26sid%3Dliteratum%253Aachs%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DWogan%26aufirst%3DM.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26atitle%3DInterstrain%2520differences%2520of%2520in%2520vitro%2520metabolic%2520stability%2520and%2520impact%2520on%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D4463%26epage%3D4468%26doi%3D10.1002%2Fjps.22179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lidOumZKVfWcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lidOumZKVfWcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tompkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillancourt, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span> </span><span class="NLM_article-title">EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F0008-5472.CAN-15-2581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1591-1602&author=Y.+Jiaauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=M.+J.+Niederstauthor=C.+Tompkinsauthor=N.+Timpleauthor=M.+T.+Vaillancourtauthor=A.+C.+Pferdekamperauthor=E.+L.+Lockermanauthor=C.+Liauthor=J.+Andersonauthor=C.+Costaauthor=D.+Liaoauthor=E.+Murphyauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=G.+Lelaisauthor=J.+Barretinaauthor=M.+McNeillauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=N.+Pathanauthor=J.+A.+Engelmanauthor=P.+Y.+Michellysauthor=P.+McNamaraauthor=J.+Harrisauthor=S.+Benderauthor=S.+Kasibhatla&title=EGF816+exerts+anticancer+effects+in+non-small+cell+lung+cancer+by+irreversibly+and+selectively+targeting+primary+and+acquired+activating+mutations+in+the+EGF+receptor&doi=10.1158%2F0008-5472.CAN-15-2581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2581%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DVaillancourt%26aufirst%3DM.%2BT.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKasibhatla%26aufirst%3DS.%26atitle%3DEGF816%2520exerts%2520anticancer%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520by%2520irreversibly%2520and%2520selectively%2520targeting%2520primary%2520and%2520acquired%2520activating%2520mutations%2520in%2520the%2520EGF%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D1591%26epage%3D1602%26doi%3D10.1158%2F0008-5472.CAN-15-2581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Tan, D. S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matushansky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu Schmitz, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span> </span><span class="NLM_article-title">First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">8013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8013&issue=Suppl.&author=D.+S.-W.+Tanauthor=T.+Setoauthor=N.+B.+Leighlauthor=G.+J.+Rielyauthor=L.+V.+Sequistauthor=E.+Felipauthor=J.+Wolfauthor=J.+C.-H.+Yangauthor=I.+Matushanskyauthor=X.+Yuauthor=S.-F.+Hsu+Schmitzauthor=X.+Cuiauthor=D.-W.+Kim&title=First-in-human+phase+I+study+of+EGF816%2C+a+third+generation%2C+mutant-selective+EGFR+tyrosine+kinase+inhibitor%2C+in+advanced+non-small+cell+lung+cancer+%28NSCLC%29+harboring+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DD.%2BS.-W.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DMatushansky%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DHsu%2BSchmitz%26aufirst%3DS.-F.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DD.-W.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520EGF816%252C%2520a%2520third%2520generation%252C%2520mutant-selective%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520harboring%2520T790M%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%26spage%3D8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0ljT1uG-LOthZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lhXpKCghgfFIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustyakimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urzhumtsev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span> </span><span class="NLM_article-title">Towards automated crystallographic structure refinement with phenix.refine</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1107/S0907444912001308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0907444912001308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22505256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=352-367&author=P.+V.+Afonineauthor=R.+W.+Grosse-Kunstleveauthor=N.+Echolsauthor=J.+J.+Headdauthor=N.+W.+Moriartyauthor=M.+Mustyakimovauthor=T.+C.+Terwilligerauthor=A.+Urzhumtsevauthor=P.+H.+Zwartauthor=P.+D.+Adams&title=Towards+automated+crystallographic+structure+refinement+with+phenix.refine&doi=10.1107%2FS0907444912001308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Towards automated crystallographic structure refinement with phenix.refine</span></div><div class="casAuthors">Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel; Headd, Jeffrey J.; Moriarty, Nigel W.; Mustyakimov, Marat; Terwilliger, Thomas C.; Urzhumtsev, Alexandre; Zwart, Peter H.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phenix.refine is a program within the PHENIX package that supports crystallog. structure refinement against exptl. data with a wide range of upper resoln. limits using a large repertoire of model parameterizations.  It has several automation features and is also highly flexible.  Several hundred parameters enable extensive customizations for complex use cases.  Multiple user-defined refinement strategies can be applied to specific parts of the model in a single refinement run.  An intuitive graphical user interface is available to guide novice users and to assist advanced users in managing refinement projects.  X-ray or neutron diffraction data can be used sep. or jointly in refinement. phenix.refine is tightly integrated into the PHENIX suite, where it serves as a crit. component in automated model building, final structure refinement, structure validation and deposition to the wwPDB.  This paper presents an overview of the major phenix.refine features, with extensive literature refs. for readers interested in more detailed discussions of the methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhn9QwIEkTbVg90H21EOLACvtfcHk0lhXpKCghgfFIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D&md5=1cc7da2cea396f1a75646ea709140cf1</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS0907444912001308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444912001308%26sid%3Dliteratum%253Aachs%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DMustyakimov%26aufirst%3DM.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DTowards%2520automated%2520crystallographic%2520structure%2520refinement%2520with%2520phenix.refine%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D352%26epage%3D367%26doi%3D10.1107%2FS0907444912001308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0lhQj9eohttqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span> </span><span class="NLM_article-title">Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1016/j.ab.2009.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.ab.2009.04.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2009&pages=31-38&author=L.+Hongauthor=C.+M.+Quinnauthor=Y.+Jia&title=Evaluating+the+utility+of+the+HTRF+Transcreener+ADP+assay+technology%3A+a+comparison+with+the+standard+HTRF+assay+technology&doi=10.1016%2Fj.ab.2009.04.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2009.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2009.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DJia%26aufirst%3DY.%26atitle%3DEvaluating%2520the%2520utility%2520of%2520the%2520HTRF%2520Transcreener%2520ADP%2520assay%2520technology%253A%2520a%2520comparison%2520with%2520the%2520standard%2520HTRF%2520assay%2520technology%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D391%26spage%3D31%26epage%3D38%26doi%3D10.1016%2Fj.ab.2009.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Kelstrup, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavallee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, J. V.</span><span> </span><span class="NLM_article-title">Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole orbitrap mass spectrometer</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3487</span><span class="NLM_x">–</span> <span class="NLM_lpage">3497</span><span class="refDoi"> DOI: 10.1021/pr3000249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr3000249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFGhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3487-3497&author=C.+D.+Kelstrupauthor=C.+Youngauthor=R.+Lavalleeauthor=M.+L.+Nielsenauthor=J.+V.+Olsen&title=Optimized+fast+and+sensitive+acquisition+methods+for+shotgun+proteomics+on+a+quadrupole+orbitrap+mass+spectrometer&doi=10.1021%2Fpr3000249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Fast and Sensitive Acquisition Methods for Shotgun Proteomics on a Quadrupole Orbitrap Mass Spectrometer</span></div><div class="casAuthors">Kelstrup, Christian D.; Young, Clifford; Lavallee, Richard; Nielsen, Michael L.; Olsen, Jesper V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3487-3497</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Advances in proteomics are continually driven by the introduction of new mass spectrometric instrumentation with improved performances.  The recently introduced quadrupole Orbitrap (Q Exactive) tandem mass spectrometer allows fast acquisition of high-resoln. higher-energy collisional dissocn. (HCD) tandem mass spectra due to the parallel mode of operation, where the generation, filling, and storage of fragment ions can be performed while simultaneously measuring another ion packet in the Orbitrap mass analyzer.  In this study, data-dependent acquisition methods for "fast" or "sensitive" scanning were optimized and assessed by comparing stable isotope labeled yeast proteome coverage.  We discovered that speed was the most important parameter for sample loads above 125 ng, where a 95 ms HCD scanning method allowed for identification and quantification of more than 2000 yeast proteins from 1 h of anal. time.  At sample loads below 125 ng, a 156 ms HCD acquisition method improved the sensitivity, mass accuracy, and quality of data and enabled us to identify 30% more proteins and peptides than the faster scanning method.  A similar effect was obsd. when the LC gradient was extended to 2 or 3 h for the anal. of complex mammalian whole cell lysates.  Using a 3 h LC gradient, the sensitive method enabled identification of more than 4000 proteins from 1 μg of tryptic HeLa digest, which was almost 200 more identifications compared to the faster scanning method.  Our results demonstrate that peptide identification on a quadrupole Orbitrap is dependent on sample amts., acquisition speed, and data quality, which emphasizes the need for acquisition methods tailored for different sample loads and anal. preferences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeF6hkFhNDMbVg90H21EOLACvtfcHk0ljQJhPj0x4fdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFGhtL4%253D&md5=399e069d9a3349292c226faedf5133d4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fpr3000249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr3000249%26sid%3Dliteratum%253Aachs%26aulast%3DKelstrup%26aufirst%3DC.%2BD.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DR.%26aulast%3DNielsen%26aufirst%3DM.%2BL.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26atitle%3DOptimized%2520fast%2520and%2520sensitive%2520acquisition%2520methods%2520for%2520shotgun%2520proteomics%2520on%2520a%2520quadrupole%2520orbitrap%2520mass%2520spectrometer%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2012%26volume%3D11%26spage%3D3487%26epage%3D3497%26doi%3D10.1021%2Fpr3000249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 49 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2020,</strong> <em>124 </em>
                                    (28)
                                     , 5813-5824. <a href="https://doi.org/10.1021/acs.jpcb.0c03440" title="DOI URL">https://doi.org/10.1021/acs.jpcb.0c03440</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.0c03440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.0c03440%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DMechanistic%252BStudy%252Bof%252BPotent%252BFluorinated%252BEGFR%252BKinase%252BInhibitors%252Bwith%252Ba%252BQuinazoline%252BScaffold%252Bagainst%252BL858R%25252FT790M%25252FC797S%252BResistance%252BMutation%25253A%252BUnveiling%252Bthe%252BFluorine%252BSubstituent%252BCooperativity%252BEffect%252Bon%252Bthe%252BInhibitory%252BActivity%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17042020%26date%3D16062020%26date%3D30062020%26volume%3D124%26issue%3D28%26spage%3D5813%26epage%3D5824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fubao Huang, Hangchen Hu, Kai Wang, Chengyuan Peng, Wenwei Xu, Yu Zhang, Jing Gao, Yishen Liu, Hu Zhou, Ruimin Huang, Minjun Li, Jianhua Shen, <span class="NLM_string-name hlFld-ContribAuthor">Yechun Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7052-7065. <a href="https://doi.org/10.1021/acs.jmedchem.0c00372" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00372%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BHighly%252BSelective%252BLipoprotein-Associated%252BPhospholipase%252BA2%252B%252528Lp-PLA2%252529%252BInhibitors%252Bby%252Ba%252BCovalent%252BFragment-Based%252BApproach%26aulast%3DHuang%26aufirst%3DFubao%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03032020%26date%3D10062020%26date%3D27052020%26volume%3D63%26issue%3D13%26spage%3D7052%26epage%3D7065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gaochan Wu, Tong Zhao, Dongwei Kang, Jian Zhang, Yuning Song, Vigneshwaran Namasivayam, Jacob Kongsted, Christophe Pannecouque, Erik De Clercq, Vasanthanathan Poongavanam, Xinyong Liu, <span class="NLM_string-name hlFld-ContribAuthor">Peng Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of Recent Strategic Advances in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9375-9414. <a href="https://doi.org/10.1021/acs.jmedchem.9b00359" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00359%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOverview%252Bof%252BRecent%252BStrategic%252BAdvances%252Bin%252BMedicinal%252BChemistry%26aulast%3DWu%26aufirst%3DGaochan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26022019%26date%3D28052019%26date%3D03052019%26volume%3D62%26issue%3D21%26spage%3D9375%26epage%3D9414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Feng, Zhongqing Wang, Zhonghua Luo, Minghong Chen, Fang He, Bin Liu, Siegfried Goldmann, <span class="NLM_string-name hlFld-ContribAuthor">Lei Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Further Optimization of a Scalable Biocatalytic Route to (3R)-N-Boc-3-aminoazepane with Immobilized ω-Transaminase. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (3)
                                     , 355-360. <a href="https://doi.org/10.1021/acs.oprd.8b00411" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00411%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DFurther%252BOptimization%252Bof%252Ba%252BScalable%252BBiocatalytic%252BRoute%252Bto%252B%2525283R%252529-N-Boc-3-aminoazepane%252Bwith%252BImmobilized%252B%2525CF%252589-Transaminase%26aulast%3DFeng%26aufirst%3DYahui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D04122018%26date%3D28022019%26date%3D21022019%26volume%3D23%26issue%3D3%26spage%3D355%26epage%3D360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Dean G. Brown, <span class="NLM_string-name hlFld-ContribAuthor">Jonas Boström</span>. </span><span class="cited-content_cbyCitation_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (21)
                                     , 9442-9468. <a href="https://doi.org/10.1021/acs.jmedchem.8b00675" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhere%252BDo%252BRecent%252BSmall%252BMolecule%252BClinical%252BDevelopment%252BCandidates%252BCome%252BFrom%25253F%26aulast%3DBrown%26aufirst%3DDean%2BG.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D27042018%26date%3D09072018%26date%3D19062018%26volume%3D61%26issue%3D21%26spage%3D9442%26epage%3D9468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hyun-Jeong Ryu, Seung-Ju Yang, Gee-Hyung Lee, <span class="NLM_string-name hlFld-ContribAuthor">Young-Dae Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of Druglike 2-Amido Benzo[d]imidazole Analogues via Desulfurative Cyclization of Thiourea Intermediate Resin on Solid-Phase. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2018,</strong> <em>20 </em>
                                    (5)
                                     , 282-291. <a href="https://doi.org/10.1021/acscombsci.8b00004" title="DOI URL">https://doi.org/10.1021/acscombsci.8b00004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.8b00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.8b00004%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DConstruction%252Bof%252BDruglike%252B2-Amido%252BBenzo%25255Bd%25255Dimidazole%252BAnalogues%252Bvia%252BDesulfurative%252BCyclization%252Bof%252BThiourea%252BIntermediate%252BResin%252Bon%252BSolid-Phase%26aulast%3DRyu%26aufirst%3DHyun-Jeong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09012018%26date%3D17032018%26date%3D26032018%26date%3D20032018%26volume%3D20%26issue%3D5%26spage%3D282%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yahui  Feng</span>, <span class="hlFld-ContribAuthor ">Zhonghua  Luo</span>, <span class="hlFld-ContribAuthor ">Guodong  Sun</span>, <span class="hlFld-ContribAuthor ">Minghong  Chen</span>, <span class="hlFld-ContribAuthor ">Jinqiang  Lai</span>, <span class="hlFld-ContribAuthor ">Wei  Lin</span>, <span class="hlFld-ContribAuthor ">Siegfried  Goldmann</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, and <span class="hlFld-ContribAuthor ">Zhongqing  Wang</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of an Efficient and Scalable Biocatalytic Route to (3R)-3-Aminoazepane: A Pharmaceutically Important Intermediate. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2017,</strong> <em>21 </em>
                                    (4)
                                     , 648-654. <a href="https://doi.org/10.1021/acs.oprd.7b00074" title="DOI URL">https://doi.org/10.1021/acs.oprd.7b00074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.7b00074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.7b00074%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ban%252BEfficient%252Band%252BScalable%252BBiocatalytic%252BRoute%252Bto%252B%2525283R%252529-3-Aminoazepane%25253A%252BA%252BPharmaceutically%252BImportant%252BIntermediate%26aulast%3DFeng%26aufirst%3DYahui%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D01032017%26date%3D31032017%26date%3D21042017%26date%3D29032017%26volume%3D21%26issue%3D4%26spage%3D648%26epage%3D654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Xiao-E  Yan</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhao</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, and <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2944-2962. <a href="https://doi.org/10.1021/acs.jmedchem.6b01907" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01907</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01907%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-1-%2525283-%2525284-Amino-3-%2525283-chloro-4-%252528pyridin-2-ylmethoxy%252529phenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529piperidin-1-yl%252529prop-2-en-1-one%252B%252528CHMFL-EGFR-202%252529%252Bas%252Ba%252BNovel%252BIrreversible%252BEGFR%252BMutant%252BKinase%252BInhibitor%252Bwith%252Ba%252BDistinct%252BBinding%252BMode%26aulast%3DWang%26aufirst%3DAoli%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D28122016%26date%3D22032017%26date%3D13042017%26date%3D10032017%26volume%3D60%26issue%3D7%26spage%3D2944%26epage%3D2962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Misako  Nagasaka</span>, <span class="hlFld-ContribAuthor ">Viola W.  Zhu</span>, <span class="hlFld-ContribAuthor ">Sun Min  Lim</span>, <span class="hlFld-ContribAuthor ">Michael  Greco</span>, <span class="hlFld-ContribAuthor ">Fengying  Wu</span>, <span class="hlFld-ContribAuthor ">Sai-Hong Ignatius  Ou</span>. </span><span class="cited-content_cbyCitation_article-title">Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (5)
                                     , 740-763. <a href="https://doi.org/10.1016/j.jtho.2020.11.028" title="DOI URL">https://doi.org/10.1016/j.jtho.2020.11.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2020.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2020.11.028%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DBeyond%252BOsimertinib%25253A%252BThe%252BDevelopment%252Bof%252BThird-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%2525C2%2525A0For%252BAdvanced%252BEGFR%25252B%252BNSCLC%26aulast%3DNagasaka%26aufirst%3DMisako%26date%3D2021%26volume%3D16%26issue%3D5%26spage%3D740%26epage%3D763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuliya O.  Kuchkovska</span>, <span class="hlFld-ContribAuthor ">Oleksandr O.  Grygorenko</span>. </span><span class="cited-content_cbyCitation_article-title">Azepines and Their Fused-Ring Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00073-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00073-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00073-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00073-1%26sid%3Dliteratum%253Aachs%26atitle%3DAzepines%252Band%252BTheir%252BFused-Ring%252BDerivatives%26aulast%3DKuchkovska%26aufirst%3DYuliya%2BO.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba A.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Hanan M.  Refaat</span>. </span><span class="cited-content_cbyCitation_article-title">Versatile mechanisms of 2-substituted benzimidazoles in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s43094-020-00048-8" title="DOI URL">https://doi.org/10.1186/s43094-020-00048-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s43094-020-00048-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs43094-020-00048-8%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DVersatile%252Bmechanisms%252Bof%252B2-substituted%252Bbenzimidazoles%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DIbrahim%26aufirst%3DHeba%2BA.%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Surya K.  Tripathi</span>, <span class="hlFld-ContribAuthor ">Kamal  Pandey</span>, <span class="hlFld-ContribAuthor ">Kannan R. R.  Rengasamy</span>, <span class="hlFld-ContribAuthor ">Bijesh K.  Biswal</span>. </span><span class="cited-content_cbyCitation_article-title">Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2132-2176. <a href="https://doi.org/10.1002/med.21700" title="DOI URL">https://doi.org/10.1002/med.21700</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21700%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DRecent%252Bupdates%252Bon%252Bthe%252Bresistance%252Bmechanisms%252Bto%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Band%252Bresistance%252Breversion%252Bstrategies%252Bin%252Blung%252Bcancer%26aulast%3DTripathi%26aufirst%3DSurya%2BK.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2132%26epage%3D2176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuel  Saldivia</span>, <span class="hlFld-ContribAuthor ">Eric  Fang</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Ma</span>, <span class="hlFld-ContribAuthor ">Elmarie  Myburgh</span>, <span class="hlFld-ContribAuthor ">Juliana B. T.  Carnielli</span>, <span class="hlFld-ContribAuthor ">Christopher  Bower-Lepts</span>, <span class="hlFld-ContribAuthor ">Elaine  Brown</span>, <span class="hlFld-ContribAuthor ">Ryan  Ritchie</span>, <span class="hlFld-ContribAuthor ">Suresh B.  Lakshminarayana</span>, <span class="hlFld-ContribAuthor ">Yen-Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Debjani  Patra</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Ornelas</span>, <span class="hlFld-ContribAuthor ">Hazel X. Y.  Koh</span>, <span class="hlFld-ContribAuthor ">Sarah L.  Williams</span>, <span class="hlFld-ContribAuthor ">Frantisek  Supek</span>, <span class="hlFld-ContribAuthor ">Daniel  Paape</span>, <span class="hlFld-ContribAuthor ">Richard  McCulloch</span>, <span class="hlFld-ContribAuthor ">Marcel  Kaiser</span>, <span class="hlFld-ContribAuthor ">Michael P.  Barrett</span>, <span class="hlFld-ContribAuthor ">Jan  Jiricek</span>, <span class="hlFld-ContribAuthor ">Thierry T.  Diagana</span>, <span class="hlFld-ContribAuthor ">Jeremy C.  Mottram</span>, <span class="hlFld-ContribAuthor ">Srinivasa P. S.  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nature Microbiology</span><span> <strong>2020,</strong> <em>5 </em>
                                    (10)
                                     , 1207-1216. <a href="https://doi.org/10.1038/s41564-020-0745-6" title="DOI URL">https://doi.org/10.1038/s41564-020-0745-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41564-020-0745-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41564-020-0745-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Microbiology%26atitle%3DTargeting%252Bthe%252Btrypanosome%252Bkinetochore%252Bwith%252BCLK1%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DSaldivia%26aufirst%3DManuel%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D10%26spage%3D1207%26epage%3D1216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Midori  Ishii</span>, <span class="hlFld-ContribAuthor ">Bungo  Akiyoshi</span>. </span><span class="cited-content_cbyCitation_article-title">Characterization of unconventional kinetochore kinases KKT10 and KKT19 in
              Trypanosoma brucei. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cell Science</span><span> <strong>2020,</strong> <em>133 </em>
                                    (8)
                                     <a href="https://doi.org/10.1242/jcs.240978" title="DOI URL">https://doi.org/10.1242/jcs.240978</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1242/jcs.240978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1242%2Fjcs.240978%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cell%2520Science%26atitle%3DCharacterization%252Bof%252Bunconventional%252Bkinetochore%252Bkinases%252BKKT10%252Band%252BKKT19%252Bin%252BTrypanosoma%252Bbrucei%26aulast%3DIshii%26aufirst%3DMidori%26date%3D2020%26date%3D2020%26volume%3D133%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Igor P.  Oscorbin</span>, <span class="hlFld-ContribAuthor ">Alexandra S.  Shadrina</span>, <span class="hlFld-ContribAuthor ">Vadim V.  Kozlov</span>, <span class="hlFld-ContribAuthor ">Vladimir E.  Voitsitsky</span>, <span class="hlFld-ContribAuthor ">Maxim L.  Filipenko</span>. </span><span class="cited-content_cbyCitation_article-title">Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues. </span><span class="cited-content_cbyCitation_journal-name">Pathology & Oncology Research</span><span> <strong>2020,</strong> <em>26 </em>
                                    (2)
                                     , 1229-1234. <a href="https://doi.org/10.1007/s12253-019-00683-4" title="DOI URL">https://doi.org/10.1007/s12253-019-00683-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12253-019-00683-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12253-019-00683-4%26sid%3Dliteratum%253Aachs%26jtitle%3DPathology%2520%2526%2520Oncology%2520Research%26atitle%3DAbsence%252Bof%252BEGFR%252BC797S%252BMutation%252Bin%252BTyrosine%252BKinase%252BInhibitor-Na%2525C3%2525AFve%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BTissues%26aulast%3DOscorbin%26aufirst%3DIgor%2BP.%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D2%26spage%3D1229%26epage%3D1234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdulrahman A.  Almehizia</span>, <span class="hlFld-ContribAuthor ">Haitham  AlRabiah</span>, <span class="hlFld-ContribAuthor ">Ahmed H.  Bakheit</span>, <span class="hlFld-ContribAuthor ">Eman S. G.  Hassan</span>, <span class="hlFld-ContribAuthor ">Rashed N.  Herqash</span>, <span class="hlFld-ContribAuthor ">Ali Saber  Abdelhameed</span>. </span><span class="cited-content_cbyCitation_article-title">Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin. </span><span class="cited-content_cbyCitation_journal-name">Royal Society Open Science</span><span> <strong>2020,</strong> <em>7 </em>
                                    (1)
                                     , 191595. <a href="https://doi.org/10.1098/rsos.191595" title="DOI URL">https://doi.org/10.1098/rsos.191595</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1098/rsos.191595&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1098%2Frsos.191595%26sid%3Dliteratum%253Aachs%26jtitle%3DRoyal%2520Society%2520Open%2520Science%26atitle%3DSpectroscopic%252Band%252Bmolecular%252Bdocking%252Bstudies%252Breveal%252Bbinding%252Bcharacteristics%252Bof%252Bnazartinib%252B%252528EGF816%252529%252Bto%252Bhuman%252Bserum%252Balbumin%26aulast%3DAlmehizia%26aufirst%3DAbdulrahman%2BA.%26date%3D2020%26date%3D2020%26volume%3D7%26issue%3D1%26spage%3D191595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zeng</span>, <span class="hlFld-ContribAuthor ">Johnny  Castillo-Cabrera</span>, <span class="hlFld-ContribAuthor ">Mika  Manser</span>, <span class="hlFld-ContribAuthor ">Bo  Lu</span>, <span class="hlFld-ContribAuthor ">Zinger  Yang</span>, <span class="hlFld-ContribAuthor ">Vaik  Strande</span>, <span class="hlFld-ContribAuthor ">Damien  Begue</span>, <span class="hlFld-ContribAuthor ">Raffaella  Zamponi</span>, <span class="hlFld-ContribAuthor ">Shumei  Qiu</span>, <span class="hlFld-ContribAuthor ">Frederic  Sigoillot</span>, <span class="hlFld-ContribAuthor ">Qiong  Wang</span>, <span class="hlFld-ContribAuthor ">Alicia  Lindeman</span>, <span class="hlFld-ContribAuthor ">John S  Reece-Hoyes</span>, <span class="hlFld-ContribAuthor ">Carsten  Russ</span>, <span class="hlFld-ContribAuthor ">Debora  Bonenfant</span>, <span class="hlFld-ContribAuthor ">Xiaomo  Jiang</span>, <span class="hlFld-ContribAuthor ">Youzhen  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Cong</span>. </span><span class="cited-content_cbyCitation_article-title">Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2019,</strong> <em>8 </em><a href="https://doi.org/10.7554/eLife.50223" title="DOI URL">https://doi.org/10.7554/eLife.50223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.50223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.50223%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DGenome-wide%252BCRISPR%252Bscreening%252Breveals%252Bgenetic%252Bmodifiers%252Bof%252Bmutant%252BEGFR%252Bdependence%252Bin%252Bhuman%252BNSCLC%26aulast%3DZeng%26aufirst%3DHao%26date%3D2019%26date%3D2019%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana C.Z.  Gelatti</span>, <span class="hlFld-ContribAuthor ">Alexander  Drilon</span>, <span class="hlFld-ContribAuthor ">Fernando C.  Santini</span>. </span><span class="cited-content_cbyCitation_article-title">Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2019,</strong> <em>137 </em>, 113-122. <a href="https://doi.org/10.1016/j.lungcan.2019.09.017" title="DOI URL">https://doi.org/10.1016/j.lungcan.2019.09.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2019.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2019.09.017%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DOptimizing%252Bthe%252Bsequencing%252Bof%252Btyrosine%252Bkinase%252Binhibitors%252B%252528TKIs%252529%252Bin%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Bmutation-positive%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%26aulast%3DGelatti%26aufirst%3DAna%2BC.Z.%26date%3D2019%26volume%3D137%26spage%3D113%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veronica  Aran</span>, <span class="hlFld-ContribAuthor ">Jasminka  Omerovic</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in NSCLC Targeting K-RAS and EGFR. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 5701. <a href="https://doi.org/10.3390/ijms20225701" title="DOI URL">https://doi.org/10.3390/ijms20225701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20225701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20225701%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DCurrent%252BApproaches%252Bin%252BNSCLC%252BTargeting%252BK-RAS%252Band%252BEGFR%26aulast%3DAran%26aufirst%3DVeronica%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ali S.  Abdelhameed</span>, <span class="hlFld-ContribAuthor ">Mohamed W.  Attwa</span>, <span class="hlFld-ContribAuthor ">Adnan A.  Kadi</span>. </span><span class="cited-content_cbyCitation_article-title">Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites. </span><span class="cited-content_cbyCitation_journal-name">Royal Society Open Science</span><span> <strong>2019,</strong> <em>6 </em>
                                    (8)
                                     , 190852. <a href="https://doi.org/10.1098/rsos.190852" title="DOI URL">https://doi.org/10.1098/rsos.190852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1098/rsos.190852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1098%2Frsos.190852%26sid%3Dliteratum%253Aachs%26jtitle%3DRoyal%2520Society%2520Open%2520Science%26atitle%3DLiquid%252Bchromatography%2525E2%252580%252593tandem%252Bmass%252Bspectrometry%252Bmetabolic%252Bprofiling%252Bof%252Bnazartinib%252Breveals%252Bthe%252Bformation%252Bof%252Bunexpected%252Breactive%252Bmetabolites%26aulast%3DAbdelhameed%26aufirst%3DAli%2BS.%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D8%26spage%3D190852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lara  Kujtan</span>, <span class="hlFld-ContribAuthor ">Janakiraman  Subramanian</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Anticancer Therapy</span><span> <strong>2019,</strong> <em>19 </em>
                                    (7)
                                     , 547-559. <a href="https://doi.org/10.1080/14737140.2019.1596030" title="DOI URL">https://doi.org/10.1080/14737140.2019.1596030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737140.2019.1596030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737140.2019.1596030%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Anticancer%2520Therapy%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DKujtan%26aufirst%3DLara%26date%3D2019%26date%3D2019%26volume%3D19%26issue%3D7%26spage%3D547%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>, <span class="hlFld-ContribAuthor ">Mallaiah  Keesara</span>, <span class="hlFld-ContribAuthor ">Ashok G.  Moghudula</span>, <span class="hlFld-ContribAuthor ">Pranab  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1435-1439. <a href="https://doi.org/10.1016/j.bmcl.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bgeneration%252Bof%252B1%25252C2-dithiolanes%252Bas%252Bexon%252B19%252Band%252Bexon%252B21%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1435%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Clinical Trial Third-Generation EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 25-43. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00002-0" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00002-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00002-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00002-0%26sid%3Dliteratum%253Aachs%26atitle%3DApproved%252Band%252BClinical%252BTrial%252BThird-Generation%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D25%26epage%3D43%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gao-Feng  Zha</span>, <span class="hlFld-ContribAuthor ">K.P.  Rakesh</span>, <span class="hlFld-ContribAuthor ">H.M.  Manukumar</span>, <span class="hlFld-ContribAuthor ">C.S.  Shantharam</span>, <span class="hlFld-ContribAuthor ">Sihui  Long</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmaceutical significance of azepane based motifs for drug discovery: A critical review. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>162 </em>, 465-494. <a href="https://doi.org/10.1016/j.ejmech.2018.11.031" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.031%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPharmaceutical%252Bsignificance%252Bof%252Bazepane%252Bbased%252Bmotifs%252Bfor%252Bdrug%252Bdiscovery%25253A%252BA%252Bcritical%252Breview%26aulast%3DZha%26aufirst%3DGao-Feng%26date%3D2019%26volume%3D162%26spage%3D465%26epage%3D494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Fuyun  Chi</span>, <span class="hlFld-ContribAuthor ">Tong  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Youjun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (23-24)
                                     , 6087-6095. <a href="https://doi.org/10.1016/j.bmc.2018.11.009" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bsynthesis%252Bof%252B4-arylamido-2-arylaminoprimidines%252Bas%252Bpotent%252BEGFR%252BT790M%25252FL858R%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLixue%26date%3D2018%26volume%3D26%26issue%3D23-24%26spage%3D6087%26epage%3D6095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chee-Seng  Tan</span>, <span class="hlFld-ContribAuthor ">Nesaretnam Barr  Kumarakulasinghe</span>, <span class="hlFld-ContribAuthor ">Yi-Qing  Huang</span>, <span class="hlFld-ContribAuthor ">Yvonne Li En  Ang</span>, <span class="hlFld-ContribAuthor ">Joan Rou-En  Choo</span>, <span class="hlFld-ContribAuthor ">Boon-Cher  Goh</span>, <span class="hlFld-ContribAuthor ">Ross A.  Soo</span>. </span><span class="cited-content_cbyCitation_article-title">Third generation EGFR TKIs: current data and future directions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0778-0" title="DOI URL">https://doi.org/10.1186/s12943-018-0778-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0778-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0778-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DThird%252Bgeneration%252BEGFR%252BTKIs%25253A%252Bcurrent%252Bdata%252Band%252Bfuture%252Bdirections%26aulast%3DTan%26aufirst%3DChee-Seng%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sunkyu  Kim</span>, <span class="hlFld-ContribAuthor ">Ralph  Tiedt</span>, <span class="hlFld-ContribAuthor ">Alice  Loo</span>, <span class="hlFld-ContribAuthor ">Thomas  Horn</span>, <span class="hlFld-ContribAuthor ">Scott  Delach</span>, <span class="hlFld-ContribAuthor ">Steven  Kovats</span>, <span class="hlFld-ContribAuthor ">Kristy  Haas</span>, <span class="hlFld-ContribAuthor ">Barbara Schacher  Engstler</span>, <span class="hlFld-ContribAuthor ">Alexander  Cao</span>, <span class="hlFld-ContribAuthor ">Maria  Pinzon-Ortiz</span>, <span class="hlFld-ContribAuthor ">Iain  Mulford</span>, <span class="hlFld-ContribAuthor ">Michael G.  Acker</span>, <span class="hlFld-ContribAuthor ">Rajiv  Chopra</span>, <span class="hlFld-ContribAuthor ">Christopher  Brain</span>, <span class="hlFld-ContribAuthor ">Emmanuelle  di Tomaso</span>, <span class="hlFld-ContribAuthor ">William R.  Sellers</span>, <span class="hlFld-ContribAuthor ">Giordano  Caponigro</span>. </span><span class="cited-content_cbyCitation_article-title">The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (81)
                                     , 35226-35240. <a href="https://doi.org/10.18632/oncotarget.26215" title="DOI URL">https://doi.org/10.18632/oncotarget.26215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26215%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DThe%252Bpotent%252Band%252Bselective%252Bcyclin-dependent%252Bkinases%252B4%252Band%252B6%252Binhibitor%252Bribociclib%252B%252528LEE011%252529%252Bis%252Ba%252Bversatile%252Bcombination%252Bpartner%252Bin%252Bpreclinical%252Bcancer%252Bmodels%26aulast%3DKim%26aufirst%3DSunkyu%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D81%26spage%3D35226%26epage%3D35240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 32-47. <a href="https://doi.org/10.1016/j.ejmech.2017.05.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bupdates%252Bon%252Bthird%252Bgeneration%252BEGFR%252Binhibitors%252Band%252Bemergence%252Bof%252Bfourth%252Bgeneration%252BEGFR%252Binhibitors%252Bto%252Bcombat%252BC797S%252Bresistance%26aulast%3DPatel%26aufirst%3DHarun%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yao  Yao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 493-505. <a href="https://doi.org/10.1016/j.ejmech.2017.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bbinding%252Bdesign%252Bstrategy%25253A%252BA%252Bprospective%252Bmethod%252Bfor%252Bdiscovery%252Bof%252Bpotent%252Btargeted%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2017%26volume%3D142%26spage%3D493%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Zhao  Zhong</span>, <span class="hlFld-ContribAuthor ">Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">The resistance mechanisms and treatment strategies for
              EGFR
              -mutant advanced non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (41)
                                     , 71358-71370. <a href="https://doi.org/10.18632/oncotarget.20311" title="DOI URL">https://doi.org/10.18632/oncotarget.20311</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.20311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.20311%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DThe%252Bresistance%252Bmechanisms%252Band%252Btreatment%252Bstrategies%252Bfor%252BEGFR%252B-mutant%252Badvanced%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DZhong%26aufirst%3DWen-Zhao%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D41%26spage%3D71358%26epage%3D71370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiyong  Liang</span>, <span class="hlFld-ContribAuthor ">Ying  Cheng</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Yanping  Hu</span>, <span class="hlFld-ContribAuthor ">Wei-Ping  Liu</span>, <span class="hlFld-ContribAuthor ">You  Lu</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Ye  Wang</span>, <span class="hlFld-ContribAuthor ">Gang  Wu</span>, <span class="hlFld-ContribAuthor ">Jian-Ming  Ying</span>, <span class="hlFld-ContribAuthor ">He-Long  Zhang</span>, <span class="hlFld-ContribAuthor ">Xu-Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2017,</strong> <em>403 </em>, 186-194. <a href="https://doi.org/10.1016/j.canlet.2017.06.008" title="DOI URL">https://doi.org/10.1016/j.canlet.2017.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2017.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2017.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DEGFR%252BT790M%252BctDNA%252Btesting%252Bplatforms%252Band%252Btheir%252Brole%252Bas%252Bcompanion%252Bdiagnostics%25253A%252BCorrelation%252Bwith%252Bclinical%252Boutcomes%252Bto%252BEGFR-TKIs%26aulast%3DLiang%26aufirst%3DZhiyong%26date%3D2017%26volume%3D403%26spage%3D186%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin-Chi  Liao</span>, <span class="hlFld-ContribAuthor ">Chia-Chi  Lin</span>, <span class="hlFld-ContribAuthor ">Jih-Hsiang  Lee</span>, <span class="hlFld-ContribAuthor ">James Chih-Hsin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Optimal management of EGFR -mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2017,</strong> <em>110 </em>, 7-13. <a href="https://doi.org/10.1016/j.lungcan.2017.05.009" title="DOI URL">https://doi.org/10.1016/j.lungcan.2017.05.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2017.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2017.05.009%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DOptimal%252Bmanagement%252Bof%252BEGFR%252B-mutant%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bdisease%252Bprogression%252Bon%252Bfirst-line%252Btyrosine%252Bkinase%252Binhibitor%252Btherapy%26aulast%3DLiao%26aufirst%3DBin-Chi%26date%3D2017%26volume%3D110%26spage%3D7%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueqiang  Li</span>, <span class="hlFld-ContribAuthor ">Christopher P.  Guise</span>, <span class="hlFld-ContribAuthor ">Rana  Taghipouran</span>, <span class="hlFld-ContribAuthor ">Yuliana  Yosaatmadja</span>, <span class="hlFld-ContribAuthor ">Amir  Ashoorzadeh</span>, <span class="hlFld-ContribAuthor ">Woo-Kyong  Paik</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Squire</span>, <span class="hlFld-ContribAuthor ">Shuang  Jiang</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Adam V.  Patterson</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">2-Oxo-3, 4-dihydropyrimido[4, 5- d ]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>135 </em>, 531-543. <a href="https://doi.org/10.1016/j.ejmech.2017.04.049" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.049%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Oxo-3%25252C%252B4-dihydropyrimido%25255B4%25252C%252B5-%252Bd%252B%25255Dpyrimidinyl%252Bderivatives%252Bas%252Bnew%252Birreversible%252Bpan%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%252B%252528FGFR%252529%252Binhibitors%26aulast%3DLi%26aufirst%3DXueqiang%26date%3D2017%26volume%3D135%26spage%3D531%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Sullivan</span>, <span class="hlFld-ContribAuthor ">David  Planchard</span>. </span><span class="cited-content_cbyCitation_article-title">Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Medicine</span><span> <strong>2017,</strong> <em>3 </em><a href="https://doi.org/10.3389/fmed.2016.00076" title="DOI URL">https://doi.org/10.3389/fmed.2016.00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmed.2016.00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmed.2016.00076%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Medicine%26atitle%3DNext-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252BTreating%252BEGFR-Mutant%252BLung%252BCancer%252Bbeyond%252BFirst%252BLine%26aulast%3DSullivan%26aufirst%3DIvana%26date%3D2017%26date%3D2017%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam G.  Meyer</span>, <span class="hlFld-ContribAuthor ">Alex C.  Bissember</span>, <span class="hlFld-ContribAuthor ">Christopher  Hyland</span>, <span class="hlFld-ContribAuthor ">Jason A.  Smith</span>, <span class="hlFld-ContribAuthor ">Charlotte C.  Williams</span>, <span class="hlFld-ContribAuthor ">Farzad  Zamani</span>, <span class="hlFld-ContribAuthor ">Steven-Alan G.  Abel</span>. </span><span class="cited-content_cbyCitation_article-title">Seven-Membered Rings. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 579-633. <a href="https://doi.org/10.1016/B978-0-08-102310-5.00016-3" title="DOI URL">https://doi.org/10.1016/B978-0-08-102310-5.00016-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102310-5.00016-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102310-5.00016-3%26sid%3Dliteratum%253Aachs%26atitle%3DSeven-Membered%252BRings%26aulast%3DMeyer%26aufirst%3DAdam%2BG.%26date%3D2017%26spage%3D579%26epage%3D633%26pub%3DElsevier%26date%3D2017%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xiao-e  Yan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Caihong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 1107-1117. <a href="https://doi.org/10.1016/j.ejmech.2016.12.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bstructure-guided%252Boptimization%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bselective%252Binhibitors%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%26aulast%3DYu%26aufirst%3DLei%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wasim  Akhtar</span>, <span class="hlFld-ContribAuthor ">Mohemmed Faraz  Khan</span>, <span class="hlFld-ContribAuthor ">Garima  Verma</span>, <span class="hlFld-ContribAuthor ">M.  Shaquiquzzaman</span>, <span class="hlFld-ContribAuthor ">M.A.  Rizvi</span>, <span class="hlFld-ContribAuthor ">Syed Hassan  Mehdi</span>, <span class="hlFld-ContribAuthor ">Mymoona  Akhter</span>, <span class="hlFld-ContribAuthor ">M. Mumtaz  Alam</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 705-753. <a href="https://doi.org/10.1016/j.ejmech.2016.12.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTherapeutic%252Bevolution%252Bof%252Bbenzimidazole%252Bderivatives%252Bin%252Bthe%252Blast%252Bquinquennial%252Bperiod%26aulast%3DAkhtar%26aufirst%3DWasim%26date%3D2017%26volume%3D126%26spage%3D705%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianfei  Sheng</span>, <span class="hlFld-ContribAuthor ">Zhihong  Liu</span>, <span class="hlFld-ContribAuthor ">Ming  Yan</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Ensheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (23)
                                     , 4971-4977. <a href="https://doi.org/10.1039/C7OB00793K" title="DOI URL">https://doi.org/10.1039/C7OB00793K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00793K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00793K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBiomass-involved%252Bsynthesis%252Bof%252BN-substituted%252Bbenzofuro%25255B2%25252C3-d%25255Dpyrimidine-4-amines%252Band%252Bbiological%252Bevaluation%252Bas%252Bnovel%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSheng%26aufirst%3DJianfei%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D23%26spage%3D4971%26epage%3D4977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of selected EGFR inhibitors: (a) reversible pan-EGFR inhibitors; (b) irreversible pan-EGFR inhibitors; (c) irreversible mutant-selective EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) High throughput screening (HTS) approach that culminated in the identification of both allosteric and ATP-competitive EGFR hits. Biochemical IC<sub>50</sub> (μM) of ATP-competitive hit <b>7</b> as average of at least duplicate measurements assessed at 10 μM ATP concentration for either mutants (L858R and L858R-T790M) and WT EGFR constructs. (b) Docking model for the binding of <b>7</b> in the ATP-pocket of EGFR T790M-AEE788 cocrystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu">2jiu</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) DMF, DIPEA, 120 °C; (b) Pd/C, H<sub>2</sub>, MeOH; (c) CNBr, MeCN/H<sub>2</sub>O/MeOH 55 °C; (d) 3-(trifluoromethyl)benzoic acid, HATU, DIPEA, DMF or 3-(trifluoromethyl)benzoic acid, HOBt, EDCI, Et<sub>3</sub>N, DMF.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) R<sup>1</sup> = Boc: DMF, base (DIPEA or K<sub>2</sub>CO<sub>3</sub>), 110–130 °C; R<sup>1</sup> = H: neat or DMF, 130–150 °C. (b) For <b>p</b>, <b>q</b>, <b>s</b>, R<sup>1</sup> = H: Boc<sub>2</sub>O, Et<sub>3</sub>N, dioxane. (c) Pd/C, H<sub>2</sub>, MeOH; (d) CNBr, MeCN/H<sub>2</sub>O/MeOH 45–50 °C; (e) 3-(trifluoromethyl)benzoic acid, HATU, DIPEA, DMF; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (g) acryloyl chloride, with or without Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0–20 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) neat, DMA or DMF, DIPEA, 110–140 °C. (b) For <b>35</b>: Pd/C, H<sub>2</sub>, MeOH. For <b>36</b>: Zn, AcOH, room temperature. (c) CNBr, MeCN/H<sub>2</sub>O/MeOH 55 °C; (d) acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub> or acid, HATU, DIPEA, DMF; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub> or HCl, dioxane/MeOH. (g) For <b>43</b>: acryloyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, 0–20 °C. For <b>44</b>–<b>47</b>: (<i>E</i>)-4-(dimethylamino)but-2-enoic acid hydrochloride, HOBt, EDCI, Et<sub>3</sub>N, DMF or (<i>E</i>)-4-(dimethylamino)but-2-enoic acid, HATU, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of apo and drug bound hinge region. (A) Superposition of apo WT EGFR (white sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2">2gs2</a>)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and EGFR T790M mutant (cyan sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit">2jit</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Water molecules associated with the WT structure are shown in gray spheres; those associated with the T790M structure are shown in cyan spheres. Polar interaction is depicted by magenta dotted line. (B) Superposition of the apo WT EGFR (white sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2">2gs2</a>),<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> WT EGFR-<b>43</b> complex (green sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed">5fed</a>), and EGFR T790M-<b>43</b> complex (cyan sticks, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee">5fee</a>). Polar interactions are depicted by yellow dotted line. In both drug bound structures, <b>43</b> is shown in yellow sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Mouse H1975 abbreviated efficacy study. Compounds were dosed po q.d. for 5 days. Δ % body weights were recorded on day 5, and percent mean tumor volume of the drug-treated group versus mean tumor volume of the control group (<i>T</i>/<i>C</i>) was measured at end of study (day 6). (b) End of study free plasma exposure of compounds <b>45</b>–<b>47</b> for 50 mg/kg dose. Plasma PK samples were collected on day 5 at 30 min, 3 h, 7 h, and 24 h postdosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/medium/jm-2015-01985j_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds <b>46</b> and <b>47</b> bind irreversibly to EGFR constructs: (a) cocrystal structure of EGFR T790M-<b>46</b> complex; (b) deconvoluted mass spectrum of EGFR L858R-T790M after in vitro incubation with <b>47</b>; (c) MS/MS of EGFR peptide covalently modified with <b>47</b> at Cys797.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-14/acs.jmedchem.5b01985/20160722/images/large/jm-2015-01985j_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01985&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i136">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgEACSgb3ssVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Paez, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tracy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">304</span><span class="NLM_x">, </span> <span class="NLM_fpage">1497</span><span class="NLM_x">–</span> <span class="NLM_lpage">1500</span><span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lhxHrvk4GU4SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Köhler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuler, M.</span><span> </span><span class="NLM_article-title">Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review</span> <span class="citation_source-journal">Onkologie</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">510</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span><span class="refDoi"> DOI: 10.1159/000354627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1159%2F000354627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24051929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpvVymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=510-518&author=J.+K%C3%B6hlerauthor=M.+Schuler&title=Afatinib%2C+erlotinib+and+gefitinib+in+the+first-line+therapy+of+EGFR+mutation-positive+lung+adenocarcinoma%3A+a+review&doi=10.1159%2F000354627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review</span></div><div class="casAuthors">Kohler Jens; Schuler Martin</div><div class="citationInfo"><span class="NLM_cas:title">Onkologie</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">510-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined phenotypes that display an enormous genetic variability.  In recent years, epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma has emerged as a unique subset of NSCLC in terms of etiopathogenesis and tumor biology.  Since the introduction of the reversible EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib, patients with metastatic EGFR mutation-positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum-based chemotherapy.  However, primary or acquired resistance limits the therapeutic success of these targeted agents.  Irreversible inhibitors targeting all ErbB family receptor tyrosine kinases, such as afatinib and dacomitinib, have been developed to confer sustained disease control in ErbB-dependent cancers.  The large LUX-Lung 3 phase III trial recently reported afatinib to be clearly superior over the most effective platinum doublet in patients with EGFR mutation-positive lung cancer.  To fully exploit the clinical activity of afatinib, proactive management of its gastrointestinal and dermatologic toxicities is advised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_92rQXahILN0Q2ypr7jHkfW6udTcc2eaopAO6RAUahLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpvVymtA%253D%253D&md5=bd1f2c43f11a8c5de2af782a4e220d88</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000354627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000354627%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26atitle%3DAfatinib%252C%2520erlotinib%2520and%2520gefitinib%2520in%2520the%2520first-line%2520therapy%2520of%2520EGFR%2520mutation-positive%2520lung%2520adenocarcinoma%253A%2520a%2520review%26jtitle%3DOnkologie%26date%3D2013%26volume%3D36%26spage%3D510%26epage%3D518%26doi%3D10.1159%2F000354627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eaopAO6RAUahLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waltman, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dias-Santagata, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Digumarthy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turke, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergethon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gettinger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosper, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akhavanfard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wain, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vernovsky, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mark, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanuti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">75ra26</span><span class="refDoi"> DOI: 10.1126/scitranslmed.3002003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1126%2Fscitranslmed.3002003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=21430269" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=75ra26&author=L.+V.+Sequistauthor=B.+A.+Waltmanauthor=D.+Dias-Santagataauthor=S.+Digumarthyauthor=A.+B.+Turkeauthor=P.+Fidiasauthor=K.+Bergethonauthor=A.+T.+Shawauthor=S.+Gettingerauthor=A.+K.+Cosperauthor=S.+Akhavanfardauthor=R.+S.+Heistauthor=J.+Temelauthor=J.+G.+Christensenauthor=J.+C.+Wainauthor=T.+J.+Lynchauthor=K.+Vernovskyauthor=E.+J.+Markauthor=M.+Lanutiauthor=A.+J.+Iafrateauthor=M.+Mino-Kenudsonauthor=J.+A.+Engelman&title=Genotypic+and+histological+evolution+of+lung+cancers+acquiring+resistance+to+EGFR+inhibitors&doi=10.1126%2Fscitranslmed.3002003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3002003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3002003%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DWaltman%26aufirst%3DB.%2BA.%26aulast%3DDias-Santagata%26aufirst%3DD.%26aulast%3DDigumarthy%26aufirst%3DS.%26aulast%3DTurke%26aufirst%3DA.%2BB.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DBergethon%26aufirst%3DK.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DGettinger%26aufirst%3DS.%26aulast%3DCosper%26aufirst%3DA.%2BK.%26aulast%3DAkhavanfard%26aufirst%3DS.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DTemel%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWain%26aufirst%3DJ.%2BC.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DVernovsky%26aufirst%3DK.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DLanuti%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DGenotypic%2520and%2520histological%2520evolution%2520of%2520lung%2520cancers%2520acquiring%2520resistance%2520to%2520EGFR%2520inhibitors%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2011%26volume%3D3%26spage%3D75ra26%26doi%3D10.1126%2Fscitranslmed.3002003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljPneDx7fbutQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">4702</span><span class="NLM_x">–</span> <span class="NLM_lpage">4711</span><span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.-K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0ljPneDx7fbutQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0ljsp3Xxu_naZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0ljsp3Xxu_naZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lgeDSesUq-new"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lgeDSesUq-new"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+ErbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0lgeDSesUq-new"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520ErbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.-H.+Ouauthor=M.-J.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lhZaox2XyY-9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Targeted therapies: Afatinib - new therapy option for EGFR-mutant lung cancer</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.154</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnrclinonc.2013.154" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=23959269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=551-552&author=H.+A.+Yuauthor=W.+Pao&title=Targeted+therapies%3A+Afatinib+-+new+therapy+option+for+EGFR-mutant+lung+cancer&doi=10.1038%2Fnrclinonc.2013.154"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted therapies Afatinib-new therapy option for EGFR-mutant lung cancer</span></div><div class="casAuthors">Yu, Helena A.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">551-552</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Afatinib improves progression-free survival compared with cisplatin and pemetrexed as first- line treatment for patients with EGFR mutant lung cancersAfatinib monotherapy has limited efficacy in patients with EGFR-mutant lung cancers with disease progression on erlotinib or gefitinibErlotinib, gefitinib and afatinib are all viable treatment options for the first-line treatment of patients with EGFR-mutant non-small-cell lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgXgyFJULHErVg90H21EOLACvtfcHk0lhZaox2XyY-9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVWru7zE&md5=1ad24629a25d9c99d9f56cf870a5d765</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.154&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.154%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DTargeted%2520therapies%253A%2520Afatinib%2520-%2520new%2520therapy%2520option%2520for%2520EGFR-mutant%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D551%26epage%3D552%26doi%3D10.1038%2Fnrclinonc.2013.154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhZaox2XyY-9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 --> methionine790 mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%2D%2D%3E+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520--%253E%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0linCvZADJKMoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790→ methionine790 mutant</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1155</span><span class="refDoi"> DOI: 10.1039/c2md20078c</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1039%2Fc2md20078c" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1155&author=S.+Xuauthor=L.+Zhangauthor=S.+Changauthor=J.+Luoauthor=X.+Luauthor=Z.+Tuauthor=Y.+Liuauthor=Z.+zhangauthor=Y.+Xuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis+and+biological+evaluation+of+new+molecules+inhibiting+epidermal+growth+factor+receptor+threonine790%E2%86%92+methionine790+mutant&doi=10.1039%2Fc2md20078c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2Fc2md20078c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20078c%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3Dzhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520new%2520molecules%2520inhibiting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1155%26doi%3D10.1039%2Fc2md20078c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">8387</span><span class="NLM_x">–</span> <span class="NLM_lpage">8390</span><span class="refDoi"> DOI: 10.1002/anie.201302313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1002%2Fanie.201302313" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8387-8390&author=T.+Xuauthor=L.+Zhangauthor=S.+Xuauthor=C.-Y.+Yangauthor=J.+Luoauthor=F.+Dingauthor=X.+Luauthor=Y.+Liuauthor=Z.+Tuauthor=S.+Liauthor=D.+Peiauthor=Q.+Caiauthor=H.+Liauthor=X.+Renauthor=S.+Wangauthor=K.+Ding&title=Pyrimido%5B4%2C5-d%5Dpyrimidin-4%281H%29-one+derivatives+as+selective+inhibitors+of+EGFR+threonine790+to+methionine790+%28T790M%29+mutants&doi=10.1002%2Fanie.201302313"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302313%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-Y.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DPyrimido%255B4%252C5-d%255Dpyrimidin-4%25281H%2529-one%2520derivatives%2520as%2520selective%2520inhibitors%2520of%2520EGFR%2520threonine790%2520to%2520methionine790%2520%2528T790M%2529%2520mutants%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8387%26epage%3D8390%26doi%3D10.1002%2Fanie.201302313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0linCvZADJKMoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lg1L1NpV1jw4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="refDoi"> DOI: 10.1039/c2md20017a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1039%2Fc2md20017a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=780&author=J.+Singhauthor=E.+Evansauthor=M.+Hagelauthor=M.+Labinskiauthor=A.+Dubrovskiyauthor=M.+Nachtauthor=R.+C.+Petterauthor=A.+Prasadauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Tjin+Tham+Sjinauthor=W.+Westlinauthor=Z.+Zhu&title=Superiority+of+a+novel+EGFR+targeted+covalent+inhibitor+over+its+reversible+counterpart+in+overcoming+drug+resistance&doi=10.1039%2Fc2md20017a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1039%2Fc2md20017a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20017a%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DLabinski%26aufirst%3DM.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DPrasad%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSuperiority%2520of%2520a%2520novel%2520EGFR%2520targeted%2520covalent%2520inhibitor%2520over%2520its%2520reversible%2520counterpart%2520in%2520overcoming%2520drug%2520resistance%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D780%26doi%3D10.1039%2Fc2md20017a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cross, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Red Brewer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+Red+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhV6sFfPp865Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DRed%2BBrewer%26aufirst%3DM.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span>FDA approves new pill to treat certain patients with non-small cell lung cancer. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm</a> (accessed November 13,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+new+pill+to+treat+certain+patients+with+non-small+cell+lung+cancer.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm472525.htm+%28accessed+November+13%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhV6sFfPp865Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tester, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1468</span><span class="NLM_x">–</span> <span class="NLM_lpage">1479</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin+Tham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+in+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2eaZaXL24yKrk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Planchard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggstrom, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frewer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span> </span><span class="NLM_article-title">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1689</span><span class="NLM_x">–</span> <span class="NLM_lpage">1699</span><span class="refDoi"> DOI: 10.1056/NEJMoa1411817</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1056%2FNEJMoa1411817" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=25923549" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1689-1699&author=P.+A.+J%C3%A4nneauthor=J.+C.-H.+Yangauthor=D.-W.+Kimauthor=D.+Planchardauthor=Y.+Oheauthor=S.+S.+Ramalingamauthor=M.-J.+Ahnauthor=S.-W.+Kimauthor=W.-C.+Suauthor=L.+Hornauthor=D.+Haggstromauthor=E.+Felipauthor=J.-H.+Kimauthor=P.+Frewerauthor=M.+Cantariniauthor=K.+H.+Brownauthor=P.+A.+Dickinsonauthor=S.+Ghiorghiuauthor=M.+Ranson&title=AZD9291+in+EGFR+inhibitor-resistant+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1411817"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer</span></div><div class="casAuthors">Janne Pasi A; Yang James Chih-Hsin; Kim Dong-Wan; Planchard David; Ohe Yuichiro; Ramalingam Suresh S; Ahn Myung-Ju; Kim Sang-We; Su Wu-Chou; Horn Leora; Haggstrom Daniel; Felip Enriqueta; Kim Joo-Hang; Frewer Paul; Cantarini Mireille; Brown Kathryn H; Dickinson Paul A; Ghiorghiu Serban; Ranson Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1689-99</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFR mutation (EGFR-mutated lung cancer).  In preclinical models, the EGFR inhibitor AZD9291 has been shown to be effective against both EGFR tyrosine kinase inhibitor-sensitizing and T790M resistance mutations.  METHODS:  We administered AZD9291 at doses of 20 to 240 mg once daily in patients with advanced lung cancer who had radiologically documented disease progression after previous treatment with EGFR tyrosine kinase inhibitors.  The study included dose-escalation cohorts and dose-expansion cohorts.  In the expansion cohorts, prestudy tumor biopsies were required for central determination of EGFR T790M status.  Patients were assessed for safety, pharmacokinetics, and efficacy.  RESULTS:  A total of 253 patients were treated.  Among 31 patients enrolled in the dose-escalation cohorts, no dose-limiting toxic effects occurred at the doses evaluated.  An additional 222 patients were treated in five expansion cohorts.  The most common all-cause adverse events were diarrhea, rash, nausea, and decreased appetite.  The overall objective tumor response rate was 51% (95% confidence interval [CI], 45 to 58).  Among 127 patients with centrally confirmed EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70).  In contrast, among 61 patients without centrally detectable EGFR T790M who could be evaluated for response, the response rate was 21% (95% CI, 12 to 34).  The median progression-free survival was 9.6 months (95% CI, 8.3 to not reached) in EGFR T790M-positive patients and 2.8 months (95% CI, 2.1 to 4.3) in EGFR T790M-negative patients.  CONCLUSIONS:  AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01802632.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3SnGiHuhFGv8fW6udTcc2eaZaXL24yKrk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltA%253D%253D&md5=7304f406bb2e568fb08b6d524d027389</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411817%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DHaggstrom%26aufirst%3DD.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DJ.-H.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DK.%2BH.%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DRanson%26aufirst%3DM.%26atitle%3DAZD9291%2520in%2520EGFR%2520inhibitor-resistant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1689%26epage%3D1699%26doi%3D10.1056%2FNEJMoa1411817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soria, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldman, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakelee, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadimitrakopoulou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziadziuszko, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aisner, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galasso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garon, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heist, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neal, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendenhall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piotrowska, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlovich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isaacson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Despain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matheny, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolfe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">372</span><span class="NLM_x">, </span> <span class="NLM_fpage">1700</span><span class="NLM_x">–</span> <span class="NLM_lpage">1709</span><span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eZ_xtze9xn4G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span>Novartis Pharmaceuticals. A phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. NLM Identifier: NCT02108964. <a href="http://clinicaltrials.gov/show/NCT02108964" class="extLink">http://clinicaltrials.gov/show/NCT02108964</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+A+phase+I%2FII%2C+multicenter%2C+open-label+study+of+EGFRmut-TKI+EGF816%2C+administered+orally+in+adult+patients+with+EGFRmut+solid+malignancies.+NLM+Identifier%3A+NCT02108964.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02108964+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span>Novartis Pharmaceuticals. Study of efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in patients with previously treated non-small cell lung cancer. NLM Identifier: NCT02323126. <a href="http://clinicaltrials.gov/show/NCT02323126" class="extLink">http://clinicaltrials.gov/show/NCT02323126</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+Study+of+efficacy+and+safety+of+nivolumab+in+combination+with+EGF816+and+of+nivolumab+in+combination+with+INC280+in+patients+with+previously+treated+non-small+cell+lung+cancer.+NLM+Identifier%3A+NCT02323126.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02323126+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>Novartis Pharmaceuticals. Study of safety and efficacy of EGF816 in combination with INC280 in non-small cell lung cancer patients with EGFR mutation. NLM Identifier: NCT02335944. <a href="http://clinicaltrials.gov/show/NCT02335944" class="extLink">http://clinicaltrials.gov/show/NCT02335944</a> (cited December 16, 2015).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Novartis+Pharmaceuticals.+Study+of+safety+and+efficacy+of+EGF816+in+combination+with+INC280+in+non-small+cell+lung+cancer+patients+with+EGFR+mutation.+NLM+Identifier%3A+NCT02335944.+http%3A%2F%2Fclinicaltrials.gov%2Fshow%2FNCT02335944+%28cited+December+16%2C+2015%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Jia, Y.; Manuia, M.; Juarez, J.</span><span> </span><span class="NLM_article-title">HTRF kinase assay development and methods in inhibitor characterization</span>. In  <span class="citation_source-book">Methods in Molecular Biology</span>; <span class="NLM_contrib-group">Zegzouti, H.; Gouell, S. A.</span>, Eds.; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">1360</span>, pp  <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span>, DOI: <span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_1</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1007%2F978-1-4939-3073-9_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-18&author=Y.+Jia&author=M.+Manuia&author=J.+Juarezauthor=H.+Zegzouti&author=S.+A.+Gouell&title=Methods+in+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_1%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26atitle%3DHTRF%2520kinase%2520assay%2520development%2520and%2520methods%2520in%2520inhibitor%2520characterization%26btitle%3DMethods%2520in%2520Molecular%2520Biology%26aulast%3DZegzouti%26aufirst%3DH.%26pub%3DHumana%2520Press%26date%3D2016%26volume%3D1360%26spage%3D1%26epage%3D18%26doi%3D10.1007%2F978-1-4939-3073-9_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span> </span><span class="NLM_article-title">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2842</span><span class="NLM_x">–</span> <span class="NLM_lpage">2845</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2006.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=16563752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2842-2845&author=J.+P.+Powersauthor=S.+Liauthor=J.+C.+Jaenauthor=J.+Liuauthor=N.+P.+C.+Walkerauthor=Z.+Wangauthor=H.+Wesche&title=Discovery+and+initial+SAR+of+inhibitors+of+interleukin-1+receptor-associated+kinase-4&doi=10.1016%2Fj.bmcl.2006.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4</span></div><div class="casAuthors">Powers, Jay P.; Li, Shyun; Jaen, Juan C.; Liu, Jinqian; Walker, Nigel P. C.; Wang, Zhulun; Wesche, Holger</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2842-2845</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High-throughput screening of a small-mol. compd. library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-assocd. kinase-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgZ37zw75f-7Vg90H21EOLACvtfcHk0ljvJBjzAaWolw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFygsb8%253D&md5=7a8a2ebe4c155ac8999ff4a63e3ed139</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWesche%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520initial%2520SAR%2520of%2520inhibitors%2520of%2520interleukin-1%2520receptor-associated%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2842%26epage%3D2845%26doi%3D10.1016%2Fj.bmcl.2006.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span> </span><span class="NLM_article-title">Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1835</span><span class="NLM_x">–</span> <span class="NLM_lpage">1844</span><span class="refDoi"> DOI: 10.1016/j.str.2006.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.str.2006.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17161373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1835-1844&author=Z.+Wangauthor=J.+Liuauthor=A.+Sudomauthor=M.+Ayresauthor=S.+Liauthor=H.+Wescheauthor=J.+P.+Powersauthor=N.+P.+C.+Walker&title=Crystal+structures+of+IRAK-4+kinase+in+complex+with+inhibitors%3A+a+serine%2Fthreonine+kinase+with+tyrosine+as+a+gatekeeper&doi=10.1016%2Fj.str.2006.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures of IRAK-4 Kinase in Complex with Inhibitors: A Serine/Threonine Kinase with Tyrosine as a Gatekeeper</span></div><div class="casAuthors">Wang, Zhulun; Liu, Jinsong; Sudom, Athena; Ayres, Merrill; Li, Shyun; Wesche, Holger; Powers, Jay P.; Walker, Nigel P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1835-1844</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Interleukin-1 (IL-1) receptor-assocd. kinase-4 (IRAK-4) is a serine/threonine kinase that plays an essential role in signal transduction by Toll/IL-1 receptors (TIRs).  Here, we report the crystal structures of the phosphorylated human IRAK-4 kinase domain in complex with a potent inhibitor and with staurosporine to 2.0 and 2.2 Å, resp.  The structures reveal that IRAK-4 has a unique tyrosine gatekeeper residue that interacts with the conserved glutamate from helix αC.  Consequently, helix αC is "pulled in" to maintain the active orientation, and the usual pre-existing hydrophobic back pocket of the ATP-binding site is abolished.  The peptide substrate-binding site is more open when compared with other protein kinases due to a marked movement of helix αG.  The pattern of phosphate ligand interactions in the activation loop bears a close resemblance to that of a tyrosine kinase.  Our results provide insights into IRAK-4 function and the design of selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1kW8-IrZf47Vg90H21EOLACvtfcHk0lj1bLiRCOyVZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlShsrvF&md5=6a8f14729eeb6776871ff632f0822f8f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2006.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2006.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWesche%26aufirst%3DH.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26atitle%3DCrystal%2520structures%2520of%2520IRAK-4%2520kinase%2520in%2520complex%2520with%2520inhibitors%253A%2520a%2520serine%252Fthreonine%2520kinase%2520with%2520tyrosine%2520as%2520a%2520gatekeeper%26jtitle%3DStructure%26date%3D2006%26volume%3D14%26spage%3D1835%26epage%3D1844%26doi%3D10.1016%2Fj.str.2006.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeywardane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khine, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowalski, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarko, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cywin, C. L.</span><span> </span><span class="NLM_article-title">Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3660</span><span class="NLM_x">–</span> <span class="NLM_lpage">3665</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.04.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2007.04.045" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3660-3665&author=R.+J.+Snowauthor=A.+Abeywardaneauthor=S.+Campbellauthor=J.+Lordauthor=M.+A.+Kashemauthor=H.+H.+Khineauthor=J.+Kingauthor=J.+A.+Kowalskiauthor=S.+S.+Pullenauthor=T.+Romaauthor=G.+P.+Rothauthor=C.+R.+Sarkoauthor=N.+S.+Wilsonauthor=M.+P.+Wintersauthor=J.+P.+Wolakauthor=C.+L.+Cywin&title=Hit-to-lead+studies+on+benzimidazole+inhibitors+of+ITK%3A+discovery+of+a+novel+class+of+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2007.04.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.045%26sid%3Dliteratum%253Aachs%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DAbeywardane%26aufirst%3DA.%26aulast%3DCampbell%26aufirst%3DS.%26aulast%3DLord%26aufirst%3DJ.%26aulast%3DKashem%26aufirst%3DM.%2BA.%26aulast%3DKhine%26aufirst%3DH.%2BH.%26aulast%3DKing%26aufirst%3DJ.%26aulast%3DKowalski%26aufirst%3DJ.%2BA.%26aulast%3DPullen%26aufirst%3DS.%2BS.%26aulast%3DRoma%26aufirst%3DT.%26aulast%3DRoth%26aufirst%3DG.%2BP.%26aulast%3DSarko%26aufirst%3DC.%2BR.%26aulast%3DWilson%26aufirst%3DN.%2BS.%26aulast%3DWinters%26aufirst%3DM.%2BP.%26aulast%3DWolak%26aufirst%3DJ.%2BP.%26aulast%3DCywin%26aufirst%3DC.%2BL.%26atitle%3DHit-to-lead%2520studies%2520on%2520benzimidazole%2520inhibitors%2520of%2520ITK%253A%2520discovery%2520of%2520a%2520novel%2520class%2520of%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3660%26epage%3D3665%26doi%3D10.1016%2Fj.bmcl.2007.04.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaen, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudom, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomooka, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N. P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, J. P.</span><span> </span><span class="NLM_article-title">Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">5546</span><span class="NLM_x">–</span> <span class="NLM_lpage">5550</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.10.060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2015.10.060" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=5546-5550&author=Z.+Wangauthor=D.+Sunauthor=S.+Johnstoneauthor=Z.+Caoauthor=X.+Gaoauthor=J.+C.+Jaenauthor=J.+Liuauthor=S.+Livelyauthor=S.+Miaoauthor=A.+Sudomauthor=C.+Tomookaauthor=N.+P.+C.+Walkerauthor=M.+Wrightauthor=X.+Yanauthor=Q.+Yeauthor=J.+P.+Powers&title=Discovery+of+potent%2C+selective%2C+and+orally+bioavailable+inhibitors+of+interleukin-1+receptor-associate+kinase-4&doi=10.1016%2Fj.bmcl.2015.10.060"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.10.060%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DJaen%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLively%26aufirst%3DS.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DSudom%26aufirst%3DA.%26aulast%3DTomooka%26aufirst%3DC.%26aulast%3DWalker%26aufirst%3DN.%2BP.%2BC.%26aulast%3DWright%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DPowers%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520inhibitors%2520of%2520interleukin-1%2520receptor-associate%2520kinase-4%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D5546%26epage%3D5550%26doi%3D10.1016%2Fj.bmcl.2015.10.060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)</span></div><div class="casAuthors">Wissner, Allan; Overbeek, Elsebe; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Mamuya, Nellie; Rosfjord, Edward C.; Discafani, Carolyn; Davis, Rachel; Shi, Xiaoqing; Rabindran, Sridhar K.; Gruber, Brian C.; Ye, Fei; Hallett, William A.; Nilakantan, Ramaswamy; Shen, Ru; Wang, Yu-Fen; Greenberger, Lee M.; Tsou, Hwei-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles, e.g., I, that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepd.  These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles, e.g., II, with unsatd. acid chlorides or mixed anhydrides.  Competitive reactivity studies were performed, showing that attaching a dialkylamino group onto the end of the Michael acceptor results in compds. with greater reactivity due to intramol. catalysis of the Michael addn.  This, along with improved water-soly. results in compds. with enhanced biol. properties.  Mol. modeling results consistent with the proposed mechanism of inhibition are presented.  One compd., I (EKB-569), which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq317fAvBYUW7Vg90H21EOLACvtfcHk0lhFy7X9E3bLjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D&md5=db70c2f78c62824810854295d06ef6a4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0lgsb67czDErPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gureasko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">1137</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lgsb67czDErPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Richmond, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wogan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isbell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, W. P.</span><span> </span><span class="NLM_article-title">Interstrain differences of in vitro metabolic stability and impact on early drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">4463</span><span class="NLM_x">–</span> <span class="NLM_lpage">4468</span><span class="refDoi"> DOI: 10.1002/jps.22179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1002%2Fjps.22179" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=4463-4468&author=W.+Richmondauthor=M.+Woganauthor=J.+Isbellauthor=W.+P.+Gordon&title=Interstrain+differences+of+in+vitro+metabolic+stability+and+impact+on+early+drug+discovery&doi=10.1002%2Fjps.22179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjps.22179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22179%26sid%3Dliteratum%253Aachs%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DWogan%26aufirst%3DM.%26aulast%3DIsbell%26aufirst%3DJ.%26aulast%3DGordon%26aufirst%3DW.%2BP.%26atitle%3DInterstrain%2520differences%2520of%2520in%2520vitro%2520metabolic%2520stability%2520and%2520impact%2520on%2520early%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2010%26volume%3D99%26spage%3D4463%26epage%3D4468%26doi%3D10.1002%2Fjps.22179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Ryckmans, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correia, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, T.</span><span> </span><span class="NLM_article-title">Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">4406</span><span class="NLM_x">–</span> <span class="NLM_lpage">4409</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+assessment+of+a+novel+series+of+selective+CB%282%29+agonists+using+parallel+synthesis+protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lgBIrS_UvgKkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520assessment%2520of%2520a%2520novel%2520series%2520of%2520selective%2520CB%25282%2529%2520agonists%2520using%2520parallel%2520synthesis%2520protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lgBIrS_UvgKkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tompkins, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timple, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaillancourt, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pferdekamper, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockerman, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barretina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pathan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasibhatla, S.</span><span> </span><span class="NLM_article-title">EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1602</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-15-2581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1158%2F0008-5472.CAN-15-2581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1591-1602&author=Y.+Jiaauthor=J.+Juarezauthor=J.+Liauthor=M.+Manuiaauthor=M.+J.+Niederstauthor=C.+Tompkinsauthor=N.+Timpleauthor=M.+T.+Vaillancourtauthor=A.+C.+Pferdekamperauthor=E.+L.+Lockermanauthor=C.+Liauthor=J.+Andersonauthor=C.+Costaauthor=D.+Liaoauthor=E.+Murphyauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=G.+Lelaisauthor=J.+Barretinaauthor=M.+McNeillauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=N.+Pathanauthor=J.+A.+Engelmanauthor=P.+Y.+Michellysauthor=P.+McNamaraauthor=J.+Harrisauthor=S.+Benderauthor=S.+Kasibhatla&title=EGF816+exerts+anticancer+effects+in+non-small+cell+lung+cancer+by+irreversibly+and+selectively+targeting+primary+and+acquired+activating+mutations+in+the+EGF+receptor&doi=10.1158%2F0008-5472.CAN-15-2581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-15-2581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-15-2581%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DTompkins%26aufirst%3DC.%26aulast%3DTimple%26aufirst%3DN.%26aulast%3DVaillancourt%26aufirst%3DM.%2BT.%26aulast%3DPferdekamper%26aufirst%3DA.%2BC.%26aulast%3DLockerman%26aufirst%3DE.%2BL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DJ.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DLiao%26aufirst%3DD.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DBarretina%26aufirst%3DJ.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DPathan%26aufirst%3DN.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DMcNamara%26aufirst%3DP.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKasibhatla%26aufirst%3DS.%26atitle%3DEGF816%2520exerts%2520anticancer%2520effects%2520in%2520non-small%2520cell%2520lung%2520cancer%2520by%2520irreversibly%2520and%2520selectively%2520targeting%2520primary%2520and%2520acquired%2520activating%2520mutations%2520in%2520the%2520EGF%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2016%26volume%3D76%26spage%3D1591%26epage%3D1602%26doi%3D10.1158%2F0008-5472.CAN-15-2581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Tan, D. S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matushansky, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu Schmitz, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span> </span><span class="NLM_article-title">First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">8013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=8013&issue=Suppl.&author=D.+S.-W.+Tanauthor=T.+Setoauthor=N.+B.+Leighlauthor=G.+J.+Rielyauthor=L.+V.+Sequistauthor=E.+Felipauthor=J.+Wolfauthor=J.+C.-H.+Yangauthor=I.+Matushanskyauthor=X.+Yuauthor=S.-F.+Hsu+Schmitzauthor=X.+Cuiauthor=D.-W.+Kim&title=First-in-human+phase+I+study+of+EGF816%2C+a+third+generation%2C+mutant-selective+EGFR+tyrosine+kinase+inhibitor%2C+in+advanced+non-small+cell+lung+cancer+%28NSCLC%29+harboring+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DD.%2BS.-W.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26aulast%3DMatushansky%26aufirst%3DI.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DHsu%2BSchmitz%26aufirst%3DS.-F.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DD.-W.%26atitle%3DFirst-in-human%2520phase%2520I%2520study%2520of%2520EGF816%252C%2520a%2520third%2520generation%252C%2520mutant-selective%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520advanced%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520harboring%2520T790M%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26issue%3DSuppl%26spage%3D8013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Otwinowski, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minor, W.</span><span> </span><span class="NLM_article-title">Processing of X-ray diffraction data collected in oscillation mode</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">276</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1016/S0076-6879(97)76066-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2FS0076-6879%2897%2976066-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=27754618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=307-326&author=Z.+Otwinowskiauthor=W.+Minor&title=Processing+of+X-ray+diffraction+data+collected+in+oscillation+mode&doi=10.1016%2FS0076-6879%2897%2976066-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Processing of x-ray diffraction data collected in oscillation mode</span></div><div class="casAuthors">Otwinowski, Zbyszek; Minor, Wladek</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">Macromolecular Crystallography, Part A</span>),
    <span class="NLM_cas:pages">307-326</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Macromol. crystallog. is an iterative process.  Rarely do the first crystals provide all the necessary data to solve the biol. problem being studied.  Each step benefits from experience learned in previous steps.  To monitor the progress, the HKL package provides 2 tools: (1) statistics, both weighted (χ2) and unweighted (R-merge), are provided, and the Bayesian reasoning and multicomponent error model facilitates obtaining the proper error ests. and (2) visualization of the process plays a double role by helping the operator to confirm that the process of data redn., including the resulting statistics, is correct, and allowing one to evaluate problems for which there are no good statistical criteria.  Visualization also provides confidence that the point of diminishing returns in data collection and redn. has been reached.  At that point, the effort should be directed to solving the structure.  The methods presented here have been applied to solve a large variety of problems, from inorg. mols. with 5 Å unit cell to rotavirus of 700 Å diam. crystd. in 700 × 1000 × 1400 Å cell.  Overall quality of the method was tested by many researchers by successful application of the programs to MAD structure detns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA3fvBOHqhhrVg90H21EOLACvtfcHk0li-USPzv3XvFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivFehsbw%253D&md5=c9536971d4e32cc35352c40fb9368131</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2897%2976066-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252897%252976066-X%26sid%3Dliteratum%253Aachs%26aulast%3DOtwinowski%26aufirst%3DZ.%26aulast%3DMinor%26aufirst%3DW.%26atitle%3DProcessing%2520of%2520X-ray%2520diffraction%2520data%2520collected%2520in%2520oscillation%2520mode%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D276%26spage%3D307%26epage%3D326%26doi%3D10.1016%2FS0076-6879%2897%2976066-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0li-USPzv3XvFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mustyakimov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urzhumtsev, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span> </span><span class="NLM_article-title">Towards automated crystallographic structure refinement with phenix.refine</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">352</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1107/S0907444912001308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0907444912001308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=22505256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2012&pages=352-367&author=P.+V.+Afonineauthor=R.+W.+Grosse-Kunstleveauthor=N.+Echolsauthor=J.+J.+Headdauthor=N.+W.+Moriartyauthor=M.+Mustyakimovauthor=T.+C.+Terwilligerauthor=A.+Urzhumtsevauthor=P.+H.+Zwartauthor=P.+D.+Adams&title=Towards+automated+crystallographic+structure+refinement+with+phenix.refine&doi=10.1107%2FS0907444912001308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Towards automated crystallographic structure refinement with phenix.refine</span></div><div class="casAuthors">Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel; Headd, Jeffrey J.; Moriarty, Nigel W.; Mustyakimov, Marat; Terwilliger, Thomas C.; Urzhumtsev, Alexandre; Zwart, Peter H.; Adams, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">352-367</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phenix.refine is a program within the PHENIX package that supports crystallog. structure refinement against exptl. data with a wide range of upper resoln. limits using a large repertoire of model parameterizations.  It has several automation features and is also highly flexible.  Several hundred parameters enable extensive customizations for complex use cases.  Multiple user-defined refinement strategies can be applied to specific parts of the model in a single refinement run.  An intuitive graphical user interface is available to guide novice users and to assist advanced users in managing refinement projects.  X-ray or neutron diffraction data can be used sep. or jointly in refinement. phenix.refine is tightly integrated into the PHENIX suite, where it serves as a crit. component in automated model building, final structure refinement, structure validation and deposition to the wwPDB.  This paper presents an overview of the major phenix.refine features, with extensive literature refs. for readers interested in more detailed discussions of the methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnhn9QwIEkTbVg90H21EOLACvtfcHk0ljH-sGe0Iy2QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ggu7c%253D&md5=1cc7da2cea396f1a75646ea709140cf1</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS0907444912001308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444912001308%26sid%3Dliteratum%253Aachs%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DMustyakimov%26aufirst%3DM.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26atitle%3DTowards%2520automated%2520crystallographic%2520structure%2520refinement%2520with%2520phenix.refine%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2012%26volume%3D68%26spage%3D352%26epage%3D367%26doi%3D10.1107%2FS0907444912001308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohkamp, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Features and development of Coot</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">486</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span><span class="refDoi"> DOI: 10.1107/S0907444910007493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1107%2FS0907444910007493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=20383002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=486-501&author=P.+Emsleyauthor=B.+Lohkampauthor=W.+G.+Scottauthor=K.+Cowtan&title=Features+and+development+of+Coot&doi=10.1107%2FS0907444910007493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Features and development of Coot</span></div><div class="casAuthors">Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">486-501</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Coot is a mol.-graphics application for model building and validation of biol. macromols.  The program displays electron-d. maps and at. models and allows model manipulations such as idealization, real-space refinement, manual rotation/translation, rigid-body fitting, ligand search, solvation, mutations, rotamers and Ramachandran idealization.  Furthermore, tools are provided for model validation as well as interfaces to external programs for refinement, validation and graphics.  The software is designed to be easy to learn for novice users, which is achieved by ensuring that tools for common tasks are 'discoverable' through familiar user-interface elements (menus and toolbars) or by intuitive behavior (mouse controls).  Recent developments have focused on providing tools for expert users, with customisable key bindings, extensions and an extensive scripting interface.  The software is under rapid development, but has already achieved very widespread use within the crystallog. community.  The current state of the software is presented, with a description of the facilities available and of some of the underlying methods employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAKBKszbqb_7Vg90H21EOLACvtfcHk0ljH-sGe0Iy2QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksFKisb8%253D&md5=67262cbfc60004de5ef962d5c043c910</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444910007493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910007493%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DLohkamp%26aufirst%3DB.%26aulast%3DScott%26aufirst%3DW.%2BG.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DFeatures%2520and%2520development%2520of%2520Coot%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D486%26epage%3D501%26doi%3D10.1107%2FS0907444910007493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span> </span><span class="NLM_article-title">Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">391</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">38</span><span class="refDoi"> DOI: 10.1016/j.ab.2009.04.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=10.1016%2Fj.ab.2009.04.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2009&pages=31-38&author=L.+Hongauthor=C.+M.+Quinnauthor=Y.+Jia&title=Evaluating+the+utility+of+the+HTRF+Transcreener+ADP+assay+technology%3A+a+comparison+with+the+standard+HTRF+assay+technology&doi=10.1016%2Fj.ab.2009.04.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2009.04.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2009.04.033%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DQuinn%26aufirst%3DC.%2BM.%26aulast%3DJia%26aufirst%3DY.%26atitle%3DEvaluating%2520the%2520utility%2520of%2520the%2520HTRF%2520Transcreener%2520ADP%2520assay%2520technology%253A%2520a%2520comparison%2520with%2520the%2520standard%2520HTRF%2520assay%2520technology%26jtitle%3DAnal.%2520Biochem.%26date%3D2009%26volume%3D391%26spage%3D31%26epage%3D38%26doi%3D10.1016%2Fj.ab.2009.04.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Kelstrup, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavallee, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olsen, J. V.</span><span> </span><span class="NLM_article-title">Optimized fast and sensitive acquisition methods for shotgun proteomics on a quadrupole orbitrap mass spectrometer</span> <span class="citation_source-journal">J. Proteome Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3487</span><span class="NLM_x">–</span> <span class="NLM_lpage">3497</span><span class="refDoi"> DOI: 10.1021/pr3000249</span> </span><div class="citationLinks">[<a href="/doi/10.1021/pr3000249" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFGhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=3487-3497&author=C.+D.+Kelstrupauthor=C.+Youngauthor=R.+Lavalleeauthor=M.+L.+Nielsenauthor=J.+V.+Olsen&title=Optimized+fast+and+sensitive+acquisition+methods+for+shotgun+proteomics+on+a+quadrupole+orbitrap+mass+spectrometer&doi=10.1021%2Fpr3000249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Fast and Sensitive Acquisition Methods for Shotgun Proteomics on a Quadrupole Orbitrap Mass Spectrometer</span></div><div class="casAuthors">Kelstrup, Christian D.; Young, Clifford; Lavallee, Richard; Nielsen, Michael L.; Olsen, Jesper V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteome Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3487-3497</span>CODEN:
                <span class="NLM_cas:coden">JPROBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-3893</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Advances in proteomics are continually driven by the introduction of new mass spectrometric instrumentation with improved performances.  The recently introduced quadrupole Orbitrap (Q Exactive) tandem mass spectrometer allows fast acquisition of high-resoln. higher-energy collisional dissocn. (HCD) tandem mass spectra due to the parallel mode of operation, where the generation, filling, and storage of fragment ions can be performed while simultaneously measuring another ion packet in the Orbitrap mass analyzer.  In this study, data-dependent acquisition methods for "fast" or "sensitive" scanning were optimized and assessed by comparing stable isotope labeled yeast proteome coverage.  We discovered that speed was the most important parameter for sample loads above 125 ng, where a 95 ms HCD scanning method allowed for identification and quantification of more than 2000 yeast proteins from 1 h of anal. time.  At sample loads below 125 ng, a 156 ms HCD acquisition method improved the sensitivity, mass accuracy, and quality of data and enabled us to identify 30% more proteins and peptides than the faster scanning method.  A similar effect was obsd. when the LC gradient was extended to 2 or 3 h for the anal. of complex mammalian whole cell lysates.  Using a 3 h LC gradient, the sensitive method enabled identification of more than 4000 proteins from 1 μg of tryptic HeLa digest, which was almost 200 more identifications compared to the faster scanning method.  Our results demonstrate that peptide identification on a quadrupole Orbitrap is dependent on sample amts., acquisition speed, and data quality, which emphasizes the need for acquisition methods tailored for different sample loads and anal. preferences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeF6hkFhNDMbVg90H21EOLACvtfcHk0ljMqPaGZpu8Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFGhtL4%253D&md5=399e069d9a3349292c226faedf5133d4</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fpr3000249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fpr3000249%26sid%3Dliteratum%253Aachs%26aulast%3DKelstrup%26aufirst%3DC.%2BD.%26aulast%3DYoung%26aufirst%3DC.%26aulast%3DLavallee%26aufirst%3DR.%26aulast%3DNielsen%26aufirst%3DM.%2BL.%26aulast%3DOlsen%26aufirst%3DJ.%2BV.%26atitle%3DOptimized%2520fast%2520and%2520sensitive%2520acquisition%2520methods%2520for%2520shotgun%2520proteomics%2520on%2520a%2520quadrupole%2520orbitrap%2520mass%2520spectrometer%26jtitle%3DJ.%2520Proteome%2520Res.%26date%3D2012%26volume%3D11%26spage%3D3487%26epage%3D3497%26doi%3D10.1021%2Fpr3000249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jiu','PDB','2jiu'); return false;">PDB: 2jiu</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2gs2','PDB','2gs2'); return false;">PDB: 2gs2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2jit','PDB','2jit'); return false;">PDB: 2jit</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed','PDB','5fed'); return false;">PDB: 5fed</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee','PDB','5fee'); return false;">PDB: 5fee</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5feq" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5feq','PDB','5feq'); return false;">PDB: 5feq</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i130"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01985">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86784"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01985">10.1021/acs.jmedchem.5b01985</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Refinement statistics of cocrystal structures WT-EGFR-<b>43</b>, EGFR T790M-<b>43</b> and EGFR T790M-<b>46</b>; biochemical selectivity profiling of <b>47</b> against a panel of kinase and non-kinase targets; enantiopurity analysis of chiral compounds; analytical LC–MS methods for analysis of intermediates; metabolite identification studies for <b>43</b>; <sup>1</sup>H and <sup>13</sup>C NMR spectra of <b>47</b> at 300 and 383 K (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_001.pdf">jm5b01985_si_001.pdf (949.46 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01985/suppl_file/jm5b01985_si_002.csv">jm5b01985_si_002.csv (4.18 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The crystallographic coordinates and structure factors have been deposited in the Protein Data Bank, <a href="http://www.pdb.org" class="extLink">www.pdb.org</a> (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fee">5fee</a> for EGFR T790M-<b>43</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5fed">5fed</a> for WT EGFR-<b>43</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5feq">5feq</a> for EGFR T790M-<b>46</b>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01985&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-14%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01985" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01985" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5d26eda93c7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
